Barcelona, Spain
September 7-11
CIRSE 2019

POCKET GUIDE
ANNUAL MEETING
AND POSTGRADUATE COURSE
OF THE
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGICAL SOCIETY OF EUROPE

featuring
IDEAS
Interdisciplinary Endovascular Aortic Symposium

www.cirse.org
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Name</th>
<th>Stage Area</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>FS 1001</td>
<td>A2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute type B dissection</td>
<td></td>
<td>IDEAS</td>
</tr>
<tr>
<td>08:00</td>
<td>CEC 902</td>
<td>A1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diabetic foot</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>ERT 903</td>
<td>R112</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colorectal cancer lung metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>FC 904</td>
<td>R116</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pain management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>FS 905</td>
<td>R117</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pre-operative portal vein embolisation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>FS 1005</td>
<td>R112</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Update on pelvic embolisation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>IRT 1006</td>
<td>R114</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Building an IR career</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>EMT-HDT 1</td>
<td>R130</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Embolisation: materials &amp; tools – liquid agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>TA-HDT 1</td>
<td>R111</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumour ablation – MWA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>VV-HDT 1</td>
<td>R132</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Varicose veins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>SIM 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simulation Training</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basic principles of mechanical thrombectomy in ischaemic stroke (advanced)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>SED 1</td>
<td>R118</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Safe sedation application during IR procedures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>Sat. Symp.</td>
<td>p49</td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>Satellite Symposia</td>
<td>p150-151</td>
<td></td>
</tr>
</tbody>
</table>

*ENDOVASCULAR PROGRAMME*

- **ARTERIAL INTERVENTION**
- **VENOUS INTERVENTION**
- **AORTIC INTERVENTION**
- **INTERVENTIONAL ONCOLOGY**
- **EMBOLISATION**
- **NEUROINTERVENTION**
- **NON-VASCULAR INTERVENTION**
- **IR MANAGEMENT**

*Session includes lectures that are recommended for EBIR preparation*
-e-voting

**A:** Auditorium  
**R:** Room  
**NoS:** News on Stage Area
### Programme at a Glance – Tuesday, September 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Area</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>FS 2501 Radiation exposure: are we doing enough?</td>
<td>A2</td>
<td>p113</td>
</tr>
<tr>
<td>09:00</td>
<td>CEC 2502 Acute mesenteric arterial ischaemia</td>
<td>A1</td>
<td>p114</td>
</tr>
<tr>
<td>10:00</td>
<td>ERT 2601 Don’t forget the iliacs!</td>
<td>A1</td>
<td>p117</td>
</tr>
<tr>
<td>11:00</td>
<td>ERT 2602 Open questions in below-the-knee procedures</td>
<td>A1</td>
<td>p117</td>
</tr>
<tr>
<td>12:00</td>
<td>FS 2702 Radial access: how and when</td>
<td>R117</td>
<td>p121</td>
</tr>
<tr>
<td>13:00</td>
<td>FC 2503 Intra-arterial stroke management</td>
<td>R117</td>
<td>p121</td>
</tr>
<tr>
<td></td>
<td>FS 2505 Standardising planning to achieve optimal ablation</td>
<td>R112</td>
<td>p115</td>
</tr>
<tr>
<td></td>
<td>FS 2504 Urinary tract embolisation</td>
<td>R116</td>
<td>p115</td>
</tr>
<tr>
<td></td>
<td>IRT 2606 IRs: from the angi-suite to industry boardrooms and the road to innovation</td>
<td>R114</td>
<td>p119</td>
</tr>
<tr>
<td></td>
<td>EMT-HDT 5 Embolisation: materials &amp; tools – particulate agents</td>
<td>R130</td>
<td>p35</td>
</tr>
<tr>
<td></td>
<td>TA-HDT 5 Tumour ablation – Image guided navigation &amp; targeting</td>
<td>R111</td>
<td>p37</td>
</tr>
<tr>
<td></td>
<td>VA-HDT 1 Vertebral augmentation</td>
<td>R132</td>
<td>p38</td>
</tr>
<tr>
<td></td>
<td>SIM 4 Simulation Training – Peripheral artery disease: angioplasty and stenting (core)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SED 7 Safe sedation application during IR procedures (advanced)</td>
<td>R118</td>
<td>p40-41</td>
</tr>
</tbody>
</table>

**ENDOVASCULAR PROGRAMME**
- **ARTERIAL INTERVENTION**
- **VENOUS INTERVENTION**
- **AORTIC INTERVENTION**
- **INTERVENTIONAL ONCOLOGY**
- **EMBOLISATION**
- **NEUROINTERVENTION**
- **NON-VASCULAR INTERVENTION**
- **IR MANAGEMENT**

**Session includes lectures that are recommended for EBIR preparation**

**A:** Auditorium  **NoS:** News on **Stage Area**
Download CIRSE 2019 in the CIRSE society app!

Your toolkit for the 2019 Annual Meeting in Barcelona:

• browse the programme
• build your personal schedule
• complete the session evaluation
• participate in e-voting polls
• send questions to the moderators
• find your way around using the interactive floor plans
• browse the list of exhibitors
• watch sessions Live and On Demand
• ... and much more!

Plan and participate using the CIRSE 2019 mobile app!
WHERE THE WORLD OF IR MEETS

CIRSE 2019
LIVE AND ON DEMAND

Can’t decide which session to go to?
Pick your favourite and watch the other lectures on demand at the CIRSE Library!

live.cirse.org

Cardiovascular and Interventional Radiological Society of Europe
<table>
<thead>
<tr>
<th>14</th>
<th>General Information from A to Z</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Session Types, 24 Film Interpretation Quiz, 25 Opening Ceremony, 26 News on Stage, 31 First@CIRSE, 32 Hands-on Device Training, 40 Safe Sedation Training, 42 Simulation Training</td>
</tr>
</tbody>
</table>

| 47 | Saturday – Scientific Programme |

| 70 | Sunday – Scientific Programme |

| 90 | Monday – Scientific Programme |

| 113 | Tuesday – Scientific Programme |

| 133 | Wednesday – Scientific Programme |

| 138 | Posters |

<table>
<thead>
<tr>
<th>143</th>
<th>Corporate Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>146</td>
<td>Satellite Symposia, 169 Learning Centres, 182 Industry Training Village, 185 Hands-on Device Training Sponsors, 187 Safe Sedation &amp; Simulation Training Sponsors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>192</th>
<th>Technical Exhibition</th>
</tr>
</thead>
</table>

* advertisement-free section in accordance with the document UEMS 2016/20 – the Accreditation of Live Educational Events of the EACCME*
General Information from A to Z

App
Let the CIRSE app take care of your congress planning. Newcomers, please download the CIRSE society app, which is available for iPhone, iPad and Android, and install the CIRSE 2019 event. If the CIRSE society app is already on your smartphone, please update the app and install the CIRSE 2019 event in order to have the best toolkit to plan your personal congress programme, evaluate sessions, browse the exhibition, take part in e-votings and submit questions to the moderator in selected sessions.

- build your personal schedule
- complete the session evaluation
- search for exhibitors by product category
- and much more...

Badges
Your personalised badge is your admission card to the congress. For organisational and security reasons, badges must be worn at the congress venue at all times. A lanyard will be given to you with the congress bag. Identity checks in the congress centre may occur at any time. In case of loss, a replacement badge will be provided at an administrative charge of €80.

Certificate of Attendance
To obtain your certificate of attendance, you can choose one of the following options:

Print your certificate onsite at the congress
From 14:00 on Monday, September 9, you can use one of the dedicated workstations in the registration area to print your certificate. All you need is your congress badge.

Print your certificate at home
After the congress, you will be able to print your certificate of attendance at www.cirse.org. All you need is your last name and badge number. Alternatively, you could log into your CIRSE account at www.cirse.org with your personal log-in details.

CIRSE Library – library.cirse.org
The CIRSE Library is the largest online presentation database for interventional radiology, featuring slides and webcasts from past CIRSE meetings. With monthly compiled topic packages, the CIRSE Library is the ideal tool for your research and educational needs. Presentations recorded at CIRSE 2019 will be available shortly after.
**CME Credit Allowance**

**CIRSE 2019**, Barcelona, Spain, September 7-11, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 34 European CME credits (ECMEC®s).

**IDEAS 2019**, Barcelona, Spain, September 8-10, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of *AMA PRA Category 1 Credits™*. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

**Coffee & Snacks**

Refreshments can be purchased at the cash bar.

**Disclaimer**

CIRSE cannot accept any liability for the acts of the suppliers to this meeting or the attendees’ safety while travelling to or from the congress. All participants are strongly advised to carry adequate travel and health insurance, as CIRSE cannot accept liability for accidents or injuries that may occur.

**Disclosures**

For financial disclosures and conflict-of-interest statements, please refer to [www.cirse.org](http://www.cirse.org).

**Evaluation**

To complete the session evaluation and obtain credits for your attendance at CIRSE and IDEAS 2019 sessions, please use the online evaluation system, accessible through the CIRSE mobile app (please see page 11) and at [programme.cirse.org](http://programme.cirse.org).
Hotels | Social Events | City Information
For information regarding hotels, transfers, restaurants and excursions, please contact our official travel partner, Kuoni Congress, whose information desk is located in the entrance hall of the congress centre. Kuoni Congress will be pleased to help you with all matters relating to your stay in Barcelona.

**Opening Hours**
- Friday, September 6: 16:00-18:00
- Saturday, September 7: 07:00-18:00
- Sunday, September 8: 07:30-18:00
- Monday, September 9: 08:00-18:00
- Tuesday, September 10: 08:00-18:00
- Wednesday, September 11: 08:00-13:00

**Internet/Wifi**
A free wireless service is available to all delegates throughout the congress centre.

Network: CIRSE 2019
Password: Barcelona19

**Live and On Demand – live.cirse.org**
All sessions are being livestreamed and will be available on demand in the CIRSE Library shortly after. Never miss another session! CIRSE members have year-round free access to all live congresses and webcast recordings. Find out more about our various access options for non-members at cirse.org/library/access.

**Members’ Lounge**
All members are invited to relax and enjoy a snack in the Members’ Lounge, which is located in the exhibition hall.

**Mobile Phones**
Please do not forget to turn your mobile phone to silent mode during the sessions.

**Photographs and Video Recording**
Please note that any form of recording, filming or photographing of presentation material during the sessions is strictly forbidden. Subject to the authors’ consent, all presentation material will be made available online in the CIRSE Library (library.cirse.org).

**Poster Area**
All accepted scientific and educational posters as well as case reports will be presented electronically through CIRSE’s Electronic Poster Online System.

The Poster Area is located in the exhibition hall of the congress centre (please see the floorplan on page 275). 36 computers will be available to view the CIRSE 2019 posters.
Opening Hours
Saturday, September 7  07:30-18:30
Sunday, September 8  07:30-18:30
Monday, September 9  07:30-18:30
Tuesday, September 10  07:30-18:30

Onsite staff will be glad to assist you during these hours.

Publication in CVIR
Meeting abstracts are published in CIRSE’s official journal, CVIR, as an electronic supplementary issue and are therefore citable publications (Online Publication Number: 10.1007/s00270-019-02282-x).

We encourage submission of the complete manuscript of oral or poster presentations for consideration to CVIR. Please submit your manuscript through the CVIR submission website on www.editorialmanager.com/cvir. Please note that all submissions have to comply with the “CVIR Instructions for Authors” specified on the CVIR submission website.

Radiation Protection Pavilion
The Radiation Protection Pavilion (RPP) is CIRSE’s interactive awareness campaign for radiation safety and dose management and is located in the exhibition hall. The RPP offers best-practice guides, a comprehensive programme of Radiation Safety Talks and information on the latest products for protection and dose management. Make sure to visit the Pavilion and learn more about how to best protect yourself, your patients and your team. Please find a detailed description of the initiative and its sponsors on pages 252-260 or visit www.cirse.org/rpp.

Registration Desk – Opening Hours
Friday, September 6  16:00-18:00
Saturday, September 7  07:00-18:00
Sunday, September 8  07:30-18:00
Monday, September 9  08:00-18:00
Tuesday, September 10  08:00-18:00
Wednesday, September 11  08:00-13:00

Smoking
The CIRSE Annual Meeting is a non-smoking congress. Smoking is permitted outside the congress centre only.
**Speaker Centre**

The Speaker Centre is located in the mezzanine of the congress centre. All material must be in English and provided on a USB flash drive to be placed on the central server onsite. All presentation files must be uploaded at least 3 hours prior to the beginning of the corresponding session.

Computers connected to the central server allowing access to the speakers’ presentations are available in every lecture room. These computers are equipped with Microsoft Windows 10 Professional and Microsoft Office Professional Plus 2016. Please note that speakers are not allowed to use their own laptops for their presentations.

**Opening Hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, September 6</td>
<td>16:00-18:30</td>
</tr>
<tr>
<td>Saturday, September 7</td>
<td>07:30-18:30</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>07:30-18:30</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>07:30-18:30</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>07:30-18:00</td>
</tr>
<tr>
<td>Wednesday, September 11</td>
<td>07:30-12:00</td>
</tr>
</tbody>
</table>

**Students’ Lounge**

The Students’ Lounge will act as a home base for all participants of the CIRSE 2019 Student Programme, enabling students to meet with their peers, have lunch together and find out more about IR and CIRSE in a relaxed, comfortable environment. The Students’ Lounge will also be the location of the Mentoring Breakfast and the Students’ Quiz.

**Technical Exhibition**

The CIRSE Technical Exhibition is located on the entrance level. Please find a floor plan of the exhibition on pages 274-275 and a detailed list of all exhibitors on pages 192-251.

**Opening Hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, September 7</td>
<td>09:00-18:00</td>
</tr>
<tr>
<td>Sunday, September 8</td>
<td>09:00-18:00</td>
</tr>
<tr>
<td>Monday, September 9</td>
<td>09:00-18:00</td>
</tr>
<tr>
<td>Tuesday, September 10</td>
<td>09:00-18:00</td>
</tr>
</tbody>
</table>
Trainees, Residents and young IRs
As in previous years, CIRSE will feature tailor-made content for IR trainees and residents. This includes four IR trainee sessions, several short talks at noon, the ETF networking event and the ETF Quiz, which all young IRs are invited to join in order to measure their IR knowledge through friendly rivalry.

Transportation in Barcelona

Public transportation
The Centre de Convencions Internacional de Barcelona “CCIB” can be reached with Metro line L4 – exit “El Maresme | Forum”.

All CIRSE 2019 delegates with full congress registration (scientific badge) will receive a complimentary "Hola BCN!" 5-day travel pass. This pass allows delegates to travel on 5 consecutive days within Zone 1, making the congress centre easily accessible during the congress dates.

Travel passes will be available at the e-badge stations and registration desk. Please be aware that travel passes are limited to one per person.

Taxis
Taxis will be available in front of the congress centre.
The cost to go to the city centre is €15-20.

Important Travel Notice: Wednesday, September 11
Please note that September 11 is Catalonia’s national holiday. It may be more difficult than usual to get around the city, as public ceremonies will be going on throughout the day.

For more information, please visit the "Hotels | Social Events | City Information" desk located in the entrance area.
September 2019

Read the latest CVIR issue with a special section dedicated to oncology:

• what IRs need to know about IO and
• oncology-specific procedures on targeted organs

www.cvironline.org/read
Session Types

Amazing Interventions
During this session, acclaimed experts in interventional radiology will talk about their most unusual and challenging procedures. The goal will be to highlight innovative ways in which interventional radiologists can solve difficult problems and overcome tough situations. The session aims to be both educational and entertaining.

Case-based Discussions
The Case-based Discussions are divided into several topics. This format is designed to provide a platform for experts with different skills and views, who can each present their unique approach. Interesting cases, where different treatment options seem possible, will be presented, followed by a lively discussion involving the speakers and the audience. These interactive sessions provide an excellent learning experience on how to approach and work through difficult cases.

CIRSE meets…
The "CIRSE meets..." programme has proved to be an important platform for establishing and strengthening the relations between CIRSE and other societies in the field of interventional and vascular therapy. At CIRSE 2019, CIRSE's guests will be APSCVIR and CAIR.

Clinical Evaluation Sessions
This session type offers a step-by-step guide through the disease management of different maladies. These clinical-focused training sessions will include multidisciplinary teams made up of the essential experts who design a patient’s care pathway and offer the best therapeutic measures. The sessions will analyse themes from a diagnostic point of view, including pros and cons of different therapy options, considerations before, during and after the procedure, possible complications and the follow-up of the patient.

Controversy Sessions
During Controversy Sessions, two experts will present opposing views on controversial and current topics, after which a short debate will ensue. The moderator will ask the audience which position they support both before and after each new topic in order to assess whether the talks have changed their opinions. For this purpose, voting facilities for the audience will be provided.

Expert Round Tables
The Expert Round Table sessions address important aspects of interventional radiology in an informal setting. Key opinion leaders will outline their views and preferred therapy options regarding select “hot topics”, and then engage in lively discussions with both their fellow speakers and the audience.
**Film Interpretation Quiz**
The Film Interpretation Quiz will consist of two teams who will compete against each other. The teams will be given cases to diagnose and suggest treatment. One of the principle aims of the film panel is to demonstrate the approach an expert takes towards the solution of a diagnostic/therapeutic problem. This will be undertaken in an entertaining fashion and is not to be missed! The process will be a team effort.

**Free Paper Sessions**
Researchers will present original papers on new and innovative aspects of cardiovascular and interventional radiology. Select papers will be grouped by clinical focus and presented at a series of sessions. There will be time for discussion between researchers and attendees after each presentation.

**First@CIRSE**
This Free Paper Session will feature the first data releases of several trials and studies on endovascular treatment.

**Super Tuesday**
This exclusive Free Paper Session will showcase high-class research and up-to-the-minute trial results which all interventional radiologists should be aware of.

**Focus Sessions**
Focus Sessions are designed to impart the latest knowledge on topics of interest to interventional specialists. These sessions are the backbone of the CIRSE meeting and are specifically chosen by the programme planning committee because of their importance in daily practice.

**Fundamental Courses**
Fundamental Courses cover a specific area of interventional radiology, focusing on basic principles and illustrating the procedure in a step-by-step fashion. They are designed for radiologists-in-training and new consultants, as well as for experienced consultants who require a refresher course on the subject.

**Hands-on Device Training**
The Hands-on Device Training (HDT) sessions provide an overview of the different devices and techniques available for specific topics. Following a kick-off presentation by the HDT coordinators, participants will have the opportunity to learn about the specifics, as well as the safe and effective use of the available technology in a hands-on setting. Each HDT will feature a round-table discussion, allowing participants time to ask questions and give feedback.

**Hot Topic Symposia**
The Hot Topic Symposia address controversial IR topics in the setting of a plenary session. Invited speakers will give brief lectures on important aspects of the subject under discussion. A major feature of these sessions will be a round-table discussion involving the speakers and the audience.
**Session Types**

**IR Trainee Sessions**
The IR Trainee Sessions at CIRSE are aimed specifically at trainees, residents and young IRs, and cover basic IR topics as well as practical issues relating to beginning a career in interventional radiology. These sessions will also address future IR technologies and challenges the next generation of IRs may face. Organised by CIRSE's European Trainee Forum (ETF), the IR Trainee Sessions are also an opportunity to meet peers and establish relationships with other young IRs across Europe.

**Morbidity & Mortality Conference**
The Morbidity and Mortality Conference will analyse interventional radiology cases which led to complications and/or deaths that could have been avoided. This session provides a valuable learning experience for everyone involved in interventional radiology. The session will be dedicated to vascular and non-vascular cases.

**News on Stage**
News on Stage sessions will feature presentations on the latest results from multi-centric trials, groundbreaking techniques and many more IR hot topics. These sessions will give delegates the opportunity to hear from the experts personally and engage with them and other key opinion leaders in active, lively discussions. The News on Stage area is specifically designed for large-screen oral presentations and discussions in an easy and informal atmosphere.

**Satellite Symposia**
Satellite Symposia are organised by industry partners and take place at lunchtime as well as in the morning and in the evening. During these sessions, cutting-edge information on interventional equipment and techniques is provided.

**Simulation Training**
This popular series of training sessions comprises a 20-minute round-table discussion with experts in the field delivering key knowledge and practical tips, followed by one hour of hands-on experience using high-fidelity simulators.

**Video Learning Sessions**
These sessions will feature stand-alone video presentations of interventions with the purpose of teaching procedural techniques and providing a brief overview of indications and results. The aim is to demonstrate the technical aspects of the specific intervention in the best possible way and to give the audience the possibility to ask questions.

**Workshops**
Workshops provide you with the chance to learn from your colleagues’ expertise in an informal, interactive manner. Each designated workshop will entail individual cases and discussion points with regard to the particular interventional topic. Attendees can contribute their opinions and ask questions in small groups.
Film Interpretation Quiz

Monday, September 9
14:30-15:15
Auditorium 1

Coordinators: L. Crocetti (Pisa/IT), G.J. O’Sullivan (Galway/IE)

The Film Interpretation Quiz is one of CIRSE’s most popular sessions and will consist of two teams who will compete against each other.

The teams will be given cases to diagnose and suggest treatment. One of the principle aims of the film panel is to demonstrate the approach an expert takes towards the solution of a diagnostic/therapeutic problem. This will be undertaken in an entertaining fashion and is not to be missed! The process will be a team effort.

Team A:
N. McEniff (Dublin/IE) – Team leader
A.M. Barnacle (London/UK)
M. Casares Santiago (Palma de Mallorca/ES)
S. Kee (Los Angeles, CA/US)

Team B:
R. Iezzi (Rome/IT) – Team leader
G. Eldem (Ankara/TR)
J. Garnon (Strasbourg/FR)
M.R. Meijerink (Amsterdam/NL)
Join us for this year’s Opening Ceremony!
All delegates including exhibitors are cordially invited.
News on Stage

News on Stage sessions will feature presentations on the latest results from multi-centric trials, groundbreaking techniques and many more IR hot topics. These sessions will give delegates the opportunity to hear from the experts personally and engage with them and other key opinion leaders in active, lively discussions. The News on Stage area is specifically designed for large-screen oral presentations and discussions in an easy and informal atmosphere.

Saturday, September 7, 13:15-14:15, News on Stage Area

NoS 404 Peripheral interventions

Moderators: E. Stabile (Naples/IT), G. Tepe (Rosenheim/DE)

404.1 ZILVERPASS study – ZILVER PTX versus bypass surgery for long femoro-popliteal lesions: final 12-month and preliminary 24-month results
M. Bosiers; Hamme/BE

404.2 Benefits of DEB post stenting in diabetic patients and males: subgroup analysis of the randomized Freeway stent study
J. Tacke †, K.A. Hausegger², S. Müller-Hülsbeck³, H. Schröder⁴, S. Stahnke⁵, J. Dambach⁶; ¹Passau/DE, ²Klagenfurt/AT, ³Flensburg/DE, ⁴Berlin/DE, ⁵Bonn/DE

404.3 Cost-effectiveness of a polymer-coated, paclitaxel-eluting stent (Eluvia) compared to a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention: a payer perspective
S. Müller-Hülsbeck¹, P.W.M. Elroy², R. Akehurst³, S.L. Amorosi⁴, C. Giretti⁵, R.I. Griffiths⁶, W.A. Gray⁷; ¹Flensburg/DE, ²Utrecht/NL, ³Sheffield/UK, ⁴Marlborough, MA/US, ⁵Milan/IT, ⁶Maple Grove, MN/US, ⁷Philadelphia, PA/US

K.R. Deloose; Dendermonde/BE

404.5 Cost-effectiveness of drug-eluting stents versus PTA with bail-out bare metal stents for infrapopliteal lesions in critical limb ischemia (PADI Trial)
T. Wakkie¹, M. Sreeni², L. Konijn¹, J. Wever¹, R. van Eps¹, H. Veger¹, L.C. van Dijk¹, W.P.T.M. Malí³, M. Maessen³, N. van Herpen³, H. van Overhagen¹; ¹The Hague/NL, ²Utrecht/NL, ³Arnhem/NL

404.6 The Lutonix® global drug coated balloon registry real world patients with below the knee disease
M. Lichtenberg¹, M. Brodmann², D. Scheinert³; ¹Arnsberg/DE, ²Graz/AT, ³Leipzig/DE

Come and meet authors of top-rated posters in an informal
Sunday, September 8, 13:15-14:15, News on Stage Area

NoS 1204 Embolisation

**Moderators:** M. Bezzi (Rome/IT), J.E. Jackson (London/UK)

1204.1 Ethylene vinyl alcohol copolymer (Onyx) for treatment of large venous vascular malformations: long term results and histology
_A.S. Gomes, P.A. Monteleone, S.V. Bukata, J.W. Sayre; Los Angeles, CA/US_

1204.2 Bronchial artery embolization for massive hemoptysis: experience from a tertiary referral center in Cape Town, South Africa
_H. Chung1, M. Wojno2, K.-L. Pool3; 1Palo Alto, CA/US, 2Cape Town/ZA, 3Los Angeles, CA/US_

1204.3 Retrospective multivariate study of the clinical outcomes in patients affected by different grades of varicocele treated using different endovascular approaches
_G. Bianchi, M.V.M. Micelli, P. Palumbo, A. Izzo, A.V. Giordano, S. Carducci, M. Varrassi, A. Barile, C. Masciocchi; L’Aquila/IT_

1204.4 Treatment of high-flow priapism: superselective arterial embolization
_G. de Magistris1, F. Pane1, F. Corvino1, F. Giurazza1, F. Amodio1, M. Coppola1, E. Cavaglià1, M. Silvestre1, G. Cangiano1, A. Borzelli2, A. Paladini2, R. Niola1; 1Naples/IT, 2Novara/IT_

1204.5 Diagnosis and management of thoracic and shoulder arteriovenous malformations
_W.F. Yakes; Englewood, CO/US_

1204.6 Percutaneous glue embolisation as a primary treatment for visceral pseudoaneurysms
_U. Gorsji, V. Bhatia, N. Kalra, M. Kang, M.S. Sandhu; Chandigarh/IN_

and open setting, join in lively debates and ask questions.
Monday, September 9, 13:15-14:15, News on Stage Area

**NoS 2004 Interventional oncology**

*Moderators: R. Lencioni (Pisa/IT), C.T. Sofocleous (New York, NY/US)*

2004.1 Performance of a new needle for the displacement of critical structure in thermal ablation  
*P. Auloge, R.L. Cazzato, J. Caudrelier, P.P. Rao, G. Koch, J. Garnon, A. Gangi; Strasbourg/FR*

2004.2 Effects of ablation on systemic therapy for metastatic pulmonary sarcoma: potential synergy?  
*K. Menon, A. Doshi, K. Ganjoo, D. Wang, G. Hwang; Stanford, CA/US*

2004.3 Randomized embolization trial for neuroendocrine tumors (RETNET): first safety report  

2004.4 Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis  
*T. Andrašina, M. Uher, T. Rohan, P. Matkulčík, J. Zavadil, B. Cechova, L. Jandurova, V. Válek; Brno/CZ*

2004.5 Transarterial chemoembolization with degradable starch microspheres (DSM-TACE) vs. selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma (HCC)  
*T.A. Auer, M. Jonczyk, F. Collettini, B. Hamm, B. Gebauer; Berlin/DE*

2004.6 Multimodality quantitative volumetric and metabolic assessment of early tumor response and survival in patients with uveal melanoma liver metastases undergoing Y90-radioembolization  

---

*Come and meet authors of top-rated posters in an informal*
News on Stage

Tuesday, September 10, 13:15-14:15, News on Stage Area

NoS 2802  From science to practice

Moderators: Y. Arai (Tokyo/JP), M.D. Darcy (St. Louis, MO/US)

2802.1 Perfusion imaging with 320-slice spiral computed tomography and color-coded digital subtraction angiography for assessing acute skeletal muscle ischemia-reperfusion injury in a rabbit model
C. Li; Guangzhou/CN

2802.2 Radiation exposure during transarterial chemoembolization: angio-CT versus cone-beam CT
L. Piron1, J. Le Roy1, C. Cassinotto1, J. Delicque1, A. Belgouri1, C. Allimant1, J.-P. Beregi2, J. Greffier2, N. Molinari1, B. Guiu1; 1Montpellier/FR, 2Nîmes/FR

2802.3 A randomized and controlled study comparing patient controlled and radiologist controlled intra-procedural conscious sedation, using midazolam and fentanyl, for patients undergoing insertion of a central venous line
W. Clements1, D. Sneddon1, H. Kavnoudias1, T. Joseph1, G.S. Goh1, J. Koukounaras1, T.M. Snow2; 1Melbourne, VIC/AU, 2Brisbane, QLD/AU

2802.4 Left distal Percutaneous Radial hEmostasis using a Truncated dEflation Algorithm; ldPROTEA: safety and nursing impact assessment
D. Klass, L. Cardarelli-Leite, A. Hadjivassiliou, J. Chung, D.M. Liu, S. Ho; Vancouver, BC/CA

2802.5 Women in interventional radiology: Australia’s gender gap
M. Foo1, J. Maingard2, M. Wang1, K. Phan3, R. Lim4, H.K. Kok5, R. Chandra2, M.J. Lee6, H. Asadi2, M. Brooks1; 1Heidelberg, VIC/AU, 2Clayton, VIC/AU, 3Liverpool, NSW/AU, 4Frankston, VIC/AU, 5Melbourne, VIC/AU, 6Dublin/IE

2802.6 Platform for preclinical MRI-guided focused ultrasound hyperthermia
U. Roy1, M. Fournelle2, S. Greiser1, R.V. Gorkum3, D. Speicher2, T. Grunwald1, S. Kozerke1, S. Tretbar2, L. Landgraf1, A. Melzer1; 1Leipzig/DE, 2St. Ingbert/DE, 3Zurich/CH

and open setting, join in lively debates and ask questions.
Open Access Articles

- are freely available online
- receive more citations
- are downloaded more often
- garner greater impact
- allow authors to retain the copyright

www.cvirendovascular.org
CIRSE 2019 will again feature a dedicated session for the first data release of several trials and studies on endovascular treatment, the authors themselves presenting the preliminary results.

Saturday, September 7, 16:15-17:15, Room 117
Free Paper Session

FP 601 FIRST@CIRSE
First data release on endovascular research

Moderators: F. Fanelli (Florence/IT), J.H. Rundback (Teaneck, NJ/US)

601.1 e-PTFE covered stent to treat stenosis in arteriovenous fistula: “first look” at the 12-month results from the randomized AVENEW study
B. Dolmatch; Mountain View, CA/US

601.2 Primary endpoint results of the IN.PACT AV access randomized trial: outcomes through six months
A. Holden; Auckland/NZ

601.3 Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoro-popliteal angioplasty: 2-year results of EffPac trial
U. Teichgräber; Jena/DE

601.4 Stellarex DCB in real world: 1000 patient analysis from the SAVER registry
B. Mees¹, F.E. Vermassen², G. Torsello³, A. Cremonesi⁴, A. Sauguet⁵; ¹Maastricht/NL, ²Ghent/BE, ³Münster/DE, ⁴Cotignola/IT, ⁵Toulouse/FR

601.5 ZILVER® PTX® drug-eluting peripheral stent: latest update
M.D. Dake; Tucson, AZ/US

601.6 Long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon vs. plain balloon angioplasty: a real-world study
K.P. Donas¹, A. Sohr¹, G.A. Pitoulias¹, F. Alfonso², G. Torsello³; ¹Münster/DE, ²Madrid/ES

This session is geared towards everyone, IRs young and old, and is not to be missed!
Hands-on Device Training

The Hands-on Device Training (HDT) sessions aim to provide an overview of the different devices and techniques available for specific topics as well as to allow hands-on experience for the participants.

After a short kick-off presentation by the HDT coordinators, participants will have the opportunity to learn about the specifics as well as safe and effective use of the available technology in an interactive setting.

Each HDT will feature a round-table discussion with the coordinators at the end of each session, allowing participants to ask questions and provide feedback.

Participating industry partners have been invited by CIRSE to provide an overview of their devices and technologies.

How to participate:

Please note that participation is free of charge, but places are limited to 25 people per session and will be allocated on a first come, first served basis.

As all Hands-on Device Training sessions offer practical medical training, participation is for qualified medical professionals only.
A CLOSER LOOK AT CLOSURE DEVICES

Closure devices are increasingly becoming a key element in all our vascular procedures. Positive results combined with a high rate of safety have contributed to their success. However, knowledge of the different systems available on the market is necessary to achieve even better results.

This Hands-on Device Training aims to provide an overview of the vascular closure devices currently available.

Saturday, September 7
CD-HDT 1 09:30-11:00
CD-HDT 2 12:30-14:00

Coordinators: J.-Y. Chun (London/UK), L. Marques (Flensburg/DE)

CENTRAL LINES AND PORTS

Central lines and ports are continually more and more important in the daily activities of interventional radiologists. Thanks to imaging and interventional capabilities, IRs are able to position these catheters in complex situations that other specialists cannot resolve.

This Hands-on Device Training will provide an overview of available devices.

Saturday, September 7
CLP-HDT 1 09:30-11:00
CLP-HDT 2 12:30-14:00

Coordinators: C.E. Althoff (Berlin/DE), J.A. Guirola (Zaragoza/ES)
**EMBOLISATION: MATERIALS AND TOOLS**

Embolisation is an important part of an IR’s work, and as such, it is essential to thoroughly understand how to perform this technique in order to avoid complications. Having substantial knowledge of available materials is absolutely necessary when selecting the most suitable device for any scenario.

This Hands-on Device Training (HDT) aims to provide an overview of the various embolic materials available as well as the different delivery techniques. Separate sessions will look at coils and plugs, liquid agents and particulate agents to ensure that participants are familiar with the most common embolic agents.

**Sunday, September 8**
- **EMT-HDT 1: liquid agents** 09:30-11:00
- **EMT-HDT 2: liquid agents** 12:30-14:00

Liquid embolic agents include polymers such as N-butyl cyanoacrylate glue and ethylene vinyl alcohol (Onyx), as well as sclerosants (alcohol, polidocanol, etc.). Liquid embolics are widely used for the management of haemorrhage, post-EVAR endoleaks and vascular malformations due to their penetrating and inflammation-inducing capacity. This Hands-on Device Training (HDT) will offer attendees the opportunity to explore and learn about the various types of liquid agents, as well as their specific advantages and disadvantages.

*Coordinators: L. Defreyne (Ghent/BE), J. Urbano (Madrid/ES)*

**Monday, September 9**
- **EMT-HDT 3: coils & plugs** 09:30-11:00
- **EMT-HDT 4: coils & plugs** 12:30-14:00

Metallic coils (pushable/injectable or detachable) and detachable plugs are established permanent mechanical embolic materials for the treatment of active bleeding, pseudoaneurysms and true aneurysms. Coils and plugs may also be used to prevent non-target embolisation or establish flow redistribution in patients undergoing transarterial tumour treatment, such as radioembolisation. This Hands-on Device Training (HDT) will offer attendees the opportunity to explore and learn about the various types of coils and plugs.

*Coordinators: M.C. Burgmans (Leiden/NL), M. Citone (Florence/IT)*
Tuesday, September 10
EMT-HDT 5: particulate agents 09:30-11:00
EMT-HDT 6: particulate agents 12:30-14:00

Today, particulate embolic agents are used both in emergency IR and interventional oncology due to their specific properties which allow distal penetration within the microvasculature. Certain particulate agents are also capable of loading and releasing chemotherapeutic drugs, enabling loco-regional endovascular chemotherapy. This Hands-on Device Training (HDT) will offer attendees the opportunity to become familiar with the various types of particulate agents and their indications.

*Coordinators: A.G. Rampoldi (Milan/IT), S. Spiliopoulos (Athens/GR)*

PERIPHERAL MECHANICAL THROMBECTOMY

Room 132

Treatment of patients with acute occlusions of the arterial or venous bed is becoming a more and more frequent occurrence. As technology has steadily developed, several systems have become available to help restore vessel patency in a quick, safe and efficient way.

This Hands-on Device Training aims to provide an overview of the different devices which are currently being used for the treatment of peripheral occlusive disease, including acute and chronic limb ischaemia.

Saturday, September 7
PMT-HDT 1 09:30-11:00
PMT-HDT 2 12:30-14:00

*Coordinators: R. de Graaf (Friedrichshafen/DE), D.K. Tsetis (Iraklion/GR)*
STROKE THROMBECTOMY

Room 132

Stroke thrombectomy represents a new frontier for interventional radiologists. The number of patients suffering from this pathological condition is increasing and, as a consequence, it is necessary for interventional radiologists to participate in these procedures. For this, it is essential to have abundant experience as well as excellent knowledge of anatomy and the techniques and materials to be used.

Participants at this Hands-on Device Training will have the chance to familiarise themselves with the most common thrombectomy devices.

Monday, September 9

ST-HDT 1 09:30-11:00
ST-HDT 2 12:30-14:00

Coordinators: A. Krajina (Hradec Králové/CZ), H. van Overhagen (The Hague/NL)

TUMOUR ABLATION

Room 111

Ablation plays a fundamental role in the minimally invasive treatment of cancer, and ablation technologies and equipment for live image guidance continue to develop quickly.

In order to stay up to date on these developments, this Hands-on Device Training (HDT) will offer separate sessions to look at radiofrequency ablation, microwave ablation and alternative techniques, including cryoablation and other image-guided technologies.

Sunday, September 8

TA-HDT 1: MWA 09:30-11:00
TA-HDT 2: MWA 12:30-14:00

Microwave ablation has been one of the last technologies to appear in the theatre of thermal ablation. Although the mechanism of action, coagulative necrosis, is similar to that of radiofrequency ablation, MWA has some potential advantages, like faster action, higher temperatures and a lower heat-sink effect. This Hands-on Device Training will offer attendees the opportunity to explore and learn about the latest commercially available technologies.

Coordinators: J.L. del Cura Rodriguez (Bilbao/ES), A. Veltri (Orbassano/IT)
This HDT will offer attendees the opportunity to look at radiofrequency ablation. In the last 10 to 15 years, technical developments in the available RFA systems have increased ablation volumes in a controllable, versatile and relatively inexpensive manner.

As the oldest and most widely used thermal ablation modality worldwide, RFA’s effectiveness and safety have been fully proven. Radiofrequency tumour ablation has shown to be a useful method for creating thermally induced coagulation necrosis in tissues being treated. The host of clinical applications for RFA has expanded and RF has accordingly gained widespread clinical use for the treatment of hepatic, renal, lung, soft tissue and bony malignancies. RFA may also provide a means for the palliation of cancer-related pain in patients with metastatic bone disease, which may be unresponsive to other therapies.

**Coordinators:** J.-Y. Gaubert (Marseille/FR), M. Tsitskari (Athens/GR)

Tuesday, September 10

**TA-HDT 5: Image guided navigation and targeting**

This Hands-on Device Training will offer attendees the opportunity to explore and learn about the latest commercially available image-guided technologies for treatment planning and real-time navigation, as well as incorporating multi-modality image fusion, robotics and other image-guided techniques.

**Coordinators:** C. Farrelly (Dublin/IE), R. Iezzi (Rome/IT)

Tuesday, September 10

**TA-HDT 6: Cryo- and laser ablation, IRE and electrochemotherapy**

Percutaneous ablation is a key approach used within the field of interventional oncology. There are a variety of different and ever-evolving ablation techniques beyond MWA and RFA. This HDT will offer attendees the opportunity to explore and learn about modern ablation technologies, including cryoablation, laser ablation and non-thermal ablation techniques such as electroporation and electrochemotherapy.

**Coordinators:** A.H. Mahnken (Marburg/DE), M.R. Meijerink (Amsterdam/NL)
VARICOSE VEINS

Varicose veins are a manifestation of chronic venous disease, which causes a significant impairment in quality of life for both men and women, physically and aesthetically. Recent developments in the endovascular treatment of saphenous vein reflux, which is the most common cause of varicose veins, led to a change in the treatment of varicose veins: from surgery to minimally invasive treatments, and from the OR to the office. Considering the increasing demand for treatment and growing involvement of interventional radiologists, it is essential to understand the timing of such interventions and acquire basic skills in the methodology.

This Hands-on Device Training (HDT), coordinated by two experienced IRs in the field, aims to provide an overview of the range of devices available and different techniques.

**Sunday, September 8**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>VV-HDT 1</td>
<td>09:30-11:00</td>
</tr>
<tr>
<td>VV-HDT 2</td>
<td>12:30-14:00</td>
</tr>
</tbody>
</table>

*Coordinators: J.M. Regi (Sheffield/UK), F. Veloso Gomes (Lisbon/PT)*

VERTEBRAL AUGMENTATION

Every day, interventional radiologists are approached by patients to resolve their vertebral pathologies. In recent years, considerable technological progress has been made as a consequence of the extraordinary outcomes of minimally invasive techniques, which have helped countless patients achieve pain relief and avoid many of the complications associated with open surgery.

In this Hands-on Device Training, vertebroplasty, kyphoplasty and balloon kyphoplasty will be discussed, and devices for each of these procedures will be presented and available for participants to practice with.

**Tuesday, September 10**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>VA-HDT 1</td>
<td>09:30-11:00</td>
</tr>
<tr>
<td>VA-HDT 2</td>
<td>12:30-14:00</td>
</tr>
</tbody>
</table>

*Coordinators: P.N.M. Lohle (Tilburg/NL), K.E. Wilhelm (Bonn/DE)*
Access the CIRSE Library for a wealth of IR knowledge:

- 18 congresses across 5 years, including CIRSE, ECIO, ET and IROS
- 2,894 posters
- 5,114 presentations
- 3,137 speakers from around the world
- 8 core topics

Tailor your searches with flexible search filters, browse individual slides, stay up to date with monthly topic packages and prepare for the EBIR with specially selected presentations.

CIRSE Members have free access!

Join now, or choose from our range of access options! Keeping up with the world of IR has never been so easy.

library.cirse.org
Safe sedation application during IR procedures

This practical workshop will give participants the opportunity to perform procedural sedation in a simulated environment and learn about the most common respiratory problems during procedural sedation, as well as which instruments are available to make these interventions safer.

The simulation set-up consists of a full-scale patient simulator with capnography, BIS monitoring and TIVA/TCI pumps. Participants will perform these therapies under the supervision of AQAI’s experienced trainers.

In the advanced sessions, participants can additionally perform sedations in high-risk patients, e.g. those with hypertonia, severe cardiac diseases or pulmonary diseases like COPD. Participants in these sessions should visit a basic session first or should have substantial experience in procedural sedation.

**Learning objectives**
- To apply procedural sedation using different approaches
- To identify complications and challenges during procedural sedation
- To assess the value of various monitoring technologies
- To recognise the added value of capnography during sedation
- To select appropriate sedation techniques in high-risk patients
- To identify limitations and situations where the help of an anaesthesiologist is mandatory

**Coordinators:** M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)

**Location**
Room 118

**How to participate:**
Please note that participation is free of charge, but places are limited to 18 people per session (12 for advanced slots) and will be allocated on a first come, first served basis.

As Safe Sedation Training sessions offer practical medical training, participation is for qualified medical professionals only.
Sunday, September 8
SED 1 – Safe Sedation Training 08:15-09:45
SED 2 – Safe Sedation Training 12:45-14:15
SED 3 – Safe Sedation Training 16:00-17:30

Monday, September 9
SED 4 – Safe Sedation Training (advanced) 08:15-09:45
SED 5 – Safe Sedation Training 12:45-14:15
SED 6 – Safe Sedation Training 16:00-17:30

Tuesday, September 10
SED 7 – Safe Sedation Training (advanced) 08:15-09:45
SED 8 – Safe Sedation Training 12:45-14:15
Simulation Training

Participants at the Simulation Training (SIM) sessions can follow live demonstrations of interventional techniques and practice certain procedures under the guidance of a technician and/or instructor.

This popular series of training sessions is comprised of a 20-minute round-table discussion with experts in the field delivering key knowledge and practical tips, followed by one hour of hands-on experience using high-fidelity simulators.

Each session is aimed at delegates with a specific level of experience (core, intermediate or advanced), and the delivery of each session is adaptable to respond to the delegates’ interests, with emphasis placed on small-group teaching, allowing for close interaction with the expert faculty.

The round-table discussions are themed around learning objectives which relate to a specific clinical or procedural topic.

Equipment and devices related to the specific topic will be available to demonstrate deployment techniques.

There is no pre-registration required for Simulation Training sessions. Participation will be free of charge, limited to eight delegates, and will be handled on a first come, first served basis. As SIM sessions offer practical medical training, participation is for qualified medical professionals only.

**Coordinators:** R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)

**Location**
Simulator Gallery

**How to participate:**

Please note that participation is free of charge, but places are limited to 8 people per group and will be allocated on a first come, first served basis.

As all Simulation Training sessions offer practical medical training, participation is for qualified medical professionals only.
Saturday, September 7 08:30-13:50
SIM 1: Prostatic artery embolisation: basics, current role and future perspectives (advanced)

Session organiser: H. Hoppe (Bern/CH)
Instructors: A. Augustin (Würzburg/DE), M.J. Glenck (Zurich/CH), S. Kos (Luzern/CH), N. Shaida (Cambridge/UK)

SIM 1.1 (group 1) 08:30-09:50
SIM 1.2 (group 2) 09:50-11:10
SIM 1.3 (group 3) 11:10-12:30
SIM 1.4 (group 4) 12:30-13:50

Each session is comprised of a 20-minute round-table discussion and 60-minute simulation training.

Learning objectives
• To understand the management, assessment, relevant vascular anatomy and imaging of patients with benign prostatic hyperplasia
• To become familiar with the materials used for prostatic artery embolisation and precautions to be taken with polyvinyl alcohol particles/microspheres
• To learn about optimal patient selection for prostatic artery embolisation
• To understand how to improve outcomes and how to prevent non-target embolisation
• To perform prostatic artery embolisation on a simulator
Sunday, September 8 08:30-13:50
SIM 2: Basic principles of mechanical thrombectomy in ischaemic stroke (advanced)

Session organiser: K.E. Wilhelm (Bonn/DE)
Instructors: L. De Paoli (Klagenfurt/AT), E.R. Gizewski (Innsbruck/AT), C.C. Pieper (Bonn/DE), T. Struffert (Giessen/DE)

SIM 2.1 (group 1) 08:30-09:50
SIM 2.2 (group 2) 09:50-11:10
SIM 2.3 (group 3) 11:10-12:30
SIM 2.4 (group 4) 12:30-13:50

Each session is comprised of a 20-minute round-table discussion and 60-minute simulation training.

Learning objectives
• To gather insights on the management, assessment and imaging of patients with acute ischaemic stroke
• To discuss the results of landmark trials in endovascular mechanical thrombectomy
• To become familiar with stent-based mechanical thrombectomy for acute middle cerebral artery occlusion
• To understand how to manage complications resulting from mechanical thrombectomy
• To learn how to perform mechanical thrombectomy on a simulator
Monday, September 9 08:30-13:50
SIM 3: Emergency embolisation in trauma: state of the art (intermediate)

Session organiser: R. Lely (Amsterdam/NL)
Instructors: M.W. de Haan (Maastricht/NL), G.S. Goh (Melbourne, VIC/AU),
I. Insausti Gorbea (Pamplona/ES), R.W. Van der Meer (Leiden/NL)

SIM 3.1 (group 1) 08:30-09:50
SIM 3.2 (group 2) 09:50-11:10
SIM 3.3 (group 3) 11:10-12:30
SIM 3.4 (group 4) 12:30-13:50

Each session is comprised of a 20-minute round-table discussion and 60-minute simulation training.

Learning objectives
• To reinforce the principles behind the management, assessment and imaging of patients with trauma
• To become aware of treatment techniques for embolisation of solid organs, the gastrointestinal tract and blood vessels
• To understand treatment algorithms and indications for embolisation in patients with trauma
• To learn how to improve results in embolisation
• To perform particulate or coil embolisation on a simulator
Tuesday, September 10  
08:30-13:50
SIM 4: Peripheral artery disease: angioplasty and stenting (core)

Session organiser: M.A. Ruffino (Turin/IT)
Instructors: C. Del Giudice (Paris/FR), F. Fluck (Würzburg/DE), A. Moelker (Rotterdam/NL), W.E.A. Saad (Washington, DC/US)

SIM 4.1 (group 1)  
08:30-09:50
SIM 4.2 (group 2)  
09:50-11:10
SIM 4.3 (group 3)  
11:10-12:30
SIM 4.4 (group 4)  
12:30-13:50

Each session is comprised of a 20-minute round-table discussion and 60-minute simulation training.

Learning objectives
• To understand the management, assessment and imaging of patients with peripheral arterial occlusive disease
• To realise current treatment strategies (exercise, best medical therapy, POBA, DCB angioplasty, DES, stent grafting, surgery)
• To understand indications, choice of treatment modality, and choice of different access routes for endovascular procedures
• To acquire skills on how to prevent/reduce complications
• To perform balloon angioplasty and stenting in simulated conditions
Saturday, September 7

08:30-09:30, Room 117

Focus Session

FS 101 Technologies and techniques in peripheral vascular disease: evolution and outstanding questions


101.1 Practice guidelines across societies: status and critical review
   J.A. Kaufman (Portland, OR/US)
101.2 Calcium solutions: which calcium needs treatment and how?
   K. Rocha-Singh (Springfield, IL/US)
101.3 Overcoming angiography limitations: rationale for IVUS-guided revascularisation
   F. Fanelli (Florence/IT)
101.4 Drugs, doses and excipients: DCBs under the spotlight
   G. Tepe (Rosenheim/DE)
101.5 Distinguishing between class effect and device/brand-specific features: how to decide what deserves adoption?
   M. Brodmann (Graz/AT)
101.6 Dissections: do they matter and how can they be managed?
   T. Zeller (Bad Krozingen/DE)

08:30-09:30, Room 115

Focus Session

FS 102 Pancreatic cancer: role of IR


102.1 Pain management
   M. Tsitskari (Athens/GR)
102.2 Irreversible electroporation
   M.R. Meijerink (Amsterdam/NL)
102.3 Thermal ablation
   K.P. van Lienden (Amsterdam/NL)
102.4 Intra-arterial chemotherapy
   T. Tanaka (Kashihara/JP)
Fundamental Course

FC 103 Management of benign musculoskeletal tumours

Moderators: F.H. Cornelis (Paris/FR), E.P. Eyheremendy (Buenos Aires/AR)

103.1 Diagnostics and imaging
   A. Feydy (Paris/FR)
103.2 Benign bone tumours: local therapies
   U. Pua (Singapore/SG)
103.3 Desmoids and desmoid fibromatosis: the case for ablation
   J. Garnon (Strasbourg/FR)
103.4 MR-guided focused ultrasound ablation for salvage treatment of desmoids
   S.M. Tutton (Milwaukee, WI/US)

Clinical Evaluation Course

CEC 104 Ilio-femoral venous stenting masterclass

Moderators: S. Black (London/UK), G.J. O’Sullivan (Galway/IE)

104.1 Pre-operative imaging
   C.W.K.P. Arnoldussen (Venlo/NL)
104.2 How to plan for ilio-femoral venous reconstruction: what kit do you need?
   A. Bravo De Laguna Taboada (Las Palmas/ES)
104.3 How in-flow determines the access point
   N. Karunanithy (London/UK)
104.4 Balloon angioplasty or balloon angioplasty plus stent
   S.D. Qanadli (Lausanne/CH)
104.5 Surgical salvage options
   H. Jalaie (Aachen/DE)
104.6 Post-operative care
   A. Diamantopoulos (London/UK)

Round-table discussion
08:30-09:30, Room 112
Expert Round Table

ERT 105  Artificial intelligence, machine learning and robotics in IR

Moderators: T.F. Jakobs (Munich/DE), M.R. Sapoval (Paris/FR)

Introduction

105.1 Deep learning techniques
K. Seals (Los Angeles, CA/US)

105.2 Artificial intelligence and augmented reality
M.E. Krokidis (Cambridge/UK)

105.3 Virtual reality in interventional radiology training
Z.J. Haskal (Charlottesville, VA/US)

105.4 Robotics development
R.H. Kassamali (Birmingham/UK)

Round-table discussion

Conclusion and take-home points

08:30-09:50, Simulator Gallery
Simulation Training

SIM 1.1  Prostatic artery embolisation: basics, current role and future perspectives (advanced)

Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)

Session organiser: H. Hoppe (Bern/CH)
Instructors: A. Augustin (Würzburg/DE), M.J. Glenck (Zurich/CH),
S. Kos (Luzern/CH), N. Shaida (Cambridge/UK)
08:30-09:30, Room 116

**Student Programme**

**SP 106 Introducing IR**

*Moderator: R.A. Morgan (London/UK)*

106.1 Welcome from the president & general introduction to IR  
*R.A. Morgan (London/UK)*

106.2 Introduction to the congress and student programme  
*T.J. Kroencke (Augsburg/DE), O.M. van Delden (Amsterdam/NL)*

106.3 IR and its applications in modern medicine  
*A. Gangi (Strasbourg/FR), C.A. Binkert (Winterthur/CH)*

106.4 IR training and career perspectives  
*G.C. Makris (Oxford/UK), S.M. Protto (Tampere/FL)*

09:30-11:00, Room 130

**Hands-on Device Training**

**CD-HDT 1 A closer look at closure devices**

*Coordinators: J.-Y. Chun (London/UK), L. Marques (Flensburg/DE)*

09:30-11:00, Room 111

**Hands-on Device Training**

**CLP-HDT 1 Central lines and ports**

*Coordinators: C.E. Althoff (Berlin/DE), J.A. Guirola (Zaragoza/ES)*

09:30-11:00, Room 132

**Hands-on Device Training**

**PMT-HDT 1 Peripheral mechanical thrombectomy**

*Coordinators: R. de Graaf (Friedrichshafen/DE), D.K. Tsetis (Iraklion/GR)*
09:50-11:10, Simulator Gallery

**Simulation Training**

**SIM 1.2 Prostatic artery embolisation: basics, current role and future perspectives** (advanced)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: H. Hoppe (Bern/CH)*

*Instructors: A. Augustin (Würzburg/DE), M.J. Glenck (Zurich/CH), S. Kos (Luzern/CH), N. Shaida (Cambridge/UK)*

10:00-11:00, Auditorium 1

**Hot Topic Symposium**

**HTS 201 Hot debates on drug-eluting technologies**

*Moderators: A. Holden (Auckland/NZ), K. Rocha-Singh (Springfield, IL/US)*

**Introduction**

201.1 RCTs, registries and the real world: what evidence is needed? What is doable and what is utopian?
*W.A. Gray (Philadelphia, PA/US)*

201.2 Is safety a real issue for drug-eluting devices in peripheral arterial disease?
*K.N. Katsanos (Patras/GR)*

201.3 Meta-analysis: critical review of the methods
*P. Jüni (Toronto, ON/CA)*

201.4 Where do we stand? Overview of current positions
*F. Fanelli (Florence/IT)*

**Round-table discussion**

*F. Fanelli (Florence/IT), W.A. Gray (Philadelphia, PA/US), A. Holden (Auckland/NZ), P. Jüni (Toronto, ON/CA), K.N. Katsanos (Patras/GR), M.J. Lee (Dublin/IE), K. Rocha-Singh (Springfield, IL/US), T. Zeller (Bad Krozingen/DE)*

**Conclusion and take-home points**
Fundamental Course

FC 202 Ablative therapies: the basics

*Moderators: R. Iezzi (Rome/IT), D.A. Woodrum (Rochester, MN/US)*

- **202.1 Radiofrequency ablation**
  *J.M. Abadal Villayandre (Madrid/ES)*
- **202.2 Microwave ablation**
  *R. Cioni (Pisa/IT)*
- **202.3 Cryoablation**
  *J.Y. Won (Seoul/KR)*
- **202.4 Irreversible electroporation**
  *H.J. Scheffer (Amsterdam/NL)*

Focus Session

FS 203 Future trends in spine treatments

*Moderators: G.C. Anselmetti (Milan/IT), P.N.M. Lohle (Tilburg/NL)*

- **203.1 Cements in the spine: percutaneous polymethylmethacrylate and beyond**
  *X. Buy (Bordeaux/FR)*
- **203.2 Spine implants**
  *A.D. Kelekis (Athens/GR)*
- **203.3 Intervertebral disc regeneration techniques**
  *D.P. Beall (Oklahoma City, OK/US)*
- **203.4 Minimally invasive therapies for spinal stenosis**
  *S. Marcia (Cagliari/IT)*
ERT 204  Portal hypertension management

Moderators: N. McEniff (Dublin/IE), S. Sabri (Washington, DC/US)

Introduction

204.1 The increasing role of TIPS in variceal bleeding
G. M. Richter (Stuttgart/DE)

204.2 TIPS for refractory ascites
R. Loffroy (Dijon/FR)

204.3 Budd-Chiari syndrome
O. M. van Delden (Amsterdam/NL)

204.4 Hepatic encephalopathy: prevention and management
G. Maleux (Leuven/BE)

Round-table discussion

Conclusion and take-home points

10:00-11:00, Room 116
Video Learning Session

VL 205 Embolisation

Moderators: L. Defreyne (Ghent/BE), J. B. Spies (Washington, DC/US)

205.1 Prostate embolisation
C. Bent (Bournemouth/UK)

205.2 Variceal embolisation as an adjunctive procedure to TIPS
Z. L. Bercu (Atlanta, GA/US)

205.3 Bronchial artery embolisation
S. Roy-Choudhury (Stoke on Trent/UK)
10:00-11:00, Room 113

IR Trainee Session

IRT 206 Future IR technologies

*Moderators: M.S. Hamady (London/UK), G.C. Makris (Oxford/UK)*

206.1 Augmented reality for interventional oncology  
*L. Solbiati (Rozzano/IT)*

206.2 Big data, AI and machine learning  
*K. Seals (Los Angeles, CA/US)*

206.3 Robotics and guided catheters  
*M.S. Hamady (London/UK)*

206.4 Virtual reality and interventional radiology  
*Z.J. Haskal (Charlottesville, VA/US)*

206.5 Panel discussion

11:10-12:30, Simulator Gallery

Simulation Training

SIM 1.3 Prostatic artery embolisation: basics, current role and future perspectives (advanced)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: H. Hoppe (Bern/CH)*

*Instructors: A. Augustin (Würzburg/DE), M.J. Glenck (Zurich/CH), S. Kos (Luzern/CH), N. Shaida (Cambridge/UK)*
11:30-12:30, Room 117

**Focus Session**

**FS 301 Real-world endovascular management of claudication**

*Moderators: T.J. Cleveland (Sheffield/UK), C.S. Pena (Miami, FL/US)*

- **301.1** How to treat long CTOs  
  Y. Gouëffic (Nantes/FR)
- **301.2** CTO crossing: true lumen or subintimal?  
  C. Hohl (Siegen/DE)
- **301.3** Is vessel preparation required for all lesions?  
  E. Blessing (Karlsbad/DE)
- **301.4** Role of debulking: lumen gain or more than that?  
  R. Sachar (Raleigh, NC/US)
- **301.5** Drug-eluting technologies in long, real-world fem-pop segments: review of evidence  
  M.K. Razavi (Orange, CA/US)
- **301.6** DCB, DES or BMS?  
  K.R. Deloose (Dendermonde/BE)

11:30-12:30, Auditorium 2

**Clinical Evaluation Course**

**CEC 302 Intrahepatic cholangiocarcinoma**

*Moderators: A. Denys (Lausanne/CH), U. Pua (Singapore/SG)*

- **302.1** Update on recent guidelines  
  M. Bezzi (Rome/IT)
- **302.2** Established systemic therapies and pivotal trials  
  J.I. Bilbao (Pamplona/ES)
- **302.3** The surgeon’s perspective  
  D. Seehofer (Leipzig/DE)
- **302.4** Is ablation alone enough?  
  R. Duran (Lausanne/CH)
- **302.5** Intra-arterial therapies: transcatheter arterial chemoembolisation first  
  F. Orsi (Milan/IT)
- **302.6** Intra-arterial therapies: transarterial radioembolisation first  
  T.K. Helmberger (Munich/DE)

Round-table discussion
11:30-12:30, Room 112

**Focus Session**

**FS 303  Lymphatic interventions**


- 303.1 Classification and diagnosis of lymphatic malformations  
  *A. Alonso Burgos (Madrid/ES)*
- 303.2 Interventional therapy for malformations  
  *R. Müller-Wille (Regensburg/DE)*
- 303.3 Paediatric lymphatic malformations  
  *W.A. Wohlgemuth (Halle/DE)*
- 303.4 Challenging chylothorax and chyloperitoneum  
  *W. Prevoo (Amsterdam/NL)*

11:30-12:30, Auditorium 1

**Focus Session**

**FS 304  Superior vena cava syndromes**

*Moderators: G.S. Goh (Melbourne, VIC/AU), R. Lakshminarayan (Hull/UK)*

- 304.1 Malignant occlusion  
  *L. Tselikas (Villejuif/FR)*
- 304.2 Catheter-related superior vena cava syndromes  
  *J.G. Caridi (New Orleans, LA/US)*
- 304.3 Techniques for recanalisation  
  *M. Guimaraes (Charleston, SC/US)*
- 304.4 Other therapeutic options  
  *H. Jalaie (Aachen/DE)*
11:30-12:30, Room 116

**Controversy Session**

**CS 305** Fibroids and adenomyosis

*Moderators: M.P. Kohi (San Francisco, CA/US), D.A. Valenti (Montreal, QC/CA)*

305.1 UFE is a fertility-preserving procedure: pro
   *J.B. Spies (Washington, DC/US)*
305.2 UFE is a fertility-preserving procedure: con
   *A. Torre (Nottingham/UK)*
305.3 Embolisation for adenomyosis: pro
   *P.N.M. Lohle (Tilburg/NL)*
305.4 Embolisation for adenomyosis: con
   *F. Sorbi (Florence/IT)*
305.5 HIFU is better than embolisation: pro
   *M. Matzko (Dachau/DE)*
305.6 HIFU is better than embolisation: con
   *J.-P. Pelage (Caen/FR)*

11:30-12:30, Room 113

**CIRSE meets**

**CM 306** CIRSE meets APSCVIR

*Moderators: A. Holden (Auckland/NZ), R.A. Morgan (London/UK)*

306.1 Interventional radiology for the management of trauma patients
   *C.W. Kim (Busan/KR)*
306.2 New developments in TACE: super-selective and balloon-assisted TACE
   *T. Hasebe (Hachioji, Tokyo/JP)*
306.3 Experience in developing an IR practice in Myanmar, a developing country in Asia
   *K.Z. Ya (Yangon/MM)*
12:30-14:00, Room 130

**Hands-on Device Training**

**CD-HDT 2**  
A closer look at closure devices  

*Coordinators: J.-Y. Chun (London/UK), L. Marques (Flensburg/DE)*

---

12:30-14:00, Room 111

**Hands-on Device Training**

**CLP-HDT 2**  
Central lines and ports  

*Coordinators: C.E. Althoff (Berlin/DE), J.A. Guirola (Zaragoza/ES)*

---

12:30-13:50, Simulator Gallery

**Simulation Training**

**SIM 1.4**  
Prostatic artery embolisation: basics, current role and future perspectives (advanced)  

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: H. Hoppe (Bern/CH)*

*Instructors: A. Augustin (Würzburg/DE), M.J. Glenck (Zurich/CH), S. Kos (Luzern/CH), N. Shaida (Cambridge/UK)*

---

13:00-14:00

**Satellite Symposia**

For the detailed programmes, please refer to pages 146-147.
13:15-14:15, News on Stage Area

News on Stage

NoS 404 Peripheral interventions

Moderators: E. Stabile (Naples/IT), G. Tepe (Rosenheim/DE)

404.1 ZILVERPASS study - ZILVER PTX versus bypass surgery for long femoropopliteal lesions: final 12-month and preliminary 24-month results
M. Bosiers; Hamme/BE

404.2 Benefits of DEB post stenting in diabetic patients and males: subgroup analysis of the randomized Freeway stent study

404.3 Cost-effectiveness of a polymer-coated, paclitaxel-eluting stent (Eluvia) compared to a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention: a payer perspective

K.R. Deloose; Dendermonde/BE

404.5 Cost-effectiveness of drug-eluting stents versus PTA with bail-out bare metal stents for infrapopliteal lesions in critical limb ischemia (PADI Trial)

404.6 The Lutonix® global drug coated balloon registry real world patients with below the knee disease
M. Lichtenberg, M. Brodmann, D. Scheinert; Arnsberg/DE, Graz/AT, Leipzig/DE

14:00-14:30

Satellite Symposium

For the detailed programme, please refer to page 147.
14:30-16:00, Auditorium 1

**OP 500  Opening and Awards Ceremony**

Welcome Addresses

**CVIR Editor’s Medal Award:**
M.R. Meijerink (Amsterdam/NL), R.S. Puijk (Amsterdam/NL)

**The Award of Excellence and Innovation in IR:**
(R.W. Günther Foundation Award)
B. Guiu (Montpellier/FR) & M.T. Boulin (Dijon/FR)

**Distinguished Fellow: V. Bérczi** (Budapest/HU)
Laudation: T.J. Cleveland (Sheffield/UK)

**Distinguished Fellow: R.D. García-Mónaco** (Buenos Aires/AR)
Laudation: E. Brountzos (Athens/GR)

**Distinguished Fellow: J.E. Jackson** (London/UK)
Laudation: A.M. Barnacle (London/UK)

**Gold Medal: T. de Baère** (Villejuif/FR)
Laudation: J. Palussière (Bordeaux/FR)
FP 601 FIRST@CIRSE
First data release on endovascular research

Moderators: F. Fanelli (Florence/IT), J.H. Rundback (Teaneck, NJ/US)

601.1 e-PTFE covered stent to treat stenosis in arteriovenous fistula: “first look” at the 12-month results from the randomized AVeNEW study
B. Dolmatch; Mountain View, CA/US

601.2 Primary endpoint results of the IN.PACT AV access randomized trial: outcomes through six months
A. Holden; Auckland/NZ

601.3 Efficacy and safety of a novel paclitaxel-nano-coated balloon for femoro-popliteal angioplasty: 2-year results of EffPac trial
U. Teichgräber; Jena/DE

601.4 Stellarex DCB in real world: 1000 patient analysis from the SAVER registry
B. Mees¹, F.E. Vermassen², G. Torsello³, A. Cremonesi⁴, A. Sauguet⁵;
¹Maastricht/NL, ²Ghent/BE, ³Münster/DE, ⁴Cotignola/IT, ⁵Toulouse/FR

601.5 ZILVER® PTX® drug-eluting peripheral stent: latest update
M.D. Dake; Tucson, AZ/US

601.6 Long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon vs. plain balloon angioplasty: a real-world study
K.P. Donas¹, A. Sohr¹, G.A. Pitoulias¹, F. Alfonso², G. Torsello¹;
¹Münster/DE, ²Madrid/ES
16:15-17:15, Auditorium 2

**Expert Round Table**

**ERT 602** Colorectal liver metastases: treatment with curative intent

*Moderators: A. Adam (London/UK), L.M. Kenny (Brisbane, QLD/AU)*

Introduction

- 602.1 State-of-the-art imaging
  *R.G.H. Beets-Tan (Amsterdam/NL)*

- 602.2 The oncologist’s point of view
  *M. Trepel (Augsburg/DE)*

- 602.3 The surgeon’s point of view
  *to be announced*

- 602.4 The IR’s point of view
  *I. Bargellini (Pisa/IT)*

Round-table discussion

Conclusion and take-home points

16:15-17:15, Room 115

**Case-based Discussion**

**CBD 603** Treatment of abdominal fluid collections

*Moderators: M. Citone (Florence/IT), T. Sabharwal (London/UK)*

Introduction

- 603.1 Sclerotherapy of cysts
  *J.-M. Correas (Paris/FR)*

- 603.2 Treatment of hydatid cysts
  *O. Akhan (Ankara/TR)*

- 603.3 Necrotising pancreatitis
  *N. Zorger (Regensburg/DE)*

- 603.4 Complicated pelvic abscesses
  *A.M. Ierardi (Milan/IT)*

Conclusion and take-home points
16:15-17:15, Room 133

**Workshop**

**WS 604 Varicose veins**

604.1 *D. Karnabatidis (Patras/GR)*
604.2 *A. Willis (Birmingham/UK)*

16:15-17:15, Room 112

**Clinical Evaluation Course**

**CEC 605 Management of patients with benign prostate hyperplasia**

*Moderators: F.C. Carnevale (São Paulo/BR), O. Pellerin (Paris/FR)*

605.1 Underlying pathology and work-up  
*M.J. Speakman (Trull, Taunton/UK)*

605.2 Imaging  
*T. Bilhim (Lisbon/PT)*

605.3 Patient selection for PAE: good and bad candidates  
*J.M. Da Motta Leal Filho (São Paulo/BR)*

605.4 Embolisation technique  
*T. Bryant (Southampton/UK)*

605.5 Results and trials  
*M.R. Sapoval (Paris/FR)*

605.6 The surgeon's view  
*G. Siena (Florence/IT)*

Round-table discussion

16:15-17:15, Room 116

**Focus Session**

**FS 606 Collecting and evaluating evidence in IR**

*Moderators: M.S. Johnson (Indianapolis, IN/US), S.D. Qanadli (Lausanne/CH)*

606.1 How to collect high-quality data in peripheral arterial disease  
*G. Chatellier (Paris/FR)*

606.2 How to collect high-quality data in interventional oncology  
*J. Ricke (Munich/DE)*

606.3 How to perform high-quality meta-analysis and systematic reviews in IR  
*S. Sharma (Delhi/IN)*

606.4 How to interpret scientific articles in IR  
*K.A. Hausegger (Klagenfurt/AT)*

---
e-voting  
**recommended for EBIR preparation**
Free Paper Session

FP 607 Spinal interventions

Moderators: J.W. Jennings (St. Louis, MO/US), C.M. Sommer (Heidelberg/DE)

607.1 CT-guided pulsed radiofrequency for the treatment of acute low back pain and sciatica: 1-year follow-up
A. Napoli, S. Dababou, C. Marrocchio, R. Scipione, G. Alfieri, D. Fierro, C. Catalano; Rome/IT

607.2 Long term outcome from CT-guided transforaminal cervical epidural injection for pain and function. A prospective study including correlation with MRI appearances
Z.A.H. Aldin1, H. Mahmoud1, K. St Pierre2, T. Sadik1, M. Ahmed1, Z. Danawi1, A. Gul1, M.S. Hamady2, A.S. Syed-Noor3; 1Essex/UK, 2London/UK, 3Umea/SE

607.3 Preliminary results of percutaneous treatment of degenerative disc disease with intradiscal lumbar interbody fusion
R. Fiori, L. Speritiagliozi, A. D’Onofrio, M. Forcina, C. Di Donna, A.U. Cavallo, R. Floris; Rome/IT

607.4 Evaluation of the biomechanical performance of a novel transpedicular PEEK implant for the treatment of vertebral compression fracture

607.5 Does vertebroplasty increase the risk of subsequent vertebral compression fracture? An evidence-based review of the literature.
C.A. Byrne1, M.P. Bolger2, L. Greene1, A.E. Stroiescu1, J.B. Hennebry1, A.G. Ryan1; 1Waterford/IE, 2Dublin/IE

607.6 Safety and effectiveness of the SpineJack® system versus the KyphX Xpander® inflatable bone tamp for the reduction of vertebral compression fractures: a prospective, international, multicenter, randomized clinical trial (SAKOS study)

607.7 Preventive vertebroplasty for long-term consolidation of vertebral metastases
F. Deschamps, A. Delpla, L. Tselikas, T. de Baère; Villejuif/FR
16:15-17:15, Room 114

Free Paper Session

FP 608  Dialysis and AV fistula

Moderators: D.A. Brisbois (Liège/BE), D.K. Rajan (Toronto, ON/CA)

608.1 Significant reduction in radiation using intraoperative ultrasound and the 4 French instead of 6 Fr. WavelinQ endoAVF system in creating endovascular AV-fistulas

T.M. Steinke; Duesseldorf/DE

608.2 Initial experience with the Covera™ covered stent for the treatment of dysfunctional or thrombosed arterio-venous grafts. A retrospective analysis of 64 patients

P.N. Papadimatos, P.M. Kitrou, K.N. Katsanos, M. Theofanis, M. Papasotiriou, S. Papadoulas, D. Karnabatidis; Patras/GR

608.3 Stentgrafts as an endovascular option for hemodialysis-related venous occlusive disease (VOD)

T.M. Steinke, L. Nuth; Duesseldorf/DE

608.4 Outcomes of sharp recanalization for treatment of upper extremity central venous occlusions

H. Chung¹, D.Y. Sze², J. Louie²; ¹Palo Alto, CA/US, ²Stanford, CA/US

608.5 The Lutonix Global AV Registry: final 6-month results and subgroup analysis of target lesion location

P.M. Kitrou; Patras/GR

608.6 Safety and efficacy of midline and peripherally inserted central catheter for intravenous therapy: a randomized controlled trial


608.7 Impact of subcutaneous tunnels on peripherally inserted catheter placement: a multicenter retrospective study


16:15-16:35

Satellite Symposium

For the detailed programme, please refer to page 148.
17:30-18:30, Room 117

**Focus Session**

**FS 701 Management of real-world critical limb ischaemia**

*Moderators: M. Brodmann (Graz/AT), T. Rand (Vienna/AT)*

701.1 Foot perfusion assessment: the emerging role of imaging  
J.A. Reekers (Amsterdam/NL)

701.2 Angiosome re-interpretation: which vessel to open, when to insist and when to stop  
S. Kum (Singapore/SG)

701.3 The resurgence of DCB in BTK  
J.H. Rundback (Teaneck, NJ/US)

701.4 Indications and prerequisites for intervening below the ankle  
M.G. Manzi (Abano Terme/IT)

701.5 Managing the “desert foot”: new options for no-option patients?  
R. Ferraresi (Bergamo/IT)

701.6 Beyond drug-eluting devices  
A. Holden (Auckland/NZ)

17:30-18:30, Room 116

**Workshop**

**WS 702 Transcatheter arterial chemoembolisation**

702.1 F. Nasser (São Paulo/BR)

702.2 M. Burrel (Barcelona/ES)

17:30-18:30, Room 133

**Workshop**

**WS 703 Biopsies**

703.1 R. Marcello (Rome/IT)

703.2 S. Stojanovic (Novi Sad/RS)
Scientific Programme – Saturday, September 7

17:30-18:30, Room 113
Free Paper Session
FP 704 Biliary interventions

Moderators: M.E. Krokidis (Cambridge/UK), F. Mondaini (Florence/IT)

704.1 Simulation of the biliary metal stent recanalisation using endoluminal irreversible electroporation on porcine liver – in vivo experiment

704.2 Percutaneous endoluminal RFA & stenting for biliary and pancreatic duct recanalization in cases of unresectable cancer of the head of pancreas
M. Mizandari1, T. Azrumelashvili1, N. Habib2; ¹Tbilisi/GE, ²London/UK

704.3 ReCAAP (retrograde CBD access with anterograde puncture) technique to cross challenging proximal biliary strictures

704.4 Novel use of a disposable, single-use, digital endoscope for percutaneous transhepatic cholangioscopy: technical success, advantages, and cost comparison

704.5 Combined fluoroscopic and endoscopic approach to performing endoscopic ultrasound-guided hepatogastrostomy (EUS-HGS) in patients with malignant biliary obstruction
B. Moosavi, Y.-I. Chen, D.A. Valenti, L.-M.N.J. Boucher, T. Cabrera, K. Muchantef, A. Bessissow; Montreal, QC/CA

704.6 Biodegradable versus multiple plastic stent implantation in benign biliary strictures: A systematic review and meta-analysis
G.G.G. Almeida, P. Donato; Coimbra/PT

704.7 Preoperative virtual planning, 3D printing, and computer-assisted radiology and surgery (CARS) for intractable biliary strictures after liver transplantation
17:30-18:30, Room 114

**Free Paper Session**

**FP 705  Non-vascular interventions**

*Moderators: C. Nice (Newcastle-upon-Tyne/UK), M. Pieraccini (Grosseto/IT)*

705.1 Computed tomography guided percutaneous radiofrequency ablation of the splanchnic nerves for pain reduction in patients with pancreatic cancer: a single center study

*M. Ioannidi, Mazioti-Filippiadis, L. Reppas, A.D. Kelekis, E. Brountzos, N.L. Kelekis, D.K. Filippiadis; Athens/GR*

705.2 CT-guided gasserian ganglion continuous radiofrequency ablation for the treatment of trigeminal neuralgia

*M. Tsitsikari1, P. Zavridis2, D.K. Filippiadis3; 1Athens/GR, 2Nicosia/CY*

705.3 Percutaneous sclerotherapy of head and neck cystic malformations: ten years experience

*I. Paladini, R. Menozzi, A. Gritti, A. Gemignani, A. Andreone, E. Epifani, C. Marcato; Parma/IT*

705.4 Image-guided percutaneous sclerotherapy of orbital low flow vascular malformations

*O. Abdelaziz, K. Elessawy, F. Hassan, S. Emad-Eldin, R. Elessawy; Cairo/EG*

705.5 Radiofrequency treatment of benign symptomatic thyroid nodules: initial success experience of a Latin American reference center


705.6 IR and EUS guided gastro-jejunal bypass: the McGill experience

*A. Ngo, Y.-I. Chen, D.A. Valenti, L.-M.N.J. Boucher, T. Cabrera, K. Muchantef, A. Bessissow; Montreal, QC/CA*

705.7 Safety of lusutrombopag for thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure: pooled safety data from 3 studies

FP 706  Radiation safety issues

Moderators: G. Bartal (Kfar-Saba/IL), W. Jaschke (Innsbruck/AT)

706.1 Advanced robotic angiography systems for image guidance during conventional transarterial chemoembolization: impact on radiation-dose and image-quality
L.S. Alizadeh, T.J. Vogl, R. Maeder, N.N. Naguib; Frankfurt/DE

706.2 Chronic radiodermatitis following interventional radiology
J. Guersen, M. Guesnier, L. Cassagnes, B. Pereira, P. Motreff, P. Chabrot, L. Boyer, M. D’Incan; Clermont-Ferrand/FR

706.3 Surfacер inside out system – single center use demonstrates safe and effective performance and significant reduction in radiation in comparison to standard recanalisation procedures in total central venous occlusion
T.M. Steinke, L. Nuth; Duesseldorf/DE

706.4 Radiation protection – why take the risk? A study utilising real-time dose monitoring
C. Aleman, K. Harborne, W.R. Thomas, G. Hickson; Birmingham/UK

706.5 Radiation exposure in prostatic artery embolization (PAE) dependent of the interventional radiologist – implication on the procedure and protocol optimization
M. Zeile1, R.M. Wentz1, D. Rothfuchs1, M. Karul1, H.D. Nagel2, C.R. Habermann1; 1Hamburg/DE, 2Buchholz/DE

706.6 Investigating the clinical value of pelvic parametric X-ray angiography for image guidance in prostatic artery embolization
L.S. Alizadeh1, T.J. Vogl1, D. Szöllősi2, M. Gyánő2, K. Szigeti2, S. Osváth2, J.P. Kiss2, V.I. Óriás2; 1Frankfurt/DE, 2Budapest/HU

706.7 Optimizing cone-beam-CT in prostatic artery embolization (PAE) to reduce radiation exposure – proposition of a CBCT classification in PAE
M. Zeile1, R.M. Wentz1, D. Rothfuchs1, H.D. Nagel2, P. Steffen1, C.R. Habermann1; 1Hamburg/DE, 2Buchholz/DE
WITHDRAWN
Sunday, September 8

08:00-08:20
**Satellite Symposia**

For the detailed programmes, please refer to page 149.

08:15-09:45, Room 118
**Safe Sedation Training**
**SED 1 Safe sedation application during IR procedures**

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*

08:30-09:30, Auditorium 2
**Focus Session**
**FS 901 The NICE guidelines: nice or not so nice?**

*Moderators: R.M. Greenhalgh (London/UK), M.S. Hamady (London/UK)*

901.1 Reasons for NICE
*C.J. Hammond (Leeds/UK)*

901.2 Why NICE cannot be implemented
*M.P. Jenkins (London/UK)*

901.3 Why are other guidelines different?
*C.S. Pena (Miami, FL/US)*

901.4 How to improve long-term success of EVAR
*A. Holden (Auckland/NZ)*
08:30-09:30, Auditorium 1

**Clinical Evaluation Course**

**CEC 902 Diabetic foot**

*Moderators: R. Ferraresi (Bergamo/IT), S. Kum (Singapore/SG)*

- **902.1 Diabetic patient management**
  G. Clerici (Bergamo/IT)

- **902.2 Clinical evaluation of the lower limbs**
  W.A. Gray (Philadelphia, PA/US)

- **902.3 Pre-treatment vascular imaging**
  O. Mironov (Hamilton, ON/CA)

- **902.4 Percutaneous revascularisation**
  M. Palena (Abano Terme/IT)

- **902.5 Bypass and amputation**
  C.P. Twine (Bristol/UK)

- **902.6 Aftercare and rehabilitation**
  M. Monami (Florence/IT)

Round-table discussion

08:30-09:30, Room 112

**Expert Round Table**

**ERT 903 Colorectal cancer lung metastasis**

*Moderators: L. Crocetti (Pisa/IT), T.F. Jakobs (Munich/DE)*

**Introduction**

- **903.1 Concept of oligometastasis**
  T. de Baère (Villejuif/FR)

- **903.2 Advances in lung surgery**
  D.A. Saldaña Garrido (Madrid/ES)

- **903.3 Thermal ablation**
  J. Palussière (Bordeaux/FR)

- **903.4 Stereotactic body radiotherapy**
  R. Sharma (London/UK)

Round-table discussion

Conclusion and take-home points
08:30-09:30, Room 116

**Fundamental Course**

**FC 904  Pain management**

*Moderators: D.K. Filippiadis (Athens/GR), P.M. Paprottka (Munich/DE)*

- **904.1** Interventional radiology techniques for sports athletes  
  *L.M. Sconfienza (Milan/IT)*

- **904.2** Pulsed radiofrequency stimulation for pain syndromes  
  *S. Masala (Rome/IT)*

- **904.3** Neurolysis for benign pain  
  *C.S. Georgiades (Baltimore, MD/US)*

- **904.4** Neurolysis for malignant pain  
  *M. Pantel (The Hague/NL)*

08:30-09:30, Room 117

**Focus Session**

**FS 905  Pre-operative portal vein embolisation**

*Moderators: R.-T. Hoffmann (Dresden/DE), K.P. van Lienden (Amsterdam/NL)*

- **905.1** Indications and patient selection  
  *B. Guiu (Montpellier/FR)*

- **905.2** Technique and materials  
  *D.C. Madoff (New Haven, CT/US)*

- **905.3** Augmented portal vein embolisation techniques  
  *A. Lunardi (Pisa/IT)*

- **905.4** Follow-up and complications  
  *B. Gebauer (Berlin/DE)*

08:30-09:50, Simulator Gallery

**Simulation Training**

**SIM 2.1  Basic principles of mechanical thrombectomy in ischaemic stroke** (advanced)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: K.E. Wilhelm (Bonn/DE)*

*Instructors: L. De Paoli (Klagenfurt/AT), E.R. Gizewski (Innsbruck/AT), C.C. Pieper (Bonn/DE), T. Struffert (Giessen/DE)*
09:30-11:00, Room 130
**Hands-on Device Training**

**EMT-HDT 1** Embolisation: materials and tools – liquid agents

*Coordinators: L. Defreyne (Ghent/BE), J. Urbano (Madrid/ES)*

09:30-11:00, Room 111
**Hands-on Device Training**

**TA-HDT 1** Tumour ablation – MWA

*Coordinators: J.L. Del Cura Rodriguez (Bilbao/ES), A. Veltri (Orbassano/IT)*

09:30-11:00, Room 132
**Hands-on Device Training**

**VV-HDT 1** Varicose veins

*Coordinators: J.M. Regi (Sheffield/UK), F. Veloso Gomes (Lisbon/PT)*

09:50-11:10, Simulator Gallery
**Simulation Training**

**SIM 2.2** Basic principles of mechanical thrombectomy in ischaemic stroke (advanced)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: K.E. Wilhelm (Bonn/DE)*

*Instructors: L. De Paoli (Klagenfurt/AT), E.R. Gizewski (Innsbruck/AT), C.C. Pieper (Bonn/DE), T. Struffert (Giessen/DE)
10:00-11:00, Auditorium 2

Focus Session

FS 1001 Acute type B dissection

Moderators: M.S. Hamady (London/UK), H. Rousseau (Toulouse/FR)

- 1001.1 How to define the need for urgent TEVAR
  M.D. Dake (Tucson, AZ/US)
- 1001.2 When is TEVAR alone not enough?
  G.M. Richter (Stuttgart/DE)
- 1001.3 Primary extended techniques
  E. Verhoeven (Nuremberg/DE)
- 1001.4 Outcome of TEVAR for acute type B dissection
  C. Nienaber (London/UK)

10:00-11:00, Room 117

Fundamental Course

FC 1002 Update on drug-eluting technologies

Moderators: M.K. Razavi (Orange, CA/US), T. Zeller (Bad Krozingen/DE)

- 1002.1 Different drugs and mechanisms of action
  S. Spiliopoulos (Athens/GR)
- 1002.2 Drug-coated balloons: are there any differences?
  G. Tepe (Rosenheim/DE)
- 1002.3 Drug-eluting stents: are there any differences?
  S. Müller-Hülsbeck (Flensburg/DE)
- 1002.4 Adjunctive therapies to enhance drug-eluting efficacy
  A. Holden (Auckland/NZ)

10:00-11:00, Room 116

Video Learning Session

VL 1003 Interventional Oncology

Moderators: I. Bargellini (Pisa/IT), K. Malagari (Athens/GR)

- 1003.1 DEB TACE for hepatic metastasis in colorectal cancer
  F. Orsi (Milan/IT)
- 1003.2 Thermoablation in primary or secondary lung cancer
  M. Al Ahmar (Villejuif/FR)
- 1003.3 Renal cryoablation
  E. de Kerviler (Paris/FR)
ERT 1004  
**Vertebral augmentation: alive and kicking**

*Moderators: G.C. Anselmetti (Milan/IT), D.P. Beall (Oklahoma City, OK/US)*

Introduction

1004.1 The latest data on percutaneous vertebroplasty  
*A.G. Ryan (Waterford City/IE)*

1004.2 The role of spinal surgery  
*P. Clavert (Strasbourg/FR)*

1004.3 The rheumatologist’s point of view  
*A. Cauli (Cagliari/IT)*

1004.4 Alternative techniques  
*M. Muto (Naples/IT)*

Round-table discussion

Conclusion and take-home points

---

FS 1005  
**Update on pelvic embolisation**

*Moderators: R.E. Beasley (Miami Beach, FL/US), T.J. Kroencke (Augsburg/DE)*

1005.1 Pelvic congestion syndrome  
*J. Egge (Haugesund/NO)*

1005.2 Complicated pelvic vein embolisation  
*A.C. Roberts (La Jolla, CA/US)*

1005.3 Varicocele  
*M. Citone (Florence/IT)*

1005.4 Haemorrhoids  
*V. Vidal (Marseille/FR)*
10:00-11:00, Room 114

**IR Trainee Session**

**IRT 1006** Building an IR career

_Moderators: K. Pyra (Lublin/PL), L. Ratnam (London/UK)_

- **1006.1** Welcome and introduction to the ETF  
  _G.C. Makris (Oxford/UK)_
- **1006.2** Developing your academic career as an IR  
  _L. Ratnam (London/UK)_
- **1006.3** How to write a scientific paper  
  _J.A. Reekers (Amsterdam/NL)_
- **1006.4** The EBIR Exam  
  _R. Uberoi (Oxford/UK)_
- **1006.5** Establishing private clinics and clinical entrepreneurship  
  _D.J. West (Stoke-on-Trent/UK)_

11:10-12:30, Simulator Gallery

**Simulation Training**

**SIM 2.3** Basic principles of mechanical thrombectomy in ischaemic stroke (advanced)

_Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)_

_Session organiser: K.E. Wilhelm (Bonn/DE)_

_Instructors: L. De Paoli (Klagenfurt/AT), E.R. Gizewski (Innsbruck/AT), C.C. Pieper (Bonn/DE), T. Struffert (Giessen/DE)_
11:30-12:30, Auditorium 1

Controversy Session

CS 1101 Carotid artery disease

Moderators: T. Jargiello (Lublin/PL), S. Müller-Hülsbeck (Flensburg/DE)

1101.1 Carotid artery stenting for asymptomatic patients
   D. Vorwerk (Ingolstadt/DE)
1101.2 Carotid artery stenting is just for symptomatic patients
   T.J. Cleveland (Sheffield/UK)
1101.3 Single-layer technology is still valid
   R. Sachar (Raleigh, NC/US)
1101.4 Multi-layer technology can improve outcomes
   E. Stabile (Naples/IT)
1101.5 Stenting is the first option
   W.A. Gray (Philadelphia, PA/US)
1101.6 Surgery in all patients
   S. Michelagnoli (Florence/IT)

11:30-12:30

Satellite Symposia

For the detailed programmes, please refer to pages 150-151.

12:30-14:00, Room 130

Hands-on Device Training

EMT-HDT 2 Embolisation: materials and tools – liquid agents

Coordinators: L. Defreyne (Ghent/BE), J. Urbano (Madrid/ES)

12:30-13:50, Simulator Gallery

Simulation Training

SIM 2.4 Basic principles of mechanical thrombectomy in ischaemic stroke (advanced)

Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)

Session organiser: K.E. Wilhelm (Bonn/DE)
Instructors: L. De Paoli (Klagenfurt/AT), E.R. Gizewski (Innsbruck/AT),
C.C. Pieper (Bonn/DE), T. Struffert (Giessen/DE)

---

e-voting

recommended for EBIR preparation
12:30-14:00, Room 111
**Hands-on Device Training**

**TA-HDT 2  Tumour ablation – MWA**

*Coordinators: J.L. Del Cura Rodriguez (Bilbao/ES), A. Veltri (Orbassano/IT)*

12:30-14:00, Room 132
**Hands-on Device Training**

**VV-HDT 2  Varicose veins**

*Coordinators: J.M. Regi (Sheffield/UK), F. Veloso Gomes (Lisbon/PT)*

12:45-14:15, Room 118
**Safe Sedation Training**

**SED 2  Safe sedation application during IR procedures**

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*

13:00-14:00
**Satellite Symposia**

For the detailed programmes, please refer to pages 153-156.
13:15-14:15, News on Stage Area

**News on Stage**

**NoS 1204 Embolisation**

*Moderators: M. Bezzi (Rome/IT), J.E. Jackson (London/UK)*

1204.1 Ethylene vinyl alcohol copolymer (Onyx) for treatment of large venous vascular malformations: long term results and histology

*A. S. Gomes, P.A. Monteleone, S.V. Bukata, J.W. Sayre; Los Angeles, CA/US*

1204.2 Bronchial artery embolization for massive hemoptysis: experience from a tertiary referral center in Cape Town, South Africa

*H. Chung¹, M. Wojno², K.-L. Pool³; ¹Palo Alto, CA/US, ²Cape Town/ZA, ³Los Angeles, CA/US*

1204.3 Retrospective multivariate study of the clinical outcomes in patients affected by different grades of varicocele treated using different endovascular approaches

*G. Bianchi, M.V.M. Micelli, P. Palumbo, A. Izzo, A.V. Giordano, S. Carducci, M. Varrassi, A. Barile, C. Masciocchi; L’Aquila/IT*

1204.4 Treatment of high-flow priapism: superselective arterial embolization

*G. de Magistris¹, F. Pane¹, F. Corvino¹, F. Giurazza¹, F. Amodio¹, M. Coppola¹, E. Cavaglià¹, M. Silvestre¹, G. Cangiano¹, A. Borzelli¹, A. Paladini², R. Niola¹; ¹Naples/IT, ²Novara/IT*

1204.5 Diagnosis and management of thoracic and shoulder arteriovenous malformations

*W.F. Yakes; Englewood, CO/US*

1204.6 Percutaneous glue embolisation as a primary treatment for visceral pseudoaneurysms

*U. Gorsi, V. Bhatia, N. Kalra, M. Kang, M.S. Sandhu; Chandigarh/IN*

14:30-15:00, Auditorium 1

**Honorary Lecture**

**HL 1301 Andreas Gruentzig Lecture**

*Moderator: R.A. Morgan (London/UK)*

*Laudation: J. Lammer (Vienna/AT)*

1301.1 25 years of endovascular therapy of abdominal aortic aneurysms: where do we stand now?

*W. Jaschke (Innsbruck/AT)*
15:00-16:00, Auditorium 1

Hot Topic Symposium

**HTS 1302 Does ATTRACT change our DVT management practice?**

*Moderators: M. Das (Duisburg/DE), S.O. Trerotola (Philadelphia, PA/US)*

Introduction

1302.1 What is ATTRACT?  
*W.E.A. Saad (Washington, DC/US)*

1302.2 What is wrong with ATTRACT?  
*G.J. O’Sullivan (Galway/IE)*

1302.3 Has ATTRACT affected my practice?  
*R. de Graaf (Friedrichshafen/DE)*

1302.4 Where will we be in five years’ time?  
*S. Black (London/UK)*

Round-table discussion

Conclusion and take-home points

14:30-15:30  
Satellite Symposia

For the detailed programmes, please refer to pages 156-157.

15:00-16:00, Auditorium 2

Workshop

**WS 1303 Fundamentals in EVAR**

1303.1 *F. Fanelli (Florence/IT)*

1303.2 *N.J. Mosquera (Ourense/ES)*

16:00-17:30, Room 118

Safe Sedation Training

**SED 3 Safe sedation application during IR procedures**

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*
CBD 1401  My worst day in the angiosuite I

Moderators: R.G. McWilliams (Liverpool/UK), S. Michelagnoli (Florence/IT)

Introduction

1401.1 Case topic 1  
F.E. Vermassen (Ghent/BE)
1401.2 Case topic 2  
H. Rousseau (Toulouse/FR)
1401.3 Case topic 3  
P. Geisbuesch (Heidelberg/DE)
1401.4 Case topic 4  
M.D. Dake (Tucson, AZ/US)

Conclusion and take-home points

ERT 1402  Aorto-iliac stenotic occlusive disease

Moderators: A. Buecker (Homburg/DE), J.H. Peregrin (Prague/CZ)

Introduction

1402.1 Kissing stents  
M.W. de Haan (Maastricht/NL)
1402.2 Bare-metal vs. covered stents  
J.P. Schaefer (Kiel/DE)
1402.3 Balloon-expandable vs. self-expanding stents  
D.K. Tsetis (Iraklion/GR)
1402.4 Re-entry devices  
T. Rand (Vienna/AT)

Round-table discussion

Conclusion and take-home points
16:15-17:15, Room 115

**Workshop**

**WS 1403** Biliary interventions

1403.1 W. Uller (Regensburg/DE)
1403.2 C. Gonzalez-Junyent (Barcelona/ES)

16:15-17:15, Room 116

**Case-based Discussion**

**CBD 1404** Arteriovenous malformations and lymphatics

*Moderators: P. Haage (Wuppertal/DE), W.S. Rilling (Milwaukee, WI/US)*

**Introduction**

1404.1 High- vs. low-flow malformations
   J.A. Brookes (London/UK)
1404.2 How to approach a craniofacial arteriovenous malformation
   R. van den Berg (Amsterdam/NL)
1404.3 Lymphatic malformations
   S. Sierre (Buenos Aires/AR)
1404.4 Interventional radiology in the lymphatic system
   M. Itkin (Philadelphia, PA/US)

**Conclusion and take-home points**

16:15-17:15, Auditorium 1

**AI 1405** Amazing interventions

*Coordinator: C.A. Binkert (Winterthur/CH)*

*Case presenters: A. Koops (Berlin/DE), M. Guimaraes (Charleston, SC/US), T. Sabharwal (London/UK), F. Orsi (Milan/IT), X. Buy (Bordeaux/FR), K.N. Katsanos (Patras/GR)*
Free Paper Session
FP 1406 Ablation of liver tumours

Moderators: R. Argirò (Rome/IT), F.G. Irani (Singapore/SG)

1406.1 Radiofrequency versus microwave liver ablation: intermediate analysis of a randomized clinical trial
A. Radosevic, R. Quesada, A. Zugazaga, J. Sanchez Parrilla, F. Burdio; Barcelona/ES

1406.2 Comparison of microwave and radiofrequency ablation for the treatment of liver metastases: randomized prospective study (MIRA study)

1406.3 A preoperative mathematic model for computed tomographic guided microwave ablation treatment of hepatic dome tumors
F. Gao; Guangzhou/CN

1406.4 Microwave ablation outperforms RFA in the treatment of HCC
J.F. Amaral; Oldsmar, FL/US

1406.5 Iatrogenic arterioportal fistula caused by radiofrequency ablation of hepatocellular carcinoma: clinical courses and treatment outcomes
J.W. Choi¹, H.J. Jae¹, W.S. Choi², B. Kang¹, Y.S. Jeong¹, H.-C. Kim¹, J.W. Chung¹; ¹Seoul/KR, ²Seongnam/KR

1406.6 Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study
H. Yuan, P. Cao, H.L. Li, H.T. Hu, C.Y. Guo, Y. Zhao, Q.J. Yao, X. Geng; Zhengzhou/CN

1406.7 Locoregional treatments for unresectable early stage HCC in patients with high risk for intraprocedural bleeding: is single-step combined therapy safe and feasible?
F. Carchesio, R. Iezzi, A. Posa, A. Tansili, A. Gasbarrini, R. Manfredi; Rome/IT
Free Paper Session

FP 1407 Experimental studies in IR

1407.1 Analysis of circulating hypoxia-related microRNAs in transarterial chemoembolization with biodegradable and non-degradable embolic agents – preliminary results

J. Zavadil, T. Andrašina, J. Juracek, B. Cechova, O. Slaby, N. Goldberg; 1Brno/CZ, 2Jerusalem/IL

1407.2 In-vitro evaluation of tissue adhesives in lymphatic fluids – influences of glue type and procedural parameters

C.C. Pieper, D. Kütting; Bonn/DE

1407.3 pHPC hydrophilic antithrombogenic NiTi coating: evaluation of bare and surface modified low profile flow diverters using the Chandler Loop

T. Lenz-Habijan, M. Brodde, C. Bannewitz, M. Aguilar Perez, H. Monstadt, H. Henkes; 1Bochum/DE, 2Münster/DE, 3Stuttgart/DE

1407.4 Pickering-emulsion for local delivery of immunotherapies


1407.5 Intra-arterial CT hepatic angiography for tumor detection and ablation endpoint assessment: a proof-of-concept analysis

E.Y. Lin, G. Chintalapani, K. Brock, R. Avritscher, B.C. Odisio; 1Sugar Land, TX/US, 2Houston, TX/US

1407.6 In vivo feasibility of arterial embolization with permanent and absorbable suture: The FAIREMBO concept

V. Vidal, J.-F. Hak, P. Brige, G. Soulez, J.-M. Bartoli, B. Guillet; 1Marseille/FR, 2Montreal, QC/CA

1407.7 Reduced non-target embolization and increased targeted delivery with SEQUERE microcatheter demonstrated in swine model

G. Maleux, T. de Baère, F. Sun, N. Holtzman, O. Harbater, S. Rizzitelli, P. Robert, C. Robic, A. Seron, C. Corot; 1Leuven/BE, 2Villejuif/FR, 3Caceres/ES, 4Rehovot/IL, 5Roissy/FR
16:15-17:15, Room 133

**Free Paper Session**

**FP 1408**  **Aortic interventions**

*Moderators: M. Cariati (Milan/IT), M. Midulla (Dijon/FR)*

1408.1 Early outcomes of the off-the-shelf t-branch for the treatment of thoracoabdominal aneurysms: a post-market registry
*M. J. Bosiers, M. Austermann; Münster/DE*

1408.2 Impact of aortic stent-graft oversizing on outcomes of the chimney endovascular technique based on a new analysis of the PERICLES Registry
*M. V. Usai1, K. P. Donas1, G. Torsello1, F. J. Veith2; 1Münster/DE, 2New York, NY/US*

1408.3 A novel technique to flush and de-air unsheathed TEVAR stent-grafts to reduce gaseous embolisation during stent-graft deployment
*L. Hanna, R. G. J. Gibbs, M. S. Hamady; London/UK*

1408.4 Performance of BeGraft and BeGraft+ stent-grafts as bridging devices for fenestrated endovascular aneurysm repair – an in-vitro study
*G. F. Torsello1, M. Herten2, A. Frank3, M. Müller3, G. Torsello3, M. Austermann3; 1Berlin/DE, 2Essen/DE, 3Münster/DE*

1408.5 Rethinking our treatment paradigm for EVAR: mid-term results from a vascular centre
*K. Khan, R. K. Fisher; Liverpool/UK*

1408.6 Investigation of the quality reserve provided by digital variance angiography in fenestrated and branched endovascular aortic aneurysm repair setting
*E. Verhoeven1, A. Katsargyris1, D. Szöllősi2, M. Gyánó2, K. Szigeti2, S. Osváth2, J. P. Kiss2, V. I. Óriás2; 1Nuremberg/DE, 2Budapest/HU*

1408.7 Remodeling of aorta after thoracic endovascular aortic repair (TEVAR) for aortic dissection
*K. Nakajima1, N. Kato1, T. Hashimoto1, T. Higashigawa1, T. Ouchi1, S. Chino1, H. Sakuma1, T. Tokui2; 1Tsu/JP, 2Ise/JP*

16:15-16:35

**Satellite Symposium**

For the detailed programme, please refer to page 157.

16:45-17:15

**Satellite Symposium**

For the detailed programme, please refer to page 158.
17:30-18:30, Auditorium 2

**Focus Session**

**FS 1501  Subacute and chronic type B dissection**

*Moderators: P. Geisbuesch (Heidelberg/DE), J.P. Schaefer (Kiel/DE)*

1501.1 Imaging findings supporting TEVAR  
*A. Chavan (Neustadt/DE)*

1501.2 Knickerbockers and candy plugs: do they work?  
*T. Kölbel (Hamburg/DE)*

1501.3 When do we need fenestrated stent-grafts?  
*K. Oikonomou (Regensburg/DE)*

1501.4 Prevention and management of spinal cord ischaemia  
*M.A. Funovics (Vienna/AT)*

17:30-18:30, Room 133

**Workshop**

**WS 1502  Radial access**

1502.1  
*L. Moretti Monsignore (São Paulo/BR)*

1502.2  
*D. Klass (Vancouver, BC/CA)*

17:30-18:30, Room 116

**Case-based Discussion**

**CBD 1503  IR salvage for abdominal surgical disasters**

*Moderators: P. Lucatelli (Rome/IT), D.Y. Sze (Stanford, CA/US)*

**Introduction**

1503.1 Biliary tract surgery  
*V. Pedicini (Rozzano/IT)*

1503.2 Pancreatic surgery  
*P. Reimer (Karlsruhe/DE)*

1503.3 Bowel surgery  
*P.A.M.S. Almeida (Viseu/PT)*

1503.4 Kidney transplantation  
*G.S. Goh (Melbourne, VIC/AU)*

**Conclusion and take-home points**
17:30-18:30, Room 113

**Free Paper Session**

**FP 1504 Venous interventions**

*Moderators: M. Al Hajriy (Muscat/OM), F. Wolf (Vienna/AT)*

1504.1 Treatment of venous iliofemoral occlusive disease with a self-expanding venous stent: a “first look” at 24-month results from the prospective, multicenter VERNACULAR trial

*M.D. Dake¹, G.J. O’Sullivan²; ¹Tucson, AZ/US, ²Galway/IE*

1504.2 Safety, procedural success and outcome of the Aspirex S endovascular thrombectomy system in the treatment of iliofemoral deep vein thrombosis: data from the Arnsberg Aspirex registry

*M. Lichtenberg¹, R. de Graaf²; ¹Arnsberg/DE, ²Friedrichshafen/DE*

1504.3 Acute deep vein thrombosis: early and midterm results of a multicenter prospective Zéle registry of desobstruction using a rheolytic thrombectomy device

*C. Del Giudice¹, C. Zadro², A. Galloula¹, P. Marek², E. Messas¹, A. Bura-Rivière², M.R. Sapoval¹, H. Rousseau²; ¹Paris/FR, ²Toulouse/FR*

1504.4 Patency rates, safety and clinical results of the sinus-Obliquus venous stent in the treatment of chronic ilio-femoral venous outflow obstruction: data from the Arnsberg venous registry

*M. Lichtenberg¹, R. de Graaf²; ¹Arnsberg/DE, ²Friedrichshafen/DE*

1504.5 Risk stratification of inferior vena cava (IVC) filters in preparation for safe retrieval: the Alfred guideline

*H.K. Moriarty, G.S. Goh, W. Clements; Melbourne, VIC/AU*

1504.6 Mechanochemical endovenous ablation of lateral marginal vein in pediatric patients with Klippel-Trenaunay syndrome

*G. Lambert, M.W. Silva, D.J. Teplisky, I. Szhafir, J.F. Lutereau, M. Garriga, S. Sierre; Buenos Aires/AR*

1504.7 The results of balloon angioplasty of the pulmonary artery in patients with chronic thromboembolic pulmonary hypertension

*N. Marukyan, V. Privorotsky, D. Zverev, O. Moiseeva; Saint-Petersburg/RU*
FP 1505 Interventional oncology beyond liver

Free Paper Session

17:30-18:30, Room 134

Moderators: B. Gonçalves (Porto/PT), B. Rafiee (Karaj/IR)

1505.1 Should lung nodule biopsy be performed prior to or concomitantly with thermal ablation?
Z. Hartley-Blossom, T. Healey; Providence, RI/US

1505.2 Ablation therapy compared to SBRT and no treatment for unresectable non–small cell lung cancer: a National Cancer Data Base study
J. Wu¹, H.X. Bai², Z.-S. Zhang³; ¹Changsha/CN, ²Philadelphia, PA/US, ³Hunan/CN

1505.3 Mutation status Is not a significant predictor of local recurrence in patients undergoing image-guided ablation of lung metastases

1505.4 A phase 2 study of transarterial chemoperfusion treatment with Cisplatin, Methotrexate and Gemcitabine in patients with unresectable pleural mesothelioma – initial results
B. Kis, M. Pereira, J. Logeman, G. El-Haddad, J. Choi, J. Fontaine, B. Creelan, T. Tanvetyanon; Tampa, FL/US

1505.5 Cryoablation for stage 1 renal cell carcinoma: oncologic outcomes from a 10-year, prospective study

1505.6 Outcome predictors in percutaneous cryoablation for renal cell carcinoma: single center cohort study

1505.7 Prostate cancer chemoembolization in dog pet model: DOGXEL a proof of concept study
O. Pellerin¹, S. Djaber¹, C. Déan¹, P. Reb², C. Chaix², D. Tierny³, M.R. Sapoval¹; ¹Paris/FR, ²Roissy En France/FR, ³Villeneuve d’Ascq/FR
17:30-18:30, Room 114

**Free Paper Session**

**FP 1506** Peripheral vascular disease intervention 1

*Moders: A. Cannavale (Rome/IT), N.D. Ptohis (Athens/GR)*

1506.1 Results of the BIOFLEX-COF RCT, comparing high vs low chronic outward force of nitinol stents in the SFA

*A. Wressnegger, M.A. Funovics; Vienna/AT*

1506.2 The hemodynamical significance of low-grade serial stenoses

*L. van de Velde, E. Groot Jeibbink, M. Versluis, M.M.P.J. Reijnen; 1Arnhem/NL, 2Enschede/NL*

1506.3 Bollinger scoring application in evaluation of infrainguinal peripheral arterial disease in MR angiography

*A.G. Smith, S. Seedat, L. Kenning, D.F. Ettles, R. Lakshminarayan; Hull/UK*

1506.4 The utility of two-dimensional perfusion angiography (2D-PA) in critical limb ischemia (CLI): a single center experience

*A.J. Alvi, Z.A. Asseri, A. Bin Habjar, M. Al-Moaigil; Riyadh/SA*

1506.5 Demonstrating compliance in Thiel-embalmed arteries: implications for image-guided, minimally-invasive therapies

*C. Fitzton, H. Donald-Simpson, R. Ross, T. Wilkinson, J.G. Houston; Dundee/UK*

1506.6 BioMimics 3D Stent System. 2-year results of the MIMICS-2 Study

*P.A. Gaines; Sheffield/UK*

1506.7 Next generation of DCB: efficacy and tolerance of drug-coated hyper-compliant balloons (DCHCB) in peripheral arteries of swine

*M. Kusmierczuk, S. Bienek, S. Schurmann-Kaufeld, A. Mittag, U. Speck; 1Berlin/DE, 2Rottmersleben/DE, Homburg/DE*

17:30-17:50

**Satellite Symposium**

For the detailed programme, please refer to page 158.
Monday, September 9

07:50-08:20

**Satellite Symposia**

For the detailed programmes, please refer to page 159.

08:15-09:45, Room 118

**Safe Sedation Training**

**SED 4** *Safe sedation application during IR procedures* (advanced)

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*

08:30-09:30, Auditorium 2

**Expert Round Table**

**ERT 1701** *How I treat bad necks in EVAR*

*Moderators: A. Holden (Auckland/NZ), E. Verhoeven (Nuremberg/DE)*

Introduction

1701.1 How I treat short necks
*K.P. Donas (Münster/DE)*

1701.2 How I treat angulated necks
*R. Uberoi (Oxford/UK)*

1701.3 How I treat wide necks
*L.B. Lönn (Copenhagen/DK)*

1701.4 How I treat the short, angulated and wide neck
*M. Gargiulo (Bologna/IT)*

Round-table discussion

Conclusion and take-home points
08:30-09:30, Room 112

**Focus Session**

**FS 1702** Endovascular masterclass: intermittent claudication

*Moderators: K.R. Deloose (Dendermonde/BE), M. Katoh (Krefeld/DE)*

- 1702.1 Supervised exercise therapy and lifestyle  
  B.S. Tan (Singapore/SG)
- 1702.2 Guidewire and crossing techniques  
  C.S. Pena (Miami, FL/US)
- 1702.3 Drug-eluting technology: randomised trials and real-world practice  
  K. Rocha-Singh (Springfield, IL/US)
- 1702.4 Plaque modification vs. debulking  
  E. Blessing (Karlsbad/DE)

08:30-09:30, Room 116

**Focus Session**

**FS 1703** Everything you wanted to know about immunotherapy in IR

*Moderators: A. Adam (London/UK), T.K. Helmberger (Munich/DE)*

- 1703.1 Immunotherapy: big business vs. evidence  
  D.Y. Sze (Stanford, CA/US)
- 1703.2 Ablative therapies as a primer for immunotherapies and vice versa  
  R. Lencioni (Pisa/IT)
- 1703.3 Transarterial delivery of immunotherapy: how could it work – does it make sense?  
  B.J. Wood (Bethesda, MD/US)
- 1703.4 Imagining the ideal minimally invasive treatment concept  
  D. Arnold (Hamburg/DE)
08:30-09:30, Room 117

**Fundamental Course**

**FC 1704** Porto-mesenteric vein thrombosis


1704.1 Background in pathophysiology and imaging  
A.J. Wigham (Oxford/UK)

1704.2 When to intervene  
E. Velasco Sánchez (Madrid/ES)

1704.3 How to intervene  
S. Kee (Los Angeles, CA/US)

1704.4 The role of surgery  
D. Seehofer (Leipzig/DE)

08:30-09:30, Auditorium 1

**Clinical Evaluation Course**

**CEC 1705** Trauma

*Moderators:* C. Nice (Newcastle-upon-Tyne/UK), A.G. Ryan (Waterford City/IE)

1705.1 Work-up of the polytraumatised patient in the trauma team  
C. Dodt (Munich/DE)

1705.2 Imaging algorithms  
V. Miele (Florence/IT)

1705.3 Chest trauma  
T. Kratimenos (Athens/GR)

1705.4 Solid organ injury (liver, spleen, kidney)  
I. Robertson (Glasgow/UK)

1705.5 Pelvic fracture  
O. Pellerin (Paris/FR)

1705.6 Damage-control surgery  
K.J. Ponsen (Alkmaar/NL)

Round-table discussion
08:30-09:50, Simulator Gallery

**Simulation Training**

**SIM 3.1 Emergency embolisation in trauma: state of the art** (intermediate)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: R. Lely (Amsterdam/NL)*
*Instructors: M.W. de Haan (Maastricht/NL), G.S. Goh (Melbourne, VIC/AU), I. Insausti Gorbea (Pamplona/ES), R.W. Van der Meer (Leiden/NL)*

09:30-11:00, Room 130

**Hands-on Device Training**

**EMT-HDT 3 Embolisation: materials and tools – coils & plugs**

*Coordinators: M.C. Burgmans (Leiden/NL), M. Citone (Florence/IT)*

09:30-11:00, Room 132

**Hands-on Device Training**

**ST-HDT 1 Stroke thrombectomy**

*Coordinators: A. Krajina (Hradec Králové/CZ), H. van Overhagen (The Hague/NL)*

09:30-11:00, Room 111

**Hands-on Device Training**

**TA-HDT 3 Tumour ablation – RFA**

*Coordinators: J.-Y. Gaubert (Marseille/FR), M. Tsitskari (Athens/GR)*

09:50-11:10, Simulator Gallery

**Simulation Training**

**SIM 3.2 Emergency embolisation in trauma: state of the art** (intermediate)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: R. Lely (Amsterdam/NL)*
*Instructors: M.W. de Haan (Maastricht/NL), G.S. Goh (Melbourne, VIC/AU), I. Insausti Gorbea (Pamplona/ES), R.W. Van der Meer (Leiden/NL)*
10:00-11:00, Auditorium 2

**Focus Session**

**FS 1801** Endoleaks in EVAR

*Moderators: J.A. Brennan (Liverpool/UK), F. Nasser (São Paulo/BR)*

1801.1 When to embolise pre-operatively?
*D. Branzan (Leipzig/DE)*

1801.2 Aneurysm growth without endoleak
*I. Loftus (London/UK)*

1801.3 Reasons and treatment options for late type I endoleaks
*S. Michelagnoli (Florence/IT)*

1801.4 Reasons and treatment options for late type II endoleaks
*A. Chavan (Neustadt/DE)*

10:00-11:00, Room 115

**Focus Session**

**FS 1802** Medical therapy to improve outcomes of PAD interventions

*Moderators: A. Micari (Bergamo/IT), R. Sachar (Raleigh, NC/US)*

1802.1 The role of statins
*T.W.I. Clark (Philadelphia, PA/US)*

1802.2 Single vs. double antiplatelet therapy: any evidence?
*N.D. Ptohis (Athens/GR)*

1802.3 A new generation of anticoagulation
*A. Cannavale (Rome/IT)*

1802.4 Risk stratifications for strong anticoagulation regimens
*M. Burbelko (Berlin/DE)*
Expert Round Table

ERT 1803  Current management of metastatic lesions from breast cancer

Moderators: S.J. Park (Incheon/KR), L. Solbiati (Rozzano/IT)

Introduction

1803.1 Recent guidelines
    J. Kettenbach (Wiener Neustadt/AT)
1803.2 The role of radiotherapy
    L.M. Kenny (Brisbane, QLD/AU)
1803.3 The role of IR
    B. Gonçalves (Porto/PT)
1803.4 Oligometastatic patients
    F. Deschamps (Villejuif/FR)

Round-table discussion

Conclusion and take-home points

Focus Session

FS 1804  Dialysis masterclass

Moderators: D. Karnabatidis (Patras/GR), B.S. Tan (Singapore/SG)

1804.1 Failing arteriovenous fistulas and grafts: epidemiology and pathobiology
    B. Dolmatch (Palo Alto, CA/US)
1804.2 Haemodialysis access: randomised trials of drug-coated balloons and covered stents
    S.O. Trerotola (Philadelphia, PA/US)
1804.3 Balloon angioplasty of the central outflow venous system: indications and results
    P.M. Kitrou (Patras/GR)
1804.4 Percutaneous creation of haemodialysis arteriovenous fistulas:
    technique and early results
    D.K. Rajan (Toronto, ON/CA)
10:00-11:00, Room 117

**Fundamental Course**

**FC 1805  Peripheral arteriovenous malformations**

*Moderators: J.A. Brookes (London/UK), P. Saari (Kuopio/FI)*

- 1805.1 Arteriovenous malformations  
  L.J. Schultze Kool (Nijmegen/NL)
- 1805.2 Venous malformations  
  L. Ratnam (London/UK)
- 1805.3 Arteriovenous fistula  
  W.S. Rilling (Milwaukee, WI/US)
- 1805.4 Vascular malformation in children  
  A.M. Barnacle (London/UK)

10:00-11:00, Room 114

**IR Trainee Session**

**IRT 1806  Clinical practice for trainees, residents and young IRs**

*Moderators: R. Cervelli (Pisa/IT), M.J. Lee (Dublin/IE)*

- 1806.1 Making patient checklists, approaching patients and follow ups  
  M.J. Lee (Dublin/IE)
- 1806.2 Multidisciplinary clinical collaboration  
  C.A. Binkert (Winterthur/CH)
- 1806.3 Evidence based medicine in IR and why it matters  
  K.N. Katsanos (Patras/GR)
- 1806.4 Web-based innovations, clinical practice and patient care  
  G.C. Makris (Oxford/UK)
- 1806.5 Interventional radiology in environments with limited resources  
  A. Kesselman (New York, NY/US)
11:10-12:30, Simulator Gallery

**Simulation Training**

**SIM 3.3** **Emergency embolisation in trauma: state of the art** *(intermediate)*

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: R. Lely (Amsterdam/NL)*

*Instructors: M.W. de Haan (Maastricht/NL), G.S. Goh (Melbourne, VIC/AU), I. Insausti Gorbea (Pamplona/ES), R.W. Van der Meer (Leiden/NL)*

11:30-12:30, Room 112

**Expert Round Table**

**ERT 1901** **Anaesthesia in IR activity**

*Moderators: F. Orsi (Milan/IT), R. Uberoi (Oxford/UK)*

**Introduction**

1901.1 Conscious sedation for interventional procedures:
   *how I use dexmedetomidine*
   *P. Balsorano (Florence/IT)*

1901.2 I need the anaesthesist on my team
   *M.J. Lee (Dublin/IE)*

1901.3 I do not need the anaesthesist on my team
   *C.A. Binkert (Winterthur/CH)*

1901.4 No sedation vs. sedation: outcomes in IR
   *F. Barbani (Florence/IT)*

**Round-table discussion**

**Conclusion and take-home points**

11:30-12:30

**Satellite Symposia**

For the detailed programmes, please refer to pages 161-164.
12:30-13:50, Simulator Gallery

**Simulation Training**

**SIM 3.4** Emergency embolisation in trauma: state of the art (intermediate)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: R. Lely (Amsterdam/NL)*

*Instructors: M.W. de Haan (Maastricht/NL), G.S. Goh (Melbourne, VIC/AU), I. Insausti Gorbea (Pamplona/ES), R.W. Van der Meer (Leiden/NL)*

12:30-14:00, Room 130

**Hands-on Device Training**

**EMT-HDT 4** Embolisation: materials and tools – coils & plugs

*Coordinators: M.C. Burgmans (Leiden/NL), M. Citone (Florence/IT)*

12:30-14:00, Room 132

**Hands-on Device Training**

**ST-HDT 2** Stroke thrombectomy

*Coordinators: A. Krajina (Hradec Králové/CZ), H. van Overhagen (The Hague/NL)*

12:30-14:00, Room 111

**Hands-on Device Training**

**TA-HDT 4** Tumour ablation – RFA

*Coordinators: J.-Y. Gaubert (Marseille/FR), M. Tsitskari (Athens/GR)*

12:45-14:15, Room 118

**Safe Sedation Training**

**SED 5** Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*
13:00-14:00
**Satellite Symposia**

For the detailed programmes, please refer to pages 164-165.

13:15-14:15, News on Stage Area
**News on Stage**

**NoS 2004 Interventional oncology**

*Moderators: R. Lencioni (Pisa/IT), C.T. Sofocleous (New York, NY/US)*

- **2004.1** Performance of a new needle for the displacement of critical structure in thermal ablation
  
  *P. Auloge, R.L. Cazzato, J. Caudrelie, P.P. Rao, G. Koch, J. Garnon, A. Gangi; Strasbourg/FR*

- **2004.2** Effects of ablation on systemic therapy for metastatic pulmonary sarcoma: potential synergy?
  
  *K. Menon, A. Doshi, K. Ganjoo, D. Wang, G. Hwang; Stanford, CA/US*

- **2004.3** Randomized embolization trial for neuroendocrine tumors (RETNET): first safety report
  

- **2004.4** Chemoembolization for treatment of hepatocellular carcinoma: national registry-based analysis
  
  *T. Andrašina, M. Uher, T. Rohan, P. Matkulčík, J. Zavadil, B. Cechova, L. Jandurova, V. Válek; Brno/CZ*

- **2004.5** Transarterial chemoembolization with degradable starch microspheres (DSM-TACE) vs. selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma (HCC)
  
  *T.A. Auer, M. Jonczyk, F. Collettini, B. Hamm, B. Gebauer; Berlin/DE*

- **2004.6** Multimodality quantitative volumetric and metabolic assessment of early tumor response and survival in patients with uveal melanoma liver metastases undergoing Y90-radioembolization
  
14:30-15:15, Auditorium 1

**FIQ 2101 Film Interpretation Quiz**

*Moderators: L. Crocetti (Pisa/IT), G.J. O’Sullivan (Galway/IE)*

**Team A:** N. McEniff (Dublin/IE), A.M. Barnacle (London/UK), M. Casare Santiago (Palma de Mallorca/ES), S. Kee (Los Angeles, CA/US),  
**Team B:** R. Iezzi (Rome/IT), G. Eldem (Ankara/TR), J. Garnon (Strasbourg/FR), M.R. Meijerink (Amsterdam/NL)

14:30-15:30  
**Satellite Symposium**

For the detailed programme, please refer to page 166.

15:15-16:00, Auditorium 1  
**Hot Topic Symposium**

**HTS 2102 Is renal tumour ablation ready for prime time?**  

*Moderators: X. Buy (Bordeaux/FR), R.F. Grasso (Rome/IT)*

Introduction

- **2102.1** Latest guidelines  
  A. Veltri (Orbassano/IT)
- **2102.2** The urologist’s point of view  
  G. Siena (Florence/IT)
- **2102.3** State-of-the-art of interventional radiology treatment  
  D.J. Breen (Southampton/UK)
- **2102.4** What can we expect in the next five years?  
  A. Gangi (Strasbourg/FR)

Round-table discussion

Conclusion and take-home points
14:30-15:30, Auditorium 2

**Case-based Discussion**

**CBD 2103**  My worst day in the angiosuite II

*Moderators: H. Rousseau (Toulouse/FR), E. Verhoeven (Nuremberg/DE)*

**Introduction**

2103.1  Case topic 1  
*R.G.J. Gibbs (London/UK)*

2103.2  Case topic 2  
*A. Holden (Auckland/NZ)*

2103.3  Case topic 3  
*H. Kobeiter (Créteil/FR)*

2103.4  Case topic 4  
*V. Riambau (Barcelona/ES)*

**Conclusion and take-home points**

15:30-16:00

**Satellite Symposia**

For the detailed programmes, please refer to pages 166-167.

16:00-17:30, Room 118

**Safe Sedation Training**

**SED 6**  Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*
ERT 2201 How to achieve durability in F-/B-EVAR

Moderators: G.M. Richter (Stuttgart/DE), F.E. Vermassen (Ghent/BE)

Introduction

2201.1 Landing zone
K. Kichikawa (Kashihara/JP)

2201.2 Choice of fenestration and branches
H. Meissner (Stuttgart/DE)

2201.3 Target vessels
R. Ghotbi (Munich/DE)

2201.4 Surveillance
A. Winterbottom (Cambridge/UK)

Round-table discussion

Conclusion and take-home points

16:15-17:15, Room 133

WS 2202 Thermal protection for ablative therapies

2202.1 E. de Kerviler (Paris/FR)

2202.2 A.N. Kurup (Rochester, MN/US)
16:15-17:15, Room 115

**Case-based Discussion**

**CBD 2203** IR in gynaecological emergencies

*Moderators: J.-P. Pelage (Caen/FR), A.C. Roberts (La Jolla, CA/US)*

**Introduction**

2203.1 Postpartum haemorrhage  
*T.J. Kroencke (Augsburg/DE)*

2203.2 Abnormal placentation  
*A.V. Giordano (L’Aquila/IT)*

2203.3 Gynaecological malignancies  
*M.P. Kohi (San Francisco, CA/US)*

2203.4 Septic conditions  
*S. Ameli-Renani (London/UK)*

**Conclusion and take-home points**

16:15-17:15, Room 117

**Focus Session**

**FS 2204** New in endovascular thrombectomy

*Moderators: S. Mangiafico (Florence/IT), H. van Overhagen (The Hague/NL)*

2204.1 What do the DAWN and the DEFUSE-3 trials tell us about stroke imaging?  
*P. Mordasini (Bern/CH)*

2204.2 What can be learned from the thrombus removal trials?  
*W.H. van Zwam (Maastricht/NL)*

2204.3 New tips and tricks  
*J.D. Molina Nuevo (Albacete/ES)*

2204.4 Carotid stenting during stroke treatment  
*L.C. van Dijk (The Hague/NL)*
ERT 2205  SFA - the unsolved question: angioplasty vs. stent

Moderators: Y. Gouëffic (Nantes/FR), B.T. Katzen (Miami, FL/US)

Introduction

2205.1 Drug-coated balloons in 2019
M. Brodmann (Graz/AT)

2205.2 New data to support the use of drug-eluting stents
T. Zeller (Bad Krozingen/DE)

2205.3 A new generation of percutaneous transluminal angioplasty
J.H. Rundback (Teaneck, NJ/US)

2205.4 The new generation of stents
K.R. Deloose (Dendermonde/BE)

Round-table discussion

Conclusion and take-home points
16:15-17:15, Room 113

Free Paper Session

FP 2206 Prostate artery embolisation

Moderators: L. Novosel (Zagreb/HR), U. Teichgräber (Jena/DE)

2206.1 A CT protocol for 4D angiography and perfusion imaging of the prostate for embolization planning: proof of concept study
A. Kobe¹, G. Puippe¹, E. Klotz², H. Alkadhi², T. Pfammatter³; ¹Zurich/CH, ²Forchheim/DE

2206.2 Prostatic artery embolization with HydroPearls: safety and efficacy
A. Kovács, P. Bischoff, A. Schäfer, A. El Mansouri; Bonn/DE

2206.3 Prostatic artery embolization for benign prostatic hyperplasia: anatomical, technical and radiation exposure considerations in 168 cases
M. Shaker, E.Y. Hashem, A.A.M.B. Okba, R.T.M. Khafagy, K. Abd El Tawab; Cairo/EG

2206.4 PAE provides a proportionately greater change in storage symptoms compared with surgery: multivariate analysis of the UK-ROPE database
G. Vigneswaran, D. Maclean, S. Modi, M.R. Harris, T.J. Bryant, N. Hacking; Southampton/UK

2206.5 Correlation between peri-procedural prostate enhancement and the number of prostatic arterial targets during prostate artery embolisation
T.F. Barge, A.C. Macdonald, P. Boardman, C.R. Tapping; Oxford/UK

2206.6 Outcome of prostatic artery embolization for benign prostatic hyperplasia: 1550 patients follow up to 10 years
J.M. Pisco †, T. Bilhim, N.V. Costa, L.C. Pinheiro, D. Torres, J. Pisco, A.G. Oliveira; Lisbon/PT

2206.7 The proSTatic aRtery EmbolizAtion for the treatMent of benign prostatic hyperplasia (STREAM) study: two-year results from a prospective cohort
A.C. Macdonald¹, T. MacKinnon¹, J. El-Sheikha¹, D. Kearns¹, R. Macpherson¹, J. Crew¹, M.W. Little¹, P. Boardman¹, C.R. Tapping¹; ¹Oxford/UK, ²Reading/UK
FP 2207 Transarterial approaches for liver tumours

Moderators: T.F. Jakobs (Munich/DE), P. Reimer (Karlsruhe/DE)

2207.1 Spectral CT-based iodized oil quantification to develop a tumor response prediction model for chemoembolization of hepatocellular carcinoma

2207.2 Efficacy and feasibility of temporary protective embolization of non-target liver vessels in 90Y-radioembolization

2207.3 Comparison of the efficacy of hypertrophy induction by unilobar 90Y radioembolisation vs portal vein embolization: a prospective animal study

2207.4 Transarterial chemoembolization of hepatic neuroendocrine metastases: the effect of fatty liver on treatment response
K. Jumaa, D. Wiseman, A. Mujoomdar; London, ON/CA

2207.5 A phase II open-label, single centre, non-randomised trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: an interim analysis

2207.6 LifePearl® Anthracyclin registry in selective chemo-embolization of patients with unresectable hepatocellular carcinoma: safety, tolerability and efficacy (PARIS study)
T. de Baère¹, L. Tselikas¹, G. Verset², B. Guiu³, M. Ronot⁴, P. Chevallier⁵, G. Sergent⁶, P.P. Goffette⁷; ¹Villejuif/FR, ²Brussels/BE, ³Montpellier/FR, ⁴Clichy/FR, ⁵Nice/FR, ⁶Lille/FR

2207.7 HepaSphere (30–60 μm) transarterial chemoembolization vs. conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma: propensity score matched analysis of early clinical outcomes
Free Paper Session

FP 2208  Peripheral vascular disease intervention 2

Moderators: G.N. Kouvelos (Larissa/GR), L. Patrone (London/UK)

2208.1 Risk factors of distal edge stenosis after stenting for isolated mesenteric artery dissection
Z. Jia; Changzhou/CN

2208.2 The peripheral bleeding score: a novel easy-to-use preprocedural score to predict bleeding complications of endovascular peripheral arterial interventions
M. Boulougouri, L. Reppas, S. Spiliopoulos, A. Tschatzis, G. Festas, F. Christidi, K. Palialexis, E. Broutzos; Athens/GR

2208.3 Can legflow improve treatment of long femoropopliteal lesions: the REFLOW outcomes
J. Wauters, M. Bosiers; Dendermonde/BE

2208.4 BIO4AMB: a multicenter, controlled trial evaluating ambulatory endovascular treatment of PAD for 4 French and 6 French femoral access strategies
M. Brodmann¹, J.C. van den Berg², K.R. Deloose³, E. Steinmetz⁴; ¹Graz/AT, ²Lugano/CH, ³Dendermonde/BE, ⁴Dijon/FR

2208.5 The Ulysse prospective single center registry: midterm angiographic and clinical outcomes of ultrasound plasty associated to plain angioplasty for below the knee lesions in patient with critical limb ischemia
C. Del Giudice¹, R. Gandini²; ¹Paris/FR, ²Rome/IT

2208.6 Final 1-year outcomes of the KANSHAS 1 study of the novel KANSHAS drug-coated balloon for treatment of femoropopliteal occlusive disease: the first-in-human study
M. Lichtenberg¹, G. Tepe², S. Müller-Hülsbeck³, K.R. Deloose⁴, J. Verbist⁵, P. Goverde⁶, T. Zeller⁷; ¹Arnsberg/DE, ²Rosenheim/DE, ³Flensburg/DE, ⁴Dendermonde/BE, ⁵Bonheiden/BE, ⁶Antwerp/BE, ⁷Bad Krozingen/DE

2208.7 Tackling challenging infrainguinal arterial recanalization through retrograde use of the Outback re-entry catheter: a multi-centre cohort experience
B. Dharmarajah¹, L. Patrone¹, S. Theivacumar¹, E. Blessing²; ¹London/UK, ²Karlsbad/DE
16:15-16:35

**Satellite Symposium**

For the detailed programme, please refer to page 167.

17:30-18:30, Auditorium 2

**Workshop**

**WS 2301 Fundamentals in TEVAR**

2301.1  *P. Holt (London/UK)*
2301.2  *R. Philip Thomas (Marburg/DE)*

17:30-18:30, Room 113

**Workshop**

**WS 2302 Genitourinary IR interventions: basic and advanced**

2302.1  *G. Gabbani (Florence/IT)*
2302.2  *R. Das (London/UK)*

17:30-18:30, Room 114

**Workshop**

**WS 2303 Pulmonary and bronchial artery embolisation**

2303.1  *J. Rodríguez Mesa (Málaga/ES)*
2303.2  *A. Khalil (Paris/FR)*
17:30-18:30, Room 115

**Free Paper Session**

**FP 2304** TIPS and portal vein intervention

*Moderators: G. Maleux (Leuven/BE), S. Sabri (Washington, DC/US)*

2304.1 Indications for transjugular portosystemic shunts (TIPS) at a US liver transplant center: trends during the last 10 years

*K.J. Moore, P.F. Laeseke, M.A. Woods, O. Ozkan; Madison, WI/US*

2304.2 Percutaneous transhepatic creation of intrahepatic portosystemic shunt with a combination of tip-angled guiding needle and coaxial straight needle

*Y. Takeuchi1, N. Sakamoto2, H. Morishita1, Y. Arai3; 1Kyoto/JP, 2Hyogo/JP, 3Tokyo/JP*

2304.3 Stability over time of global and intra-stent pressure gradients in under-dilated TIPS placed for refractory/recurrent ascites in cirrhotic patients

*F. Prampolini, G. Musacchia, S. Pizzuto, F. Casari, C. Caporali, P. Torricelli, L. Turco, F. Schepis; Modena/IT*

2304.4 Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for the treatment of variceal bleeding with hepatocellular carcinoma meeting the Milan criteria: a propensity score-matching analysis

*J. Luo, M. Li, Z. Jiang, M. Huang; Guangzhou/CN*

2304.5 Association of sarcopenia and growth rate of the future liver remnant after portal vein embolization

*M. Schulze-Hagen, D. Truhn, F. Duong, F. Pedersoli, C.K. Kuhl, G. Lurje, P. Isfort, P. Bruners, M. Zimmermann; Aachen/DE*

2304.6 HCC complication by PVT – percutaneous management by image-guided endoportal RFA, followed by metal stent implantation

*M. Mizandari1, T. Azrumelashvili1, N. Habib2; 1Tbilisi/GE, 2London/UK*

2304.7 Primary tumor location is an independent prognostic factor for time-to-progression in patients with colorectal liver metastases undergoing portal vein embolization and subsequent right hepatectomy

*L. Hitpaß, F. Pedersoli, M. Schulze-Hagen, P. Isfort, C.K. Kuhl, P. Bruners, M. Zimmermann; Aachen/DE*
FP 2305  Musculoskeletal interventions

Moderators: M. Cifrian Perez (Valencia/ES), S.M. Tutton (Milwaukee, WI/US)

2305.1 Utilization of motor and somatosensory evoked potentials for neural thermoprotection in ablations of musculoskeletal lesions
J.T. Yoon, J. Nesbitt, B.L. Raynor, M. Roth, C.C. Zertan, J.W. Jennings; St. Louis, MO/US

2305.2 Ablation-osteoplasty-reinforcement-internal fixation (AORIF) for osteolytic skeletal metastases
I. Latich, F. Lee; New Haven, CT/US

2305.3 Cryoablation as second line treatment for fibro-adipose vascular anomaly (FAVA)
C. Kaufman, A.E. Frodsham, R. Arnold; Salt Lake City, UT/US

2305.4 Magnetic resonance-guided high intensity focused ultrasound (MRgFUS) for the treatment of oligometastatic prostate cancer bone metastases: non-invasive use of sound waves can downstage cancer spread
C. Marrocchio, A. Napoli, R. Scipione, S. Dababou, H.-P. Erasmus, C. Catalano; Rome/IT

2305.5 Feasibility, safety and efficacy of genicular artery embolization for relief of knee pain related to osteoarthritis
S. Sharma, R. Rajagopal, S. Kumar, V. Verma, R. Malhotra; Delhi/IN

2305.6 MR-guided focused ultrasound (MRgFUS) in the treatment of osteoid osteoma: a safe, effective and durable therapeutic option
S. Dababou, A. Napoli, C. Marrocchio, R. Scipione, G. Alfieri, D. Fierro, C. Catalano; Rome/IT

2305.7 Evaluation of the role and feasibility of radiofrequency ablation for chondroblastoma: experience from tertiary care centre in India
N.S. Shetty, S.S. Kulkarni, K.B. Gala, S. Mohd, A. Puri, A. Gulia; Mumbai/IN
FP 2306 Embolotherapy

**Moderators:** H. Kidikas (Riga/LV), M.J.M. Sousa (Porto/PT)

**2306.1** Geniculate artery embolisation in patients with osteoarthritis of the knee (GENESIS): preliminary results from the first European prospective study  
*M.W. Little, M. Gibson; Reading/UK*

**2306.2** Clinical outcomes of transcatheter arterial embolization for chronic knee pain: severe versus mild to moderate knee osteoarthritis  

**2306.3** Effects of transcatheter arterial embolization for persistent trapezius myalgia refractory to conservative treatment  
*M. Shibuya, Y. Okuno; Yokohama/JP*

**2306.4** Impact of uterine fibroids embolization on uterine contractility and female quality of life  
*V.A.V. Fornazari¹, D. Szejnfeld¹, S.M. Goldman¹, J. Szejnfeld¹, T.F. Nunes², G.M. Salazar³, S.A. Vayego⁴; ¹São Paulo/BR, ²Campo Grande/BR, ³Boston, MA/US, ⁴Curitiba/BR*

**2306.5** Comparison of embolization of the superior rectal arteries with conventional surgical correction in the treatment of internal hemorrhoidal disease: initial results  
*P.M. Falsarella, S.E.A. Araujo, F. Nasser, A.S. Portilho, B.B. Vailati, F.L. Galastri, B.B. Affonso, J.M. Da Motta Leal Filho, R.G. Garcia, M. Katz; São Paulo/BR*

**2306.6** Assessment of angiographic outcome using 2D parametric parenchymal blood flow (2D-PPBF) technique in patients with hypersplenism undergoing partial spleen embolization (PSE)  
*T.C. Meine¹, S.K. Maschke¹, M. Kirstein¹, T. Werncke¹, J. Baumgart², C.L.A. Dewald¹, F. Wacker¹, B.C. Meyer¹, J.B. Hinrichs¹; ¹Hannover/DE, ²Chicago, IL/US*

**2306.7** Identifying active extravasation on arteriograms using artificial intelligence  
*M. Shen¹, M. Ozturk², P.-L. Loh¹, V. Jog¹, P.F. Laeseke¹, D. Morgan¹, M. Kleedehn¹; ¹Madison, WI/US, ²Samsun/TR*
17:30-18:30, News on Stage Area

**News on Stage**

**SP-NoS 2307 Students on Stage**

*Moderators: G.M. Jorgensen (Odense/DK), G.C. Makris (Oxford/UK)*

2307.1 A single center study on the risk of mortality in patients treated with paclitaxel-coated devices for femoropopliteal disease

*V. Linehan¹, M. Doyle¹, H.M. Coffey¹, M. Earle², B. Barrett¹, R. Gullipalli¹;*

¹St. John’s, NL/CA, ²Toronto, ON/CA

2307.2 UK radiology and IR career promotion on the RiiSE: two years of Radiological Imaging and Intervention Symposium Edinburgh – an annual event for medical students and foundation doctors

*N.P. Burke, K. Kind; Edinburgh/UK*

2307.3 Developing sarcopenia predicts long-term mortality after elective EVAR

*I.A. Lindström, S.M. Protto, N. Khan, N. Sillanpää, J. Hernesniemi, N. Oksala; Tampere/FI*

2307.4 Initial experience using a novel magnetic-catheter based IVC filter retrieval device

*S. Periyasamy, K.J. Moore, W. Flanigan, J. Ashley, A. Doersch, E. Foran, B. Struthers, M.A. Woods, P.F. Laeseke; Madison, WI/US*

2307.5 Comparison of TROcar versus SELdinger technique for percutaneous cholecystostomy: the multicenter TROSELC study

*D. Konstantopoulos¹, L. Reppas¹, N. Arkoudis¹, M. Theofanis², S. Spiliopoulos¹, P.M. Kitrou², D.K. Fillipiadis¹, K.N. Katsanos², K. Palialexis¹, A.D. Kelekis¹, D. Karnabatidis², E. Brontzos¹; ¹Athens/GR, ²Patras/GRC*

2307.6 Clinical outcomes in patients who had delayed cholecystectomy or percutaneous biliary endoscopy following percutaneous cholecystostomy for acute cholecystitis: ten-year, single-center retrospective review

*B.J. Amos, R. Artrip, A. Burdette; Hershey, PA/US*

17:30-18:30, Room 116

**GA 2308 General Assembly – members only**
Tuesday, September 10

08:15-09:45, Room 118

**Safe Sedation Training**

**SED 7  Safe sedation application during IR procedures** (advanced)

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*

08:30-09:30, Auditorium 2

**Focus Session**

**FS 2501  Radiation exposure: are we doing enough?**

*Moderators: W. Jaschke (Innsbruck/AT), M.P. Jenkins (London/UK)*

- 2501.1 Radiation exposure of EVAR/TEVAR: present status in the EU  
  *W. Jaschke (Innsbruck/AT)*
- 2501.2 How to use high-quality hardware responsibly  
  *G. Bartal (Kfar-Saba/IL)*
- 2501.3 The importance of software in exposure reduction  
  *T. Trabold (Stuttgart/DE)*
- 2501.4 The importance of training and skills in exposure reduction  
  *E. Brountzos (Athens/GR)*
08:30-09:30, Auditorium 1

Clinical Evaluation Course

CEC 2502  Acute mesenteric arterial ischaemia

Moderators: T.W.I. Clark (Philadelphia, PA/US), G.S. Goh (Melbourne, VIC/AU)

2502.1 Clinical presentation  
M.C. Ferraro (Florence/IT)

2502.2 Diagnostic imaging  
G. Papageorgiou (N. Faliro/GR)

2502.3 Guidelines  
M. Szczerbo-Trojanowska (Lublin/PL)

2502.4 The role of interventional radiology  
J.A. Kaufman (Portland, OR/US)

2502.5 The role of surgery  
C. Pilasi Menichetti (London/UK)

2502.6 Post-procedural management and follow-up  
M. Cejna (Feldkirch/AT)

Round-table discussion

08:30-09:30, Room 117

Fundamental Course

FC 2503  Intra-arterial stroke management

Moderators: A. Consoli (Suresnes/FR), K.A. Hausegger (Klagenfurt/AT)

2503.1 For whom should thrombectomy be considered?  
P. Mordasini (Bern/CH)

2503.2 Imaging the brain and the clot  
T. Struffert (Giessen/DE)

2503.3 Thrombectomy and aspiration  
S. Hopf-Jensen (Flensburg/DE)

2503.4 What do the trials tell us?  
E.R. Gizewski (Innsbruck/AT)
08:30-09:30, Room 116

**Focus Session**

**FS 2504 Urinary tract embolisation**


- **2504.1 Iatrogenic bleeding**
  *J. Irurzun (Alicante/ES)*

- **2504.2 Angiomyolipoma**
  *N. Moussa (Paris/FR)*

- **2504.3 Pre-operative embolisation**
  *F. Mondaini (Florence/IT)*

- **2504.4 Haematuria**
  *C. Scheurig-Muenkler (Augsburg/DE)*

08:30-09:30, Room 112

**Focus Session**

**FS 2505 Standardising planning to achieve optimal ablation**

*Moderators: T. de Baère (Villejuif/FR), C.T. Sofocleous (New York, NY/US)*

- **2505.1 Why we need standardisation**
  *M.R. Callstrom (Rochester, MN/US)*

- **2505.2 Simulation planning before radiofrequency ablation**
  *M. Reinhardt (Leipzig/DE)*

- **2505.3 Simulation planning before cryoablation**
  *C. Essert (Strasbourg/FR)*

- **2505.4 Simulation planning before microwave ablation**
  *J. Chiang (Los Angeles, CA/US)*

08:30-09:50, Simulator Gallery

**Simulation Training**

**SIM 4.1 Peripheral artery disease: angioplasty and stenting** *(core)*

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: M.A. Ruffino (Turin/IT)*

*Instructors: C. Del Giudice (Paris/FR), F. Fluck (Würzburg/DE), A. Moelker (Rotterdam/NL), W.E.A. Saad (Washington, DC/US)*
09:30-11:00, Room 130
Hands-on Device Training

EMT-HDT 5  Embolisation: materials and tools – particulate agents

*Coordinators: A.G. Rampoldi (Milan/IT), S. Spiliopoulos (Athens/GR)*

09:30-11:00, Room 111
Hands-on Device Training

TA-HDT 5  Tumour ablation – Image guided navigation and targeting

*Coordinators: C. Farrelly (Dublin/IE), R. Iezzi (Rome/IT)*

09:30-11:00, Room 132
Hands-on Device Training

VA-HDT 1  Vertebral augmentation

*Coordinators: P.N.M. Lohle (Tilburg/NL), K.E. Wilhelm (Bonn/DE)*

09:50-11:10, Simulator Gallery
Simulation Training

SIM 4.2  Peripheral artery disease: angioplasty and stenting (core)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

Session organiser: M.A. Ruffino (Turin/IT)
Instructors: C. Del Giudice (Paris/FR), F. Fluck (Würzburg/DE),
A. Moelker (Rotterdam/NL), W.E.A. Saad (Washington, DC/US)
ERT 2601  Don’t forget the iliacs!

Moderators: K.P. Donas (Münster/DE), L.B. Lönn (Copenhagen/DK)

Introduction

2601.1 Narrow iliacs  
J.L. De Bruin (London/UK)

2601.2 Wide iliacs  
M.W. de Haan (Maastricht/NL)

2601.3 Hypogastric perfusion  
J. Wilkins (London/UK)

2601.4 Aneurysmal iliacs  
G.N. Kouvelos (Larissa/GR)

Round-table discussion

Conclusion and take-home points

ERT 2602  Open questions in below-the-knee procedures

Moderators: E. Blessing (Karlsbad/DE), K.N. Katsanos (Patras/GR)

Introduction

2602.1 Is percutaneous transluminal angioplasty still the first option?  
R. Ferraresi (Bergamo/IT)

2602.2 Drug-eluting stents in critical limb ischaemia: cost-effective compared to percutaneous transluminal angioplasty?  
M. Brodmann (Graz/AT)

2602.3 Lessons learned from the first generation of drug-coated balloons  
S. Kum (Singapore/SG)

2602.4 Treatment of heavily calcified lesions  
M.G. Manzi (Abano Terme/IT)

Round-table discussion

Conclusion and take-home points
10:00-11:00, Room 116

Video Learning Session

VL 2603 Neurointervention

Moderators: M. Ribó (Barcelona/ES), W.H. van Zwam (Maastricht/NL)

2603.1 Aneurysm coiling
K. Zeleňak (Martin/SK)

2603.2 Endovascular treatment of intracranial aneurysm
K. Zeleňák (Martin/SK)

2603.3 CT guided cervical epidural injection
Z.A.H. Aldin (Essex/UK)

10:00-11:00, Room 117

Focus Session

FS 2604 Gastrointestinal bleeding

Moderators: P.E. Andersen (Odense/DK), P. Vilares Morgado (Porto/PT)

2604.1 Imaging work-up
N.L. Kelekis (Athens/GR)

2604.2 The endoscopist’s role
G. Braun (Augsburg/DE)

2604.3 Upper GI
A. Basile (Catania/IT)

2604.4 Lower GI
R. Uberoi (Oxford/UK)
10:00-11:00, Room 112

Clinical Evaluation Course

**CEC 2605 Strategies for T1 renal cell carcinoma**

*Moderators: G. Papageorgiou (N. Faliro/GR), O. Pellerin (Paris/FR)*

- **2605.1** State-of-the-art imaging  
  *E. Bertelli (Florence/IT)*

- **2605.2** The role of active surveillance  
  *A. Alcaraz (Barcelona/ES)*

- **2605.3** When to biopsy  
  *R.E. Beasley (Miami Beach, FL/US)*

- **2605.4** Partial nephrectomy  
  *G. Siena (Florence/IT)*

- **2605.5** Percutaneous ablation  
  *D.K. Filippiadis (Athens/GR)*

- **2605.6** Combined treatments  
  *A.H. Mahnken (Marburg/DE)*

Round-table discussion

10:00-11:00, Room 114

IR Trainee Session

**IRT 2606 IRs: from the angiosuite to industry boardrooms and the road to innovation**

*Moderators: A. Gangi (Strasbourg/FR), S.M. Protto (Tampere/Fl)*

- **2606.1** Medical devices, innovation and venture capital firms; a beginners’ guide  
  *A. Gkelou (Paris/FR)*

- **2606.2** Experience with the IR Venture Forum  
  *T.P. Murphy (Providence, RI/US)*

- **2606.3** Building your own start-up as an IR  
  *A. El Zein (Oxford/UK)*

- **2606.4** Working with the medical devices industry as an IR  
  *A. Gangi (Strasbourg/FR)*

- **2606.5** Panel discussion
11:10-12:30, Simulator Gallery

**Simulation Training**

**SIM 4.3 Peripheral artery disease: angioplasty and stenting** (core)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: M.A. Ruffino (Turin/IT)*

*Instructors: C. Del Giudice (Paris/FR), F. Fluck (Würzburg/DE), A. Moelker (Rotterdam/NL), W.E.A. Saad (Washington, DC/US)*

11:30-12:30, Auditorium 2

**Expert Round Table**

**ERT 2701 What’s next for EVAR?**

*Coordinators: F. Fanelli (Florence/IT), R.M. Greenhalgh (London/UK)*

**Introduction**

2701.1 Device development  
*V. Riambau (Barcelona/ES)*

2701.2 Individualised follow-up  
*C.S.P. van Rijswijk (Leiden/NL)*

2701.3 Fusion imaging and virtual reality  
*G.M. Richter (Stuttgart/DE)*

2701.4 More off-the-shelf in emergency  
*T. Kölbel (Hamburg/DE)*

**Round-table discussion**

**Conclusion and take-home points**
11:30-12:30, Room 117

Focus Session

FS 2702 Radial access: how and when

Moderators: D. Mullan (Manchester/UK), K.H. Stensaeth (Trondheim/NO)

2702.1 The rationale behind it
   M. Guimaraes (Charleston, SC/US)
2702.2 Radial vs. femoral vs. brachial
   E. Brountzos (Athens/GR)
2702.3 Which procedure, which devices?
   G. Andrade (Recife/BR)
2702.4 Complications and their management
   M. Schoder (Vienna/AT)

11:30-12:30, Room 112

Clinical Evaluation Course

CEC 2703 Stroke management

Moderators: R. Gandini (Rome/IT), P. Mordasini (Bern/CH)

2703.1 Logistics in stroke
   M. Ribó (Barcelona/ES)
2703.2 Essential imaging for treatment
   S. Duda (Berlin/DE)
2703.3 Are the time windows extended by the new trials?
   S. Mangiafico (Florence/IT)
2703.4 Should patients with basilar artery thrombosis be randomised?
   J.A. Vos (Nieuwegein/NL)
2703.5 How to deal with difficult access
   A. Consoli (Suresnes/FR)
2703.6 How to deal with complications
   A. Krajina (Hradec Králové/CZ)

Round-table discussion
11:30-12:30, Room 115

**Fundamental Course**

**FC 2704** Essential skills for a clinical interventional radiologist

*Moderators: A.-M. Belli (London/UK), D. Vorwerk (Ingolstadt/DE)*

- **2704.1** 10 commandments for interventional radiologists  
  *B.T. Katzen (Miami, FL/US)*
- **2704.2** What you need to know about coagulation  
  *J. Garnon (Strasbourg/FR)*
- **2704.3** Pain management  
  *A. Buecker (Homburg/DE)*
- **2704.4** Consulting and breaking bad news  
  *J.C. van den Berg (Lugano/CH)*

11:30-12:30, Room 116

**Focus Session**

**FS 2705** Musculoskeletal: metastatic disease

*Moderators: A.D. Kelekis (Athens/GR), S. Masala (Rome/IT)*

- **2705.1** Biopsy in the spine and the peripheral skeleton  
  *M. Cifrian Perez (Valencia/ES)*
- **2705.2** Advanced image guidance for musculoskeletal interventions  
  *S.M. Tutton (Milwaukee, WI/US)*
- **2705.3** Treatment algorithm in spinal metastatic disease  
  *J.W. Jennings (St. Louis, MO/US)*
- **2705.4** Treatment algorithm in peripheral skeleton metastatic disease  
  *R.F. Grasso (Rome/IT)*

11:30-12:30, Room 113

**CIRSE meets**

**CM 2706** CIRSE meets CAIR

*Moderators: R.A. Morgan (London/UK), J.K. Wong (Calgary, AB/CA)*

- **2706.1** From CIRA to CAIR, the evolution of IR in Canada  
  *R. Abraham (Halifax, NS/CA)*
- **2706.2** Endovascular stroke therapy: a Canadian perspective  
  *M. Eesa (Calgary, AB/CA)*
- **2706.3** Experience and lessons learned in a stroke endovascular thrombectomy programme performed by IRs  
  *A. Menard (Kingston, ON/CA)*
12:30-14:00, Room 130

**Hands-on Device Training**

**EMT-HDT 6** Embolisation: materials and tools – particulate agents

*Coordinators: A.G. Rampoldi (Milan/IT), S. Spiliopoulos (Athens/GR)*

12:30-13:50, Simulator Gallery

**Simulation Training**

**SIM 4.4** Peripheral artery disease: angioplasty and stenting (core)

*Coordinators: R. Kickuth (Würzburg/DE), J.C. van den Berg (Lugano/CH)*

*Session organiser: M.A. Ruffino (Turin/IT)*

*Instructors: C. Del Giudice (Paris/FR), F. Fluck (Würzburg/DE), A. Moelker (Rotterdam/NL), W.E.A. Saad (Washington, DC/US)*

12:30-14:00, Room 111

**Hands-on Device Training**

**TA-HDT 6** Tumour ablation – Cryo- and laser ablation, IRE and electrochemotherapy

*Coordinators: A.H. Mahnken (Marburg/DE), M.R. Meijerink (Amsterdam/NL)*

12:30-14:00, Room 132

**Hands-on Device Training**

**VA-HDT 2** Vertebral augmentation

*Coordinators: P.N.M. Lohle (Tilburg/NL), K.E. Wilhelm (Bonn/DE)*

12:45-14:15, Room 118

**Safe Sedation Training**

**SED 8** Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)*

13:00-14:00

**Satellite Symposium**

For the detailed programme, please refer to page 168.
13:15-14:15, News on Stage Area

**News on Stage**

**NoS 2802** From science to practice

*Moders: Y. Arai (Tokyo/JP), M.D. Darcy (St. Louis, MO/US)*

2802.1 Perfusion imaging with 320-slice spiral computed tomography and color-coded digital subtraction angiography for assessing acute skeletal muscle ischemia-reperfusion injury in a rabbit model
*C. Li; Guangzhou/CN*

2802.2 Radiation exposure during transarterial chemoembolization: angio-CT versus cone-beam CT
*L. Piron1, J. Le Roy1, C. Cassinotto1, J. Delicque1, A. Belgour1, C. Allimant1, J.-P. Beregi2, J. Greffier2, N. Molinari1, B. Guiu1; 1Montpellier/FR, 2Nîmes/FR*

2802.3 A randomized and controlled study comparing patient controlled and radiologist controlled intra-procedural conscious sedation, using midazolam and fentanyl, for patients undergoing insertion of a central venous line
*W. Clements1, D. Sneddon1, H. Kavnoudias1, T. Joseph1, G.S. Goh1, J. Koukounaras1, T.M. Snow2; 1Melbourne, VIC/AU, 2Brisbane, QLD/AU*

2802.4 Left distal Percutaneous Radial hEmostasis using a Truncated dEflation Algorithm; IdPROTEA: safety and nursing impact assessment
*D. Klass, L. Cardarelli-Leite, A. Hadjivassiliou, J. Chung, D.M. Liu, S. Ho; Vancouver, BC/CA*

2802.5 Women in interventional radiology: Australia’s gender gap
*M. Foo1, J. Maingard2, M. Wang1, K. Phan1, R. Lim4, H.K. Kok2, R. Chandra2, M.J. Lee5, H. Asadi6, M. Brooks7; 1Heidelberg, VIC/AU, 2Clayton, VIC/AU, 3Liverpool, NSW/AU, 4Frankston, VIC/AU, 5Melbourne, VIC/AU, 6Dublin/IE*

2802.6 Platform for preclinical MRI-guided focused ultrasound hyperthermia
*U. Roy1, M. Fournelle2, S. Greiser1, R.V. Gorkum3, D. Speicher2, T. Grunwald1, S. Kozerke3, S. Tretbar2, L. Landgraf3, A. Melzer1; 1Leipzig/DE, 2St. Ingbert/DE, 3Zurich/CH*

14:30-15:00, Auditorium 1

**Honorary Lecture**

**HL 2901** Josef Roesch Lecture

*Moderator: R.A. Morgan (London/UK)*

*Laudation: A. Gangi (Strasbourg/FR)*

2901.1 Pathways and challenges to innovation in interventional oncology
*G. Narayanan (Miami, FL/US)*
15:00-16:00, Auditorium 1
Hot Topic Symposium

HTS 2902 Durability: the Achilles heel of EVAR

Moderators: R.A. Morgan (London/UK), G.M. Richter (Stuttgart/DE)

Introduction

2902.1 Adherence to IFU: essential to durability?
   J.C. van den Berg (Lugano/CH)
2902.2 Are more fenestrations better for longer durability?
   A. Katsargyris (Nuremberg/DE)
2902.3 New devices and adjuncts: will they improve durability?
   M.S. Hamady (London/UK)
2902.4 Take all the options into consideration
   M.P. Jenkins (London/UK)

Round-table discussion

Conclusion and take-home points

16:15-17:15, Auditorium 2
Focus Session

FS 3001 Open surgery vs. endoluminal treatment for TAAA

Moderators: M.P. Jenkins (London/UK), J. Lammer (Vienna/AT)

3001.1 Role of open surgery after failed TEVAR in the thoracic and
   thoraco-abdominal segment
   M. Shrestha (Hannover/DE)
3001.2 When is thoraco-abdominal surgery still needed?
   J. Kalder (Aachen/DE)
3001.3 De-branching surgery still needed?
   F.E. Vermassen (Ghent/BE)
3001.4 Technical options in endovascular repair
   M.S. Hamady (London/UK)
16:15-17:15, Room 133

**Workshop**

**WS 3002** Enteral feeding: gastrostomy, gastrojejunostomy and direct jejunostomy

3002.1 M.K. Glynos (Athens/GR)
3002.2 P. Vilares Morgado (Porto/PT)

16:15-17:15, Room 112

**Expert Round Table**

**ERT 3003** Controversies in endovascular thrombectomy

*Moderators: F. López Zárraga (Vitoria/ES), T. Struffert (Giessen/DE)*

Introduction

3003.1 Bypassing primary stroke centres
V. Costalat (Montpellier/FR)
3003.2 Skipping vs. bridging in tandem lesions
L. De Paoli (Klagenfurt/AT)
3003.3 Local and general anaesthesia, sedation
W.H. van Zwam (Maastricht/NL)
3003.4 Thrombectomy, aspiration first, combined treatment
A. Consoli (Suresnes/FR)

Round-table discussion

Conclusion and take-home points

16:15-17:15, Room 115

**Focus Session**

**FS 3004** Musculoskeletal: ablation, consolidation, embolisation

*Moderators: T. Heller (Rostock/DE), N. Karunanithy (London/UK)*

3004.1 Percutaneous consolidation: basics of biomechanics
P. Clavert (Strasbourg/FR)
3004.2 Overview of ablation methods
M.R. Callstrom (Rochester, MN/US)
3004.3 Ablation and consolidation
A.N. Kurup (Rochester, MN/US)
3004.4 The role of arterial embolisation
A.G. Ryan (Waterford City/IE)
16:15-17:15, Room 113

**Workshop**

**WS 3005  Venous access**

3005.1  *D. Savio (Turin/IT)*  
3005.2  *M. Casares Santiago (Palma de Mallorca/ES)*

16:15-17:15, Room 134

**Workshop**

**WS 3006  Management of visceral aneurysms and pseudoaneurysms**

3006.1  *M.A. Ruffino (Turin/IT)*  
3006.2  *F. Wolf (Vienna/AT)*

16:15-17:15, Room 116

**Case-based Discussion**

**CBD 3007  Below the knee**

*Moderators: A. Micari (Bergamo/IT), M. Palena (Abano Terme/IT)*

Introduction

3007.1  The role of perfusion angiography  
*J.A. Reekers (Amsterdam/NL)*

3007.2  The new generation of drug-coated balloons  
*K.N. Katsanos (Patras/GR)*

3007.3  The new generation of drug-eluting stents  
*H. van Overhagen (The Hague/NL)*

3007.4  Deep venous arterialisation  
*S. Kum (Singapore/SG)*

Conclusion and take-home points
FP 3008 **Super Tuesday**

**Moderators:** M.S. Johnson *(Indianapolis, IN/US)*,  
T.J. Kroencke *(Augsburg/DE)*

3008.1 Impact of combined coiling and liquid sclerotherapy compared with coiling only on symptoms of pelvic congestion syndrome: a randomised controlled trial  
**M.A.H. Soliman; Mansoura/EG**

3008.2 Randomised controlled trial comparing drug eluting balloon versus conventional balloon angioplasty for below the knee arteries in patients with critical limb ischemia  
**B.S. Tan 1, A. Patel 1, F.G. Irani 1, U. Pua 1, T.T. Chong 1, S. Leong 1, G. Tan 1, E. Chan 1, K. Damodharan 1, N.K. Karaddi 1, L.H.H. Quek 1, K.D. Zhuang 1, S.X.J.M. Chan 1, A. Gogna 1, C.W. Too 1, L. Toh 1, M.C. Burgmans 2, K. Gummalla 1, D. Matchar 1, S.P. Chng 1, H.H. Win 1, Y. Wei 1, S. Chandramohan 1, P. Kumar 1, J.M.E. Chua 1, R.H.G. Lo 1, K.-H. Tay 1; 1Singapore/SG, 2Leiden/NL

3008.3 Totally percutaneous deep foot veins arterialization: a single centre experience  
**B. Migliara; Peschiera Del Garda/IT**

3008.4 Viable allograft intervertebral disc augmentation: preliminary results and safety data in the first 24 patients  
**E. Yoon 1, D.P. Beall 2, D. Wagoner 1; 1Edmond, OK/US, 2Oklahoma City, OK/US**

3008.5 Intra-operative and post-operative pain management of conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) by different route of intraarterial lidocaine administration: a randomized controlled trial  
**Y.-D. Xiao; Changsha/CN**

3008.6 A comparison of retrievability and indwelling complications of Celect and Denali infrarenal vena cava filters: a randomized controlled trial  
**S.H. Baek, K. Han, G.M. Kim, J.H. Kwon, J.Y. Won, M.D. Kim, D.Y. Lee, J. Lee; Seoul/KR**

3008.7 MR-guided focused ultrasound (MRgFUS) versus external beam radiation therapy (EBRT) for the treatment of painful bone metastases: a multicenter, phase III, randomized case-control trial  
**S. Dababou, A. Napoli, C. Marrocchio, R. Scipione, G. Alfieri, D. Fierro, C. Catalano; Rome/IT**
17:30-18:30, Auditorium 2  
**Workshop**  
**WS 3101**  
**FEVAR and BEVAR**  
3101.1  
A. Katsargyris (Nuremberg/DE)  
3101.2  
R.G. McWilliams (Liverpool/UK)  

17:30-18:30, Room 116  
**Focus Session**  
**FS 3102**  
**Biliary**  
*Moderators: A. Hatzidakis (Iraklion/GR), A. Manca (Candiolo/IT)*  
3102.1  
PTBD for benign disease: strictures and stones  
C. Lanciego (Toledo/ES)  
3102.2  
PTBD for palliation of malignant bile duct obstruction  
P.E. Huppert (Darmstadt/DE)  
3102.3  
PTBD for biliary leakage, bowel perforation and enteral feeding  
A. Moelker (Rotterdam/NL)  
3102.4  
PTBD in the ERCP era  
H.-U. Laasch (Manchester/UK)  

17:30-18:30, Room 133  
**Workshop**  
**WS 3103**  
**Acute stroke management**  
3103.1  
R. Gandini (Rome/IT)  
3103.2  
J.D. Molina Nuevo (Albacete/ES)
Free Paper Session
FP 3104 Neurointerventions

Moderators: S. Hopf-Jensen (Flensburg/DE), F. López Zárraga (Vitoria/ES)

3104.1 Interim 30-day safety outcomes of Roadsaver dual-layer micromesh carotid artery stent: evidence from a large multicentre European study
S. Müller-Hülsbeck¹, S.A. Kedev², R. Langhoff³, K.R. Deloose⁴, R. Beelen⁵, O. Francois⁶, Z. Vajda⁷, A. Szolics⁸, B. Faurie⁹, J.-L. Banos¹⁰;

3104.2 Initial clinical results and in-vitro testings of the new CGuard™ MicroNet® covered carotid-stent: one size fits all
C. Wissgott¹, C. Brandt-Wunderlich², C. Kopetsch¹, W. Schmidt², R. Andresen¹; ¹Heide/DE, ²Rostock/DE

3104.3 Selective transvenous embolization combined with balloon angioplasty of occluded inferior petrosal sinus for the treatment of cavernous sinus dural arteriovenous fistulas
H. Kiyosue¹, S. Ide¹, K. Tokuyama², Y. Hori²; ¹Yufu/JP, ²Oira/JP

3104.4 Safety and efficacy of transvenous embolization of ruptured brain arteriovenous malformations as a last resort: a prospective single arm study
Y. He, W. Bai, L. Tianxiao; Zhengzhou/CN

3104.5 Breaking new ground – flow diversion beyond the circle of Willis: endovascular aneurysm treatment in peripheral cerebral arteries employing a novel low-profile flow diverting stent
S. Schob; Leipzig/DE

3104.6 Early cerebral vein opacification as imaging marker for hemorrhagic reconversion in ischemic stroke: a retrospective study
A. Ferrari, F. Schirru, F. Fusaro, P. Enne, C. Ganau, S. Corraine, S. Comelli; Cagliari/IT

3104.7 Preliminary results of the GPX embolic in a rabbit aneurysm model
R. Mühl-Benninghaus, F. Fries, U. Yilmaz, A. Simgen, T. Tomori, W. Reith; Homburg/DE
17:30-18:30, Room 113

**Free Paper Session**

**FP 3105**  **Gynaecology and urogenital interventions**

*Moderators: J.J. Ciampi Dopazo (Toledo/ES), A.V. Giordano (L’Aquila/IT)*

3105.1 Thermal ablation of renal tumors in patients with a solitary kidney: evaluation of renal function in patients with single tumor and with multiple tumors

_P.B. García Jurado, M.E. Perez Montilla, J.J. Espejo Herrero, S. Lombardo Galera, I.D. Domínguez Paillacho, L.J. Zurera Tendero; Córdoba/ES_

3105.2 Benign prostatic hyperplasia treated by an ultrasound guided transperineal laser ablation, in local anaesthesia, by interventional radiologists: outcome in 81 patients with at least 6 months follow-up

_G. Patelli1, S. Paganoni2, G. Mauri3, C.M. Pacella4; 1Alzano Lombardo/IT, 2Seriate/IT, 3Milan/IT, 4Albano Laziale/IT_

3105.3 Correlation of transabdominal contrast-enhanced ultrasound and magnetic resonance imaging for evaluation of prostate artery embolization procedures

_A. Massmann, C. Niklas, R. Kubale, P. Fries, G.K. Schneider, A. Buecker; Homburg/DE_

3105.4 Endometrial assessment prior to uterine artery embolisation

_M.K. O’Reilly, M.J. Lee, T. Geoghegan; Dublin/IE_

3105.5 Uterine artery embolisation for women with giant versus non-giant uterine fibroids: a systematic review & meta-analysis

_O. Llewellyn1, N.R. Patel1, D. Mallon2, M.S. Hamady2; 1Edinburgh/UK, 2London/UK_

3105.6 A new approach: unilateral UFE in women with symptomatic fibroids

_S.O.J.H. Adriaansens, A. Mohamad, A. Venmans, A.J. Smeets, P.N.M. Lohle; Tilburg/NL_

3105.7 Radial artery approach: a new opportunity

_N. Romero1, A. Alguersuari1, E. Criado Paredes1, J. Guitart2, J.F. Falco-Fages1, M. Teixidor Vinas1; 1Sabadell/ES, 2Barcelona/ES_
Free Paper Session

FP 3106 Biopsy and drainage

Moderators: J. Kettenbach (Wiener Neustadt/AT), S. Stojanovic (Novi Sad/RS)

3106.1 Minocycline hydrochloride as a soft sclerotizing agent for symptomatic simple renal and hepatic cysts: our experience
A. Paladini1, A. Borzelli2, F. Pane2, G. Guzzardi1, G.E. Vallati3, G. Pizzi3, A. Carriero1, D. Negroni1, A. Galbiati2; 1Novara/IT, 2Naples/IT, 3Rome/IT

3106.2 Efficacy of the tract embolization technique with gelatin sponge slurry to reduce pneumothorax and chest tube placement after percutaneous CT-guided lung biopsy
F. Cousin, H. Renier, L. Gérard, P. Lamborelle, R. Hustinx; Liège/BE

3106.3 Percutaneous image-guided drainage of the main pancreatic duct: what for and how
M. Mizandari1, T. Azrumelashvili1, G. Asatiani1, O. Kepuladze1, N. Habib2; 1Tbilisi/GE, 2London/UK

3106.4 Preliminary study on the catheter-based endoluminal radiofrequency sealing of pancreatic duct
E. Ewertowska1, A. Andaluz2, X. Moll2, A. Aguilar2, F. Garcia2, D. Fondevila2, R. Quesada2, M. Trujillo1, E. Berjano1, F. Burdío2; 1Valencia/ES, 2Barcelona/ES

3106.5 Feasibility of non-invasive MR-based characterization of pleural effusions and ascites in patients with suspected lymphatic leakage using the 6-point mDIXON fat quantification method
C.C. Pieper, A.M. Sprinkart, D. Kütting; Bonn/DE

3106.6 Novel use of guiding device for CT-guided transoral biopsies of challenging retropharyngeal lesions
H.Y. Tan, S. Leong, C.W. Too; Singapore/SG

3106.7 Transvenous biopsy of native kidneys and renal transplants
A. Schmid, S. Svandrlik, K.F. Hilgers, K. Amann, M. Uder; Erlangen/DE
Wednesday, September 11

08:30-09:30, Room 113

**Focus Session**

**FS 3201** The 20 most important studies on hepatocellular carcinoma

*Moderators: J.I. Bilbao (Pamplona/ES), P.L. Pereira (Heilbronn/DE)*

- **3201.1** The 5 most important studies on ablation  
  L. Crocetti (Pisa/IT)
- **3201.2** The 5 most important studies on transcatheter arterial chemoembolisation  
  K. Malagari (Athens/GR)
- **3201.3** The 5 most important studies on transarterial radioembolisation  
  A. Denys (Lausanne/CH)
- **3201.4** The 5 most important studies on systemic treatments  
  Y. Arai (Tokyo/JP)

08:30-09:30, Room 115

**Focus Session**

**FS 3202** Prostate artery embolisation: 360°

*Moderators: M. Grosso (Cuneo/IT), R. Kickuth (Würzburg/DE)*

- **3202.1** The science behind prostate artery embolisation  
  F.C. Carnevale (São Paulo/BR)
- **3202.2** Defining the anatomy  
  S. Modi (Southampton/UK)
- **3202.3** Embolisation technique  
  A.G. Rampoldi (Milan/IT)
- **3202.4** Complications and management  
  I. Insausti Gorbea (Pamplona/ES)
08:30-09:30, Room 116

**Video Learning Session**

**VL 3203**  Arterial Interventions

*Moderators: C. Del Giudice (Paris/FR), T. Zander (Santa Cruz de Tenerife/ES)*

3203.1  Long CTO of the SFA
*to be announced*

3203.2  Carotid stenting
*A. Micari (Bergamo/IT)*

3203.3  Challenge BTK recanalisation (retrograde access)
*L. Patrone (London/UK)*

10:00-11:00, Room 116

**Focus Session**

**FS 3301**  Thyroid management of nodular diseases

*Moderators: A. Bharadwaz (Aarhus/DK), G. Mauri (Milan/IT)*

3301.1  Tools and techniques for nodular thyroid diseases
*F. Stacul (Trieste/IT)*

3301.2  Interventional radiology in benign thyroid lesions: how to select the “fit” patient
*R. Cervelli (Pisa/IT)*

3301.3  Interventional radiology management options for thyroid cancer: algorithm proposal
*J.-H. Kim (Seoul/KR)*

3301.4  Treatments in metastatic thyroid cancer
*R.L. Cazzato (Strasbourg/FR)*
ERT 3302  Management of polytraumatised patients

Moderators: J.G. Moss (Glasgow/UK), O.M. van Delden (Amsterdam/NL)

Introduction

3302.1 The role of the trauma team  
C. Pilasi Menichetti (London/UK)
3302.2 Diagnostic modalities: US vs. CT  
E. Bertelli (Florence/IT)
3302.3 Interventional radiology techniques in trauma  
J. Golzarian (Minneapolis, MN/US)
3302.4 When the surgeon has to intervene  
K.J. Ponsen (Alkmaar/NL)

Round-table discussion

Conclusion and take-home points

CBD 3303  Venous mishaps, disasters and catastrophes: salvage approaches

Moderators: P.A.M.S. Almeida (Viseu/PT), A. Bravo De Laguna Taboada (Las Palmas/ES)

Introduction

3303.1 Superior vena cava rupture  
A.N. Makris (Westmont, IL/US)
3303.2 Massive pulmonary embolism during thrombectomy  
P.E. Andersen (Odense /DK)
3303.3 Iliac venous ruptures  
M. Rossi (Rome/IT)
3303.4 Stent migration  
R. Lakshminarayan (Hull/UK)

Conclusion and take-home points
11:30-12:30, Room 112

**MM 3401 Morbidity and Mortality Conference**

*Moderators: A. Hatzidakis (Iraklion/GR), A.G. Ryan (Waterford City/IE)*

3401.1 Veins against arteries  
*M. D. Darcy (St. Louis, MO/US)*

3401.2 The first cut is the deepest  
*A. M. Cahill (Philadelphia, PA/US)*

3401.3 Friday night. What else can go wrong?  
*A. Diamantopoulos (London/UK)*

3401.4 To remove or not to remove?  
*G. S. Goh (Melbourne, VIC/AU)*

3401.5 Be gentle with the liver  
*F. G. Irani (Singapore/SG)*

3401.6 We are not living this  
*K. Lagios (Athens/GR)*
The CIRSE Academy:
online IR education at its best

A comprehensive range of **online courses curated by leading IR experts** in the field. **The 26 courses across 7 topics** are reviewed by the UEMS and **CME accredited**.

Based on the European Curriculum and Syllabus in IR, all courses include interactive learning via a range of texts, graphics, videos and quizzes. Become a better IR, gain CME points and prepare for the EBIR in **less than two hours**.

For a full list of available courses visit cirse.org/education/academy
This year, a record number of abstracts have been both submitted and accepted for electronic poster presentation! A staggering 850 posters will be presented at CIRSE 2019, offering delegates a huge range of new scientific and educational material to peruse.

Posters will be available to view on computers in the Poster Area, which is located in the exhibition hall on the entrance level of the congress centre (please see the floorplan on page 275).

**Poster Area opening hours:**

- Saturday, September 7: 07:30-18:30
- Sunday, September 8: 07:30-18:30
- Monday, September 9: 07:30-18:30
- Tuesday, September 10: 07:30-18:30

In addition, the [CIRSE 2019 event app](#) will provide an overview of all available posters.

Congress attendees may browse through a wealth of scientific and educational abstracts as well as case reports, whenever they have time and at their own pace.
After the congress, all posters will be published in the CIRSE Library, our online resource for congress recordings, to which CIRSE members have free access.

In addition, the relevant abstracts can be found in the CIRSE 2019 Book of Abstracts, which will be published as a supplement of CVIRonline.

**Poster Awards**

After a careful review process, some posters have been selected for one of the prestigious poster awards:

- **Magna Cum Laude**
- **Cum Laude**
- **Certificate of Merit**

The award-winning posters and their authors will be announced in the congress newspaper.

**Congratulations to all winners!**
Trainees, residents and young IRs at CIRSE 2019!

Are you currently in training to become an IR or at the start of your IR career? Then don’t miss the exciting programme tailored especially to young IRs organised by the CIRSE European Trainee Forum (ETF)!

The ETF is an open forum aiming to enhance the participation of young physicians in international scientific and educational activities. One of the primary goals of the ETF is to facilitate career-furthering opportunities by bringing together young IRs-in-training to build a European network within CIRSE. The ETF activities are planned by the CIRSE ETF Subcommittee and executed exclusively at CIRSE’s Annual Meeting.

The CIRSE European Trainee Forum Subcommittee was established in 2015, and since then it has become the voice of young European IRs-in-training, providing important input on IR training pathways across European countries. This crucial feedback from 25 European countries enables the Subcommittee to adjust the European Trainee Forum activities accordingly, highlighting all the benefits of the field for the next generation of IRs.

The ETF Subcommittee at ECIO 2019

The ETF Subcommittee has been very active throughout the past year and has put together a wide-ranging programme for this year’s CIRSE, including both educational sessions and networking events. Trainees and residents can again look forward to popular ETF Short Talks and IR Trainee Sessions focused on future IR technologies, building an IR career, clinical practice or topics related to IR innovations. Additionally, all trainees and residents will have a chance to informally network with their peers at the ETF Networking Event and to put their knowledge gained at CIRSE 2019 to the test by taking part in the ETF Quiz!
Boost your career by joining our ETF community and attending the special events and sessions organised by the European Trainee Forum!

**IR Trainee Sessions**

Future IR technologies  
Saturday, Sept 7, 10:00-11:00, Room 113

Building an IR career  
Sunday, Sept 8, 10:00-11:00, Room 114

Clinical practice for trainees, residents and young IRs  
Monday, Sept 9, 10:00-11:00, Room 114

IRs: From the angiosuite to industry boardrooms and the road to innovation  
Tuesday, Sept 10, 10:00-11:00, Room 114

**ETF Short Talks**

Clinical and academic opportunities in and outside the EU  
Saturday, Sept 7, 11:45-12:45, News-on-Stage area

Interventional radiology, global health and reaching out to the rest of the world!  
Sunday, Sept 8, 11:45-12:45, News-on-Stage area

Practical career advice for young IRs  
Monday, Sept 9, 11:30-12:45, News-on-Stage area

**ETF Networking Event**

Sunday, Sept 8, 13:00-14:00, Foyer Rambla

**ETF Quiz**

Tuesday, Sept 10, 14:30-16:00, Foyer Rambla

The European Trainee Forum looks forward to welcoming you!
Come join us to celebrate the end of another successful Annual Congress!

The CIRSE 2019 Dinner & Farewell Party will be held at Can Travi Nou restaurant, an authentic Catalan farmhouse situated in a picturesque rustic setting. You can look forward to a delicious three-course dinner, followed by a party in the compound’s beautiful garden which is sure to last until the early morning hours.

Dinner and party tickets
(include cocktail reception, dinner, complimentary drinks, entertainment):
EUR 75 each

Party only tickets
(include free drinks and entertainment):
EUR 25 each

Don’t miss out!
Buy your tickets at the “Hotel | Social Events | City Information” desk, located in the entrance hall of the congress centre.

CIRSE supports compliance with ethical standards. Therefore, CIRSE emphasises that the present offer (made by Kuoni Congress) is directed to participants of CIRSE 2019 and recommends that the participants who want to accept the present offer shall bear any and all costs in this context themselves. Kindly note that entrance to the CIRSE 2019 Dinner & Farewell Party is NOT included in the CIRSE 2019 registration fee!
Barcelona, Spain
September 7-11
CIRSE 2019

CORPORATE ACTIVITIES & EXHIBITION

Satellite Symposia
Learning Centres
Industry Training Village
HDT Sponsors
Safe Sedation Training Sponsors
Simulation Training Sponsors
Technical Exhibition
Radiation Protection Pavilion
Societies
Proven design.

From the proximal to the distal seal, the Zenith Alpha™ Abdominal device is engineered to help you deliver a durable repair.

Zenith Alpha™
ABDOMINAL ENDOVASCULAR GRAFT

Learn more at
cookmedical.eu/aortic-intervention.

Some products or part numbers may not be available in all markets. Contact your local Cook representative or Customer Service for details.

The Zenith Alpha™ Endovascular System consists of:
Zenith Alpha Abdominal Endovascular Graft
Zenith Alpha Spiral-Z® Endovascular Leg
Can also include:
Zenith® Branch Endovascular Graft – Iliac Bifurcation

© COOK 07/2019  IR.D49842-EN-F
It’s back.

Cook Beacon® Tip 5.0 Fr
ANGIOGRAPHIC CATHETERS

Visit our booth to get hands-on with Beacon Tip.
Satellite Symposia

Saturday, September 7

13:00-14:00, Auditorium 2

**Philips**

**SY 401** Putting innovations in interventional radiology to work


401.1 How perfusion angiography benefits CLI procedures
*D.A. van den Heuvel (Nieuwegein/NL)*

401.2 See clearly. Treat optimally. The added value of intravascular imaging and vessel preparation to optimise outcomes
*F. Fanelli (Florence/IT)*

401.3 Percutaneous lung tumour biopsy under CBCT guidance with PET-CT fusion imaging
*C. Floridi (Milan/IT)*

401.4 Augmented reality based navigation during percutaneous vertebroplasty
*P. Auloge (Strasbourg/FR)*

13:00-14:00, Room 114

**PharmaCept**

**SY 402** Chemoembolisation with degradable starch microspheres (DSM): experience in liver and lung tumors

*Moderator: R. Iezzi (Rome/IT)*

402.1 The rationale for transient material in chemoembolisation – description of concept and use of DSM-TACE
*K. Malagari (Athens/GR)*

402.2 DSM for TACE in liver tumours
*T.J. Vogl (Frankfurt/DE)*

402.3 DSM for TPCE in lung tumours
*A. Kovács (Bonn/DE)*
13:00-14:00, Room 117

**Cook Medical**

**SY 403** Paclitaxel: the latest in its safety and efficacy

*Moderators: M.D. Dake (Tucson, AZ/US)*

Introduction by the moderator

403.1 Follow the data: Zilver PTX global data analysis  
*M.D. Dake (Tucson, AZ/US)*

403.2 Swedepad: an update  
*M. Delle (Stockholm/SE)*

403.3 Paclitaxel devices: real world evaluation of survival in peripheral vascular revascularisation  
*E. Secemsky (Boston, MA/US)*

403.4 Recent meta-analysis: how does this impact my daily clinical practice?  
*T. Zeller (Bad Krozingen/DE)*

Discussion and summary

14:00-14:30, Auditorium 2

**Abbott Vascular**

**SY 405** Importance of optimal diagnosis and treatment

*Moderator: C.A. Binkert (Winterthur/CH)*

Introduction by the moderator

405.1 How to recognise and optimally diagnose PCS  
*J. Urbano (Madrid/ES)*

405.2 How to best treat PCS?  
*J. Urbano (Madrid/ES)*

Take home message
16:15-16:35, Room 134

**Biotronik AG**

**SY 609** Novel efficient approach to old expensive challenge

*Moderator: K.R. Deloose (Dendermonde/BE)*

609.1 Crossing challenging lesions  
*M. Palena (Abano Terme/IT)*

609.2 Opening challenging lesions  
*J.C. van den Berg (Lugano/CH)*
Sunday, September 8

08:00-08:20, Room 134

Veryan Medical

SY 801 BioMimics 3D® – The Swirling Flow® stent – the ideal alternative to drug elution

Moderator: P.A. Gaines (Sheffield/UK)

801.1 The paclitaxel controversy: where we are now
P.A. Gaines (Sheffield/UK)

801.2 Why Swirling Flow® is the ideal alternative to drug elution
M. Piorkowski (Frankfurt/DE)

801.3 BioMimics 3D®: the latest clinical evidence
M. Lichtenberg (Arnsberg/DE)

08:00-08:20, Room 133

LifeTech Scientific

SY 802 Experience sharing of LifeTech Ankura Stent Graft System

802.1 Our TEVAR repair experience with LifeTech Ankura TAA
H.Z. İşcan (Ankara/TR)

802.2 Our EVAR repair experience with LifeTech Ankura AAA
E.U. Ünal (Ankara/TR)
11:30-12:30, Room 117

**Boston Scientific**

**SY 1102** Moving forward with drug eluting technologies: patient-centric approaches for peripheral arterial disease

*Moderator: F. Fanelli (Florence/IT)*

Introduction by the moderator

1102.1 What have we learned about the application of paclitaxel via a balloon?
*G. Tepe (Rosenheim/DE)*

1102.2 What have we learned about the application of paclitaxel via a stent?
*Y. Gouëffic (Nantes/FR)*

1102.3 Navigating societies’ and regulatory responses and next steps
*K.R. Deloose (Dendermonde/BE)*

1102.4 Discussion: how do we develop a patient centric treatment approach?
*K.R. Deloose (Dendermonde/BE), Y. Gouëffic (Nantes/FR), G. Tepe (Rosenheim/DE)*

Closing remarks and take-home message

11:30-12:30, Room 116

**Sirtex Medical Europe GmbH**

**SY 1103** Better selection – better SIRT with SIR-Spheres® Y-90 resin microspheres

*Moderator: J.I. Bilbao (Pamplona/ES)*

1103.1 Frontline treatments for mCRC: which patients should receive SIR-Spheres®?
*R. Sharma (London/UK)*

1103.2 SIRT-ablation with SIR-Spheres®: is a more flexible approach needed or is good patient selection sufficient?
*M. Vouche (Brussels/BE)*

1103.3 BCLC subclass consideration in intermediate HCC: when to SIRT and when to TACE
*P.L. Pereira (Heilbronn/DE)*

1103.4 A Game of Becquerels – the Battle of the IRon-Throne
*H. Ilhan (Munich/DE)*

1103.5 The road-map for Sirtex: vision, care, collaboration and 100 000 doses ... and counting
*W. Denman (Woburn, MA/US)*

Panel discussion
SY 1104  Optimising outcomes in FEMPOP occlusive diseases

Moderator: J.C. van den Berg (Lugano/CH)

1104.1 Radial force(s?): the concept
   J.C. van den Berg (Lugano/CH)

1104.2 High COF shows increase of neointimal proliferation: pre-clinical evaluation of low vs high COF stents
   R. Coscas (Boulogne-Billancourt/FR)

1104.3 Increased outward force of self-expanding BMS in the SFA could be a significant risk factor for restenosis
   M. Brodmann (Graz/AT)

1104.4 Difference in clinical outcomes of low COF stent vs high COF stent proven in clinical practice
   M.A. Funovics (Vienna/AT)
Future perspectives in Lipiodol® use for liver diseases management

Chairman: Prof. Ricky Sharma, UCL Cancer Institute, University College London, England

Future perspectives in HCC treatment #1: combined cTACE & Immunotherapy
Dr. Rafael Duran, CHUV University Hospital, Lausanne – Switzerland

Future perspectives in HCC treatment #2: cTACE outside intermediate stage
Dr. Roman Kloeckner, University Medical Center Mainz, Mainz – Germany

Future perspectives in lymphography for lymphatic hepatic leakages
Prof. Christof-Matthias Sommer, University Hospital Heidelberg, Heidelberg – Germany

Q&A and Conclusion
By the Chairman

Guerbet

**Future perspectives in HCC treatment #1: combined cTACE & Immunotherapy**

Dr. Rafael Duran, CHUV University Hospital, Lausanne – Switzerland

- **Future perspectives in HCC treatment #2: cTACE outside intermediate stage**
  Dr. Roman Kloeckner, University Medical Center Mainz, Mainz – Germany

- **Future perspectives in lymphography for lymphatic hepatic leakages**
  Prof. Christof-Matthias Sommer, University Hospital Heidelberg, Heidelberg – Germany

**Q&A and Conclusion**
By the Chairman

---

**Lipiodol® Ultra Lipid Composition:** Ethyl esters of iodinated fatty acids of poppy seed oil 10 ML, consisting of an iodine content of 480 mg/mL.

- **Indication:**
  - Intrathecal injection: for the diagnosis of nervous system lesions and for the treatment of nervous system tumors.
  - Intravascular injection: for the diagnosis of cardiovascular and pulmonary lesions.
  - Intravenous injection: for the diagnosis of vascular lesions.

- **Precautions:**
  - Hypersensitivity to Lipiodol® Ultra Lipid.
  - Contraindications: Hypersensitivity to Lipiodol® Ultra Lipid.
  - Contraindications for patients with a history of allergy to iodinated contrast agents.

- **Adverse Reactions:**
  - Hypersensitivity reactions: fever, chills, nausea, vomiting, dizziness, hypotension, anaphylaxis.
  - Local reactions: pain, redness, swelling, rash, urticaria.

- **Dosing:**
  - Intravenous injection: 10 mL.
  - Intravascular injection: 10 mL.
  - Intrathecal injection: 10 mL.

- **Marketing Authorization Holder:** Guerbet – Bp 57400 R-55434 Isyart C25 – FRANCE.
13:00-14:00, Room 117

**Guerbet**

**SY 1201** Future perspectives in Lipiodol® use for liver diseases management

*Moderator: R. Sharma (London/UK)*

1201.1 Future perspectives in HCC treatment #1: combined cTACE & immunotherapy
*R. Duran (Lausanne/CH)*

1201.2 Future perspectives in HCC treatment #2: cTACE outside intermediate stage
*R. Kloeckner (Mainz/DE)*

1201.3 Future perspectives in lymphography for lymphatic hepatic leakages
*C.M. Sommer (Heidelberg/DE)*

13:00-14:00, Room 112

**Terumo Interventional Systems**

**SY 1202** “Nightmares in the cath lab” – current controversies in complex lesion treatments in the lower limb

*Moderator: K.R. Deloose (Dendermonde/BE)*

Introduction by the moderator

1202.1 Case report: challenges and solutions in BTK interventions
*M. Palena (Abano Terme/IT)*

1202.2 Case report: SFA – what works and what doesn’t
*A.G. Schwindt (Münster/DE)*

1202.3 Case report: facing increasing complexities in FemPop procedures
*M.E. Krokidis (Cambridge/UK)*

Conclusion
INTERVENTION IN ALL DIMENSIONS

From access to closure. For radial and femoral.

Your preferred way: we offer a comprehensive portfolio spanning all dimensions of minimally invasive solutions from interventional cardiology to interventional oncology to peripheral procedures.
PUSHING BOUNDARIES

We strive for perfection in our craft, so that you can perfect yours.

www.terumo-europe.com
13:00-14:00, Auditorium 2

**Medtronic**

**SY 1203**  Making an impact on peripheral vascular restenosis: treatment solutions for challenging lesions

*Moderator: F. Fanelli (Florence/IT)*

Introduction by the moderator

1203.1  Let evidence guide your practice: safe, effective and durable treatment options using DCB
*M. Brodmann (Graz/AT)*

1203.2  PAD patients at high risk for restenosis: clinical evidence and effective solutions
*J.C. van den Berg (Lugano/CH)*

1203.3  The “other” high risk patient: utilisation of drug-coated balloons for AV access stenoses
*A. Holden (Auckland/NZ)*

Closing remarks

14:30-14:50, Auditorium 2

**Medtronic**

**SY 1304**  Challenges in thoracic aorta and new solutions

1304.1  The new Navion thoracic stent graft: a solution for challenging cases and fragile aortas
*T. Kratimenos (Athens/GR)*

1304.2  Application of heli-FX endoanchors in TAA: tips and tricks
*H. Rousseau (Toulouse/FR)*
14:30-15:30, Room 116
Canon
SY 1305  Interventional 4D CT imaging; current and future pathways

  Moderator: B. Guiu (Montpellier/FR)

1305.1 Expanding the boundaries of interventional oncology  
  F. Orsi (Milan/IT)
1305.2 Better, faster, clearer: interventional radiology with Alphenix 4D CT  
  J. Garnon (Strasbourg/FR)

16:15-16:35, Room 134
Straub Medical AG
SY 1409  Treatment of IF-DVT: clinical, safety and value benefits with the Aspirex®S  
  mechanical thrombectomy device

  Moderator: M. Lichtenberg (Arnsberg/DE)

1409.1 Value and safety benefits of mechanical thrombectomy with Aspirex®S over  
  lysis in the treatment of iliofemoral DVT occlusions  
  M. Lichtenberg (Arnsberg/DE)
1409.2 Iliofemoral DVT treatment after ATTRACT. Our experience using the Aspirex®S  
  thrombectomy system  
  B. Freitas (Maceió/BR)
1409.3 Recorded case: iliofemoral DVT treatment: tips and tricks  
  R. de Graaf (Friedrichshafen/DE)
16:45-17:15, Room 134

Cardionovum

SY 1410  Are all DCBs the same? The importance of coating stability

Moderators: R. Langhoff (Berlin/DE), A. Micari (Bergamo/IT)

1410.1 Randomised controlled trials in AV fistula: what is new with the Aperto trial? What have we learnt so far?
J.C. van den Berg (Lugano/CH)

1410.2 Real-life benefits from LegFlow treatment in very long femoropopliteal lesions: results from “REFLOW”
G.F. Torsello (Münster/DE)

1410.3 Can a non-crystalline coating improve complex procedures? An emblematic BTK case
K.R. Deloose (Dendermonde/BE)

17:30-17:50, Room 115

Alvimedica

SY 1411  Thinking different for SFA lesions: the NiTiDES solution

Moderators: R. Langhoff (Berlin/DE), D. Scheinert (Leipzig/DE)

1411.1 Today’s DES role in SFA treatment
S. Müller-Hülsbeck (Flensburg/DE)

1411.2 NiTiDES: the innovative approach for SFA lesions
A. Kahlberg (Milan/IT)

1411.3 ILLUMINA study: 2 years results
D. Scheinert (Leipzig/DE)

1411.4 From theory to practice
R. Langhoff (Berlin/DE)
**Monday, September 9**

07:50-08:20, Auditorium 2

**Medtronic**

**SY 1601**  *Off-the-shelf solutions to deal with hostile necks: more options for tailored treatment*

*Moderator: V. Riambau (Barcelona/ES)*

1601.1  APPROACH concept for complex aortic aneurysms  
*K.P. Donas (Münster/DE)*

1601.2  Hostile neck off-the-shelf solutions: when and how  
*V. Riambau (Barcelona/ES)*

1601.3  Potential benefits of AAA sac regression on patients and healthcare systems  
*A. Reyes De Valdivia (Madrid/ES)*

08:00-08:20, Room 134

**Abbott Vascular**

**SY 1602**  *Mimetic stents for safe and effective SFA treatment – optimal solution from simple to complex lesions*

*Moderator: M. Palena (Abano Terme/IT)*

Introduction by the moderator

1602.1  Long dissection occurred – what now?  
*L. Patrone (London/UK)*

1602.2  Calcified restenotic lesion – how do I treat?  
*A.L. Diederik (Nieuwegein/NL)*

Take home message
Vascular Embolization: Improved delivery through better flow management

Chairman: Prof. Geert Maleux, UZ Leuven, Leuven – Belgium

Monday, September 9th
11:30 - 12:30
Room 117
Barcelona, Spain

Microspheres Embolization and Flow Dynamic: what do we know?
Prof. Jafar Golzarian, University of Minnesota, Minneapolis – USA

Reduced non-target embolization & Better delivery with Sequare® innovative microcatheter
Prof. Geert Maleux, UZ Leuven, Leuven – Belgium

Clinical applications of Sequare® control reflux microcatheter
Prof. Florian Wolf, AKH, Vienna – Austria

Q&A and Conclusion
By the Chairman

Guerbet
11:30-12:30, Auditorium 2

**BTG**

**SY 1902**  **How to optimise your venous practice**

*Moderator: H. Jalaie (Aachen/DE)*

1902.1 Setting up a venous practice  
G. J. O’Sullivan (Galway/IE)

1902.2 Five year follow up for acute DVT patients treated with EKOS: experience from Aachen University Hospital  
H. Jalaie (Aachen/DE)

1902.3 Treatment of chronic DVT with EKOS: reproducing ACCESS PTS data in everyday clinical practice  
M. Dumantepe (Istanbul/TR)

**Q&A**

11:30-12:30, Room 117

**Guerbet**

**SY 1903**  **Vascular embolisation: improved delivery through better flow management**

*Moderator: G. Maleux (Leuven/BE)*

1903.1 Microspheres embolisation and flow dynamic: what do we know?  
J. Golzarian (Minneapolis, MN/US)

1903.2 Reduced non-target embolisation & better delivery with Sequare® innovative microcatheter  
G. Maleux (Leuven/BE)

1903.3 Clinical applications of Sequare® control reflux microcatheter  
F. Wolf (Vienna/AT)
Welcome to BTG at CIRSE 2019

We’re excited to be here and have a great educational programme planned for the next four days. Our booth features a variety of product and therapy presentations with expert clinicians and technical specialists.

Join the Education Theatre sessions on our booth featuring a wide range of hot and cool topics including:

- SIRT segmentectomy & lobectomy
- SIRT personalised dosimetry
- Do all T1a RCC patients need surgery?
- Assessing the cost effectiveness of TheraSphere® in HCC
- RCC ablation: accuracy vs outcomes
- RCC critical structure management & complex cases for cryoablation
- DC Bead LUMI® utility
- Can we standardise the DEB-TACE procedure further?

Monday, September 9 | 11:30–12:30
Auditorium 2 | Satellite Symposium

How to Optimise Your Venous Practice

Setting Up a Venous Practice
Dr. Gerard J. O’Sullivan  Galway University Hospital, Galway, Ireland

Five Year Follow Up for Acute DVT Patients Treated with EKOS: Experience from Aachen University Hospital
Dr. Houman Jalaie  Aachen-Maastricht University, Aachen, Germany

Treatment of Chronic DVT with EKOS: Reproducing ACCESS PTS Data in Everyday Clinical Practice
Prof. Mert Dumantepe  Acibadem University Hospital, Istanbul, Turkey
MONDAY, SEPTEMBER 9 | 13:00–14:00
Room #117 | Satellite Symposium

New Evidence for Personalised Treatment, a Proven Concept for Better SIRT Outcomes

How Can We Implement Real World Data in Our Daily Clinical Practice?
Prof. Boris Guiu  St-Eloi University Hospital, Montpellier, France

Clinical and Dosimetric Considerations for Y90: Recommendations from an International Multidisciplinary Working Group
Dr. Jon Bell  The Christie NHS Foundation Trust, Manchester, UK

MAA Based Personalised Dosimetry with TheraSphere® for HCC: Interim Analysis of the Phase II DOSISPHERE Study
Prof. Etienne Garin  Centre Eugene Marquis, Rennes, France

Multidisciplinary Panel Discussion – Case Studies
Prof. Daniel Seehofer  University of Leipzig, Leipzig, Germany
Dr. Maria Varela  Hospital Universitario Central de Asturias, Oviedo, Spain

Don’t forget to get hands-on with BTG products at these CIRSE HDT sessions. Participation is free of charge. Please register via your CIRSE account.

SITUATED, SEPTEMBER 7 | PMT-HDT 1 | 09:30–11:00 & PMT-HDT 2 | 12:30–14:00
Peripheral Mechanical Thrombectomy
Coordinators:  R. De Graaf  Friedrichshafen, Germany  D.K. Tsetis  Iraklion, Greece

TUESDAY, SEPTEMBER 10 | EMT-HDT 5  09:30–11:00 & EMT-HDT 6 | 12:30–14:00
Embolisation: Materials and Tools, Particulate Agents
Coordinators:  A.G. Rampoldi  Milan, Italy  S. Spiliopoulos  Athens, Greece

TUESDAY, SEPTEMBER 10 | TA-HDT 6 | 12:30–14:00
Cryoablation, Laser Ablation and Irreversible Electroporation
Coordinators:  A.H. Mahnken  Marburg, Germany  M.R. Meijerink  Amsterdam, Netherlands

BTG Sentry is a trademark and/or registered trademark of Novate Medical Limited. EKOS is a registered trademark in the US, EU and certain other territories. BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. Biocompatibles UK Ltd, EKOS Corporation, Gallin Medical Inc and Novate Medical Limited are BTG International group companies.
© 2019 BTG International Ltd. All rights reserved. ES-88-1900015. Marcomms. Date of preparation June 2019.
11:30-12:30, Auditorium 1

**Terumo Interventional Systems**

**SY 1904** Driving innovation to improve patient outcomes

*Moderators: T. de Baere (Villejuif/FR), R. Iezzi (Rome/IT)*

Introduction

*R. Iezzi (Rome/IT)*

1904.1 Microwave: why it expands my options in thyroid ablation

*H. Korkusuz (Frankfurt/DE)*

1904.2 Holmium SIRT: the first complete, innovative solution and promising combinations

*M.G.E.H. Lam (Utrecht/NL)*

1904.3 Flow redistribution: the key to improve TACE outcomes in challenging lesions

*P. Lucatelli (Rome/IT)*

1904.4 A glimpse into the future: the innovation never stops

*T. de Baere (Villejuif/FR)*

13:00-14:00, Auditorium 2

**W.L. Gore & Associates GmbH**

**SY 2001** State of the art & innovative solutions in iliac artery pathologies and portal hypertension

*Moderators: A. Holden (Auckland/NZ), R. Loffroy (Dijon/FR)*

Introduction by the chairman (part 1)

2001.1 Internal iliac artery preservation: the standard of care to sustain quality of life

*M.A. Ruffino (Turin/IT)*

2001.2 Treatment approach for iliac occlusive disease: what is the best option? Experience and data

*A. Massmann (Homburg/DE)*

Discussion and conclusion

Introduction by the chairman (part 2)

2001.3 Real life experience using controlled expansion TIPS and the GORE TIPS Set

*R. Miraglia (Palermo/IT)*

2001.4 Improved clinical outcomes using the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion: 1-year results

*J. Trebicka (Frankfurt/DE)*

Discussion and conclusion
13:00-14:00, Room 117

**BTG**

**SY 2002** New evidence for personalised treatment, a proven concept for better SIRT outcomes

* Moderator: B. Guiu (Montpellier/FR)

2002.1 How can we implement real world data in our daily clinical practice?
B. Guiu (Montpellier/FR)

2002.2 Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group
J.K. Bell (Manchester/UK)

2002.3 MAA based personalised dosimetry with TheraSphere for HCC: interim analysis of the phase II DOSISPHERE study
E. Garin (Rennes/FR)

2002.4 Multidisciplinary panel discussion – case studies
D. Seehofer (Leipzig/DE), M. Varela (Oviedo/ES)

Closing remarks

13:00-14:00, Room 116

**Straub Medical AG**

**SY 2003** A mechanical atherectomy PLUS thrombectomy hybrid device. Rotarex®S for treating complex lower limb occlusions: the evidence and the science behind it

* Moderator: B. Freitas (Maceió/BR)

2003.1 Rotarex®S mechanical atherectomy PLUS thrombectomy in chronic arterial de novo lesions: single center experience with 658 patients
B. Freitas (Maceió/BR)

2003.2 Retrospective analysis of initial results of an atherectomy PLUS thrombectomy device in patients with acute, subacute and chronic lower limb artery occlusion
C. Wissgott (Heide/DE)

2003.3 Atherectomy PLUS thrombectomy of chronically occluded popliteal artery
M. Bulvas (Prague/CZ)

2003.4 Rotational athero thrombectomy as a first-line treatment in patients with acute lower limb ischaemia and immediately threatened extremity (IIB category) 212 patients
M. Bulvas (Prague/CZ)

2003.5 A pilot study to determine vascular functions and patency through interventional atherectomy in peripheral artery disease (safety and efficacy of atherectomy on vascular functions – the SAVIOR trial): initial results
C. Rammos (Essen/DE)
14:30-15:30, Room 117

**BD**

**SY 2104** Novel interventional technology for dialysis patients

*Moderator: R.A. Morgan (London/UK)*

2104.1 Patient challenges and new KDOQI guidelines  
*C.E. Lok (Toronto, ON/CA)*

2104.2 Endo AVF, the evidence and patient benefits  
*D.K. Rajan (Toronto, ON/CA)*

2104.3 Endo AVF creation, the real-world experience  
*P.M. Kitrou (Patras/GR)*

2104.4 Innovative technologies for managing the patient life plan  
*B. Dolmatch (Palo Alto, CA/US)*

15:30-16:00, Auditorium 2

**Bentley**

**SY 2105** Clinical experience with next generation covered stents

*Moderator: R.G. McWilliams (Liverpool/UK)*

2105.1 “My monsters” – how I get those cases done  
*M.A. Ruffino (Turin/IT)*

2105.2 Clinical experience with a BX covered stent in BEVAR  
*E. Verhoeven (Nuremberg/DE)*

2105.3 Enhanced performance of complex fenestrated stent grafts using novel BX covered stents  
*M.S. Hamady (London/UK)*
SY 2106  The complex CTO

2106.1 Introduction to complex CTO  
  *A. Diamantopoulos (London/UK)*

2106.2 Subintimal angioplasty. Find your way (out) back  
  *A. Diamantopoulos (London/UK)*

2106.3 Tips & tricks: OUTBACK™ re-entry catheter  
  *A. Diamantopoulos (London/UK)*

Q&A

SY 2209  ELUTAX “3” experiences in different territories

  *Moderator: A. Ruebben (Monaco/MC)*

2209.1 Low paclitaxel dose in DCB – single center experience  
  *G. Isernia (Perugia/IT)*

2209.2 The need of drug coated balloons for ASIAN population with intra-cranial stenosis  
  *S. Singh (Biratnagar/NP)*
Tuesday, September 10

13:00-14:00, Room 116

Siemens Healthineers

SY 2801  Expand your clinical capabilities: a novel angio suite uniquely combining versatility and specialisation

Moderators: F.C. Carnevale (São Paulo/BR), Z.J. Haskal (Charlottesville, VA/US)

2801.1  Our new biplane angio suite – an all-rounder from head to toe
D. Vorwerk (Ingolstadt/DE)

2801.2  My first experience with a novel biplane system in the interventional radiology department
F. Wolf (Vienna/AT)

2801.3  A new approach to procedure guidance and image quality based dose regulation
B.C. Meyer (Hannover/DE)
Learning Centres at CIRSE 2019

The Learning Centres will provide an excellent opportunity for all congress delegates to test the latest interventional devices, gain hands-on experience with new equipment and talk to industry representatives.

The following companies will provide Learning Centres:

- Boston Scientific
- Guerbet
- Merit Medical
- Philips
- Straub
- Terumo Interventional Systems

Please note that CIRSE is not responsible for the information provided at the Learning Centres.
Boston Scientific

Boston Scientific has developed a dedicated Meet the Expert programme in their Learning Centre Room on the following topics:

**Downstaging the severity of the CLI lesions**
*K.N. Katsanos (Patras/GR)*
**Saturday, September 7, 13:00-14:00**

Learning objectives:
- Exchange with a leading expert the concept of vessel preparation prior adjunctive therapies
- What is the idea to downstage the severity of lesion and what are my tips and tricks to achieve optimal results

**Fighting CLI in BTK arteries**
*R. Langhoff (Berlin/DE)*
**Saturday, September 7, 16:00-17:00**

Learning objectives:
- What are my current options while treating critical limb ischemia disease in below the knee anatomy?
- How important is a good guidewire?
- My practical tips and tricks for revascularisation techniques

**Which embolics & why?**
*E. Kashef (London/UK), F. Wolf (Vienna/AT)*
**Sunday, September 8, 11:30-12:30**

Learning objectives:
- Case base discussions on identifying the most suitable embolic for the situation
- Explaining the rationale behind the choice of the embolic
- Exploring combinations to achieve optimal results
Learning Centres

**Thrombus management with AngioJet™ Thrombectomy System – when and how?**
* M. Dumantepe (Istanbul/TR), R. O’Neill (Nottingham/UK)
* **Sunday, September 8, 14:00-15:00**

Learning objectives:
This session will benefit most to current AngioJet™ Thrombectomy System users interested in expanding thrombectomy practice to arterial and/or venous indication.
- Exchange with experts on best practices and benefits of using AngioJet in clot management in a daily practice
- Learn about patient selection criteria, importance of institutional protocol and procedural tips and tricks
- Discuss specific questions on improving procedural outcomes

**Optimising procedural outcomes in venous stenting**
* A.J. Wigham (Oxford/UK)
* **Monday, September 9, 13:00-14:00**

Learning objectives:
This session is aimed at physicians interested in venous stenting with VICI™ venous stent.
- Exchange with expert on patient selection – which patient is benefiting from venous stenting the most
- Learn about the stent sizing and best practices to improve long term procedural outcomes with VICI™ venous stent
- Discuss preferred imaging modalities and the role of IVUS in venous stenting
- Understand the importance of setting up a venous service

**Thrombus management with AngioJet™ Thrombectomy System – when and how?**
* M. Dumantepe (Istanbul/TR), R. O’Neill (Nottingham/UK)
* **Monday, September 9, 15:00-16:00**

Learning objectives:
This session will benefit most to current AngioJet™ Thrombectomy System users interested in expanding thrombectomy practice to arterial and/or venous indication.
- Exchange with experts on best practices and benefits of using AngioJet in clot management in a daily practice
- Learn about patient selection criteria, importance of institutional protocol and procedural tips and tricks
- Discuss specific questions on improving procedural outcomes
**Hands-on experience** will also be offered:

Expert guided simulation sessions offer a 30-minute hands-on experience using simulators while discussing with expert in the field delivering key knowledge and practical tips.

**UFE expert guided simulation training for qualified medical professionals only**
*E. Kashef (London/UK)*

- **Tuesday, September 10, 13:30-14:00**
- **Tuesday, September 10, 14:00-14:30**

Limited to 12 seats per 30 minutes sessions

Learning objective:
Learn the procedural components of a UFE procedure in a risk-free learner focused environment with expert in the field delivering key knowledge and practical tips.

**PAE expert guided simulation training for qualified medical professionals only**
*H. Rio Tinto (Lisbon/PT)*

- **Tuesday, September 10, 15:00-15:30**
- **Tuesday, September 10, 15:30-16:00**

Limited to 12 delegates per 30 minutes sessions

Learning objective:
Learn the procedural components of a PAE procedure in a risk-free learner focused environment with expert in the field delivering key knowledge and practical tips.

**Hands-On Simulator Training in PAE**
*Tuesday, September 10, 16:30-17:00*

Limited to 4 delegates

Learning objectives:
- Advance your embolisation skills and train on real clinical cases in a completely safe environment
- Learn procedural steps of PAE treatments

Online pre-registration to the above sessions is available via the CIRSE 2019/ Learning Centres webpage.
**Hands-On Workshop - Undergraduate Medical Students**  
**Tuesday, September 10, 09:00-11:00**

The session will be broken down into 5 rotations enabling the undergraduate medical students to get hands-on with different products and when and how they are used. Besides handling the products, participants will have the opportunity to deploy coils and use the MENTICE simulator for UFE, PAE and HCC indications.

Registration via CIRSE

Boston Scientific Learning Centre will remain open for delegates who would like to learn more about our broad range of high-performance solutions in the vascular and interventional oncology & embolisation fields.

To learn more about our EDUCARE program, please visit our booth.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Indications, operating specifications and availability may vary by country. Check with local product representation and country-specific information for use for your country. This material is not approved for use or distribution in France.

©2019 Boston Scientific Corporation or its affiliates. All rights reserved.
Guerbet

Interventional Imaging, is offering interactive programmes on novel devices designed to secure your embolization procedures.

Join Guerbet experts within our Innovation Labs for Interactive hands-on sessions:

**September 7 – September 10, 2019**

---

**Learn more on cTACE mixture standardization using Vectorio®**

**Saturday, Sunday, Monday, Tuesday**

09:00-12:00

13:00-18:00

*P. Havard (Global Head of Marketing), A. Wei (Global Product Manager)*

Guerbet Innovation Lab – Vectorio®

---

**Discover SeQure® Control Reflux microcatheter – Flow dynamics based technology**

**Saturday, Sunday, Monday, Tuesday**

09:00-12:00

13:00-18:00

*E. Manca (EMEA Applications Specialist), E.-M. Nam (Global Product Manager)*

Guerbet Innovation Lab – SeQure®
**Philips**

**Saturday, September 7**

09:00-10:30  
*See clearly. Treat optimally: effective vessel preparation for better outcomes. (Focus on vessel prep – hands-on on all technologies)*  
*M. Mende (Hoxter/DE)*

11:00-12:30  
*Prostate Artery Embolization with XperCT*  
*N.V. Costa (Lisbon/PT)*

**Sunday, September 8**

09:00-10:30  
*See clearly. Treat optimally: effective vessel preparation for better outcomes. (Focus on vessel prep – hands-on on all technologies)*  
*M. Mende (Hoxter/DE)*

14:00-15:30  
*Prostate Artery Embolization with XperCT*  
*N.V. Costa (Lisbon/PT)*

16:00-17:30  
*See clearly. Treat optimally: optimizing outcomes in deep venous stenting with IVUS guidance. (Focus on venous IVUS – hands-on on all technologies)*  
*T. Khan (Manchester/UK)*

**Max. 10 participants per session**
Monday, September 9

09:00-10:30
See clearly. Treat optimally: effective vessel preparation for better outcomes. (Focus on vessel prep – hands-on on all technologies)
M. Mende (Hoxter/DE)

11:00-12:00
Interactive Perfusion Angiography case discussions
J.A. Reekers (Amsterdam/NL)

Student session
12:00-13:00
The future of functional vascular imaging
J. A. Reekers (Amsterdam/NL)

Student session
14:00-15:30
TACE & SIRT procedures using CBCT and automatic feeder detection software
G. Maleux (Leuven/BE)

16:00-17:30
See clearly. Treat optimally: optimizing outcomes in aortic procedures with IVUS guidance. (Focus on IVUS in aortic – hands-on on all technologies)
F. Fanelli (Florence/IT)
Tuesday, September 10

Student session
10:00 – 11:15
The benefit of multimodality fusion and needle guidance software in percutaneous biopsy and ablation procedures
C. Floridi (Milan/IT)

11:30-13:00
See clearly. Treat optimally: effective vessel preparation for better outcomes. (Focus on vessel prep – hands-on on all technologies)
M. Mende (Hoxter/DE)

14:00-15:30
See clearly. Treat optimally: optimizing outcomes in peripheral procedures with IVUS guidance. (Focus on IVUS in peripheral arteries – hands-on on all technologies)
F. Fanelli (Florence/IT)

Max. 10 participants per session
Merit Medical

You are invited to join us at our Learning Center and learn more about Merit Medical’s innovative products, therapies and education programmes.

Our Meet the Expert sessions offer the opportunity to ask and learn about specialised topics through didactic presentations and hands-on training.

We are planning sessions on the following topics and more:

3. An overview of spinal metastatic disease and the use of RF ablation in its treatment. The STAR™ Tumour Ablation System and published clinical evidence regarding safety and efficacy will be reviewed.
4. ThinkPAE™. Rationale, Evidence, and Techniques for Prostate Artery Embolisation.
5. EmboCube™: the only gelatin foam uniformly cut and preloaded into a syringe for faster preparation and accurate delivery.
6. An overview of the ClariVein® OC Infusion Catheter which allows infusion of physician-specified agents in the peripheral vasculature for endovascular occlusion of incompetent veins in patients with superficial venous reflux.

The complete and final programme will be available on CIRSE’s website and congress app. There are limited spots available, please register at our booth.

Please visit www.merit.com for product information, including instructions for use.
Straub

Management of arterial and venous occlusive diseases with mechanical debulking
Hands-on Workshop

Topics:
• Clinical and economic benefits of mechanical debulking
• Indications, treatment specifics and success rates of Rotarex®S and Aspirex®S interventions
• In-vitro demonstration of Rotarex®S and Aspirex®S catheters

Please register at our booth no. 56.

www.straubmedical.com
Terumo Interventional Systems

Saturday, September 7

14:00-15:30
Explore our access portfolio for peripheral interventions
J. Harding (Coventry/UK)

Sunday, September 8

09:30-10:30
Radial First: Why, how to perform it safely and troubleshooting in Visceral
and Oncology Interventions”
M. Guimaraes (Charleston, SC/US)
Objectives: To learn the rationale for radial access and how to do.

11:00-12:00
NaviCross 0.018” hands-on – Beyond a support catheter
Objectives: Learn tips & tricks on the use of NaviCross 0.018” in lower limb interventions,
featuring Glidewire Advantage and NaviCross 0.035”

14:00-15:00
Optimising Referral Pathways for SIRT
M.G.E.H. Lam (Utrecht/NL), G.J. Munneke (London/UK), R. Sharma (London/UK)
Objectives: A presentation and interactive discussion based workshop on how
to improve dialogue with your referring physicians at your MDT on where SIRT
is most beneficial for patients

15:30-16:30
Thyroid Ablation: introducing Microwaves with TATO Ablation System
H. Korkusuz (Frankfurt am Main/DE)
Objective: Introducing thyroid ablation technique and protocol with TATO Ablation
system, case reports
Monday, September 9

09:30-10:30
**TACE optimisation with Microballoon Occlusafe**  
*P. Lucatelli (Rome/IT), G. Verset (Brussels, BE)*  
Objectives: To discover and discuss positive results from preliminary experience on challenging lesions & hands-on session to practice the use of Occlusafe

11:00-12:00
**Roadsaver cases review. The benefits of the dual layer micromesh carotid stent with braided design**  
*A. Tomasello (Barcelona/ES)*  
Objectives: Learn about the benefits of the Dual layer micromesh carotid stent and understand the rationale behind the stent size selection when using braided stents through case review.

14:00-15:00
**Discover our innovations in FEMPOP**  
Objectives: Understand the specifications and clinical data of our new innovative products within the FemPop indication.

15:30-16:30
**Radial first: why, how to perform it safely and troubleshooting in visceral and oncology interventions**  
*M. Guimaraes (Charleston, SC/US)*  
Objectives: To learn the rationale for radial access and how to do.

Tuesday, September 10

09:30-10:30
**Efficacy and safety of HydroPearl microspheres in PAE**  
*I. Insauti Gorbea (Pamplona/ES), A. Kovács (Bonn/DE)*  
Objectives: Demonstrate the efficacy and safety of HydroPearl bland microspheres in PAE

14:00-15:00
**HoW Azur vascular plug and coils**  
Objectives: First hands on experience with the new Azur vascular plug before the initialization of the B-tests in humans and the Azur coil family
Delegates have the opportunity to participate in free hands-on workshops to enhance their understanding of the available medical devices and procedures in the field of thoracic and abdominal aortic treatments.

Register onsite for one of the highly valued workshops at the desk at the entrance of the Industry Training Village. Our friendly staff will be available throughout the day to assist with any questions about upcoming workshops and signing up.

Browse the Industry Training Village programme at www.aorticideas.org
The Industry Training Village offers physicians the chance to engage with leading medical device companies who provide technologies and devices in the field of thoracic and abdominal aortic treatments. Delegates have the opportunity to participate in free hands-on workshops to enhance their understanding of the available medical devices.

This year, two industry partners will provide exclusive hands-on workshops giving participants the chance to communicate with expert proctors on these devices:

**Bentley**
*Monday, September 9, 08:30-10:00 | 10:00-11:30*

**Medtronic**
*Monday, September 9, 14:00-18:00*

**How to participate:**
You can register onsite at the table just outside of the Industry Training Village. Our friendly staff will be available from 1 hour before the start of the workshop. You will then be notified by the assistants regarding availability and receive a participant’s badge for the workshop accordingly. All workshops are free of charge.
Bentley

Monday, September 9 08:30-10:00 | 10:00-11:30

The CERAB technique – a tailor made solution for the treatment of aortoiliac occlusive disease

Coordinators: S. Abisi (London/UK), M.A. Ruffino (Turin/IT)

Learning goals:
• Why covered stents in AIOD
• Procedure planning
• Step by step in CERAB
• Case discussion

Practice:
• Hands-on to create a CERAB
• Tips & tricks

Medtronic

Monday, September 9 14:00-18:00

ChEVAR with the Endurant™ Stent Graft System

Coordinators: K.P. Donas (Münster/DE)

During this interactive workshop, the participants will gain deeper insight about the CE-approved indications and procedural steps of performing a ChEVAR procedure with the Endurant™ Stent Graft System. Prof. Donas will use case- and video-presentations as well as a high-fidelity simulator to demonstrate the technique and transform the according knowledge to the participants.

Upon completion of the event, participants will be able to:
• Recall the indications for ChEVAR with the Endurant™ Stent Graft System
• Describe the optimal OR-setup and material needed for ChEVAR
• State the procedural steps for performing a ChEVAR procedure for a single chimney

Kindly note: A valid congress registration is required to be able to attend sessions in the Industry Training Village.
This year’s Hands-on Device Training sessions are kindly supported by the following industry partners:

**A closer look at closure devices**
- Abbott
- Cordis (Cardinal Health)
- Teleflex Medical Europe Ltd.
- Terumo Interventional Systems

**Central lines and ports**
- BD
- Medtronic
- Smiths Medical

**Embolisation: materials and tools – coils & plugs**
- Abbott
- Cook Medical
- Medtronic
- Penumbra Europe GmbH
- Terumo Interventional Systems

**Embolisation: materials and tools – liquid agents**
- BALT International
- GEM SRL
- Medtronic
- MicroVention

**Embolisation: materials and tools – particulate agents**
- BTG
- Merit Medical
- Sirtex Medical Europe GmbH
- Terumo Interventional Systems

**Peripheral mechanical thrombectomy**
- Argon Medical Devices
- BTG
- Penumbra Europe GmbH
- Straub Medical AG

**Stroke thrombectomy**
- BALT International
- Medtronic
- Penumbra Europe GmbH
- Stryker Corporation
- Terumo (Microvention)

**Tumour ablation – MWA**
- AngioDynamics
- ECO Microwave
- Endocare, Inc.
- H.S. Hospital Service SPA
- Johnson & Johnson Medical Devices Companies | Neuwave
- Terumo Interventional Systems

**Tumour ablation – RFA**
- H.S. Hospital Service SPA
- Merit Medical
- Olympus
- RF Medical
- Terumo Interventional Systems
Tumour ablation – Cryo- and laser ablation, IRE and electrochemotherapy
• AngioDynamics
• BTG
• Clinical Laserthermia Systems AB
• Elesta S.r.l.
• Endocare, Inc.
• IceCure Medical Ltd
• IGEA

Tumour ablation – Image guided navigation and targeting
• Bracco
• Johnson & Johnson Medical Devices Companies | Neuwave
• Medtronic
• Philips

Varicose veins
• AngioDynamics
• Medtronic
• Merit Medical
• RF Medical

Vertebral augmentation
• IZI Medical
• Merit Medical
• Stryker
• Teleflex Medical Europe Ltd.

For detailed information on sessions, please refer to pages 32-38.

For further information about the industry partners, please refer to pages 192-251 of the Technical Exhibitors Guide.

If you are interested in obtaining product information outside of sessions, please visit the respective company booth in the exhibition area.
Safe Sedation Training Sponsors

The Safe Sedation Training sessions are kindly supported by Medtronic and organised in cooperation with the AQAI Simulation Center.

For detailed information on the Safe Sedation Training sessions, please refer to pages 40-41.

Simulation Training Sponsors

The Simulation Training sessions are kindly supported by:

- 3D Systems
- Abbott Vascular
- Asahi
- Bentley
- Boston Scientific
- Cook Medical
- Cordis (Cardinal Health)
- Mentice
- Merit Medical
- Microvention
- Optimed
- Penumbra
- Philips
- Stryker
- W.L. Gore & Associates

For detailed information on the Simulation Training sessions, please refer to pages 42-46.

For further information about the industry partners, please refer to pages 192-251 of the Technical Exhibitors Guide.
BURNING ISSUES IN RADIATION PROTECTION: CRITICAL DOSE LEVELS AND SUBSTANTIAL RADIATION DOSE

Interventional radiologists are exposed to high levels of radiation in daily practice and therefore face particular health risks. Learn how to reduce and protect against exposure as well as the health hazards linked to high levels of occupational exposure to radiation with our best-practice guides and information materials; or take a seat and listen to a brief talk hosted by our Subcommittee or industry partners (see the Radiation Safety Talks programme on the next page).

Explore state-of-the-art protective technologies

Discuss the latest products for protection and dose management with select industry partners, who will be on hand at the RPP exhibition to address any questions you may have.
Radiation Protection Quiz
Don’t forget to test your radiation protection skills with our electronic quiz, which you can fill out via the CIRSE app!

The CIRSE Radiation Protection Pavilion is proudly supported by:
<table>
<thead>
<tr>
<th>Time</th>
<th>Radiation Safety Talk</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT SEPT 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>Opening ceremony</td>
<td>W. Jaschke (Innsbruck/AT)</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Unintended exposures, substantial radiation dose and trigger levels</td>
<td>E. Vano (Madrid/ES)</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Development of modular protective glasses</td>
<td>D. Janssen (Hilvarenbeek/NL)</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>Advantages of electronic occupational dosimetry and impact on dose reduction for professionals</td>
<td>G. Paulo (Coimbra/PT)</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>Radiation doses to the eye lens and forehead of interventional radiologists</td>
<td>A. Ploussi (Athens/GR)</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>Think Integrated – Dosimetry &amp; Protection</td>
<td>M. Schmid (Munich/DE)</td>
</tr>
<tr>
<td>SUN SEPT 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 – 09:45</td>
<td>Radiation dose in prostatic artery embolization using CBCT and 3D-Roadmap</td>
<td>M. Katoh (Krefeld/DE)</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Radiation protection lead cap – go and get it or forget it?</td>
<td>R. Adamus (Nuremberg/DE)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>The role of artificial intelligence in radiation protection and interventional radiology</td>
<td>E. Efstathopoulos (Athens/GR)</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Image fusion/confusion: Best practices</td>
<td>L. Lönn (Copenhagen/DK)</td>
</tr>
<tr>
<td>12:30 – 12:45</td>
<td>Computational dosimetry &amp; pitfalls in personal dosimetry</td>
<td>M. Ginjaume (Barcelona/ES)</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>Sterile Radiation Shielding During CINE and DSA imaging</td>
<td>E. Radtke (Leawood, KS/US)</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Difficulties for the practical implementation of the BSS European Directive</td>
<td>E. Vano (Madrid/ES)</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>Taking the weight off clinicians’ bodies while significantly improving their radiation protection</td>
<td>P. Reim (Karlsruhe/DE)</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>National and European Diagnostic Reference Levels for interventional procedures in Europe</td>
<td>G. Paulo (Coimbra/PT)</td>
</tr>
<tr>
<td>14:00 – 14:15</td>
<td>„Visualise It!“ – Translational Radiation Protection during TIPS and Biliary Drainage Procedures</td>
<td>M. Freund/M. Steurer (Innsbruck/AT)</td>
</tr>
</tbody>
</table>
# Radiation Safety Talks in the Pavilion

<table>
<thead>
<tr>
<th>Time</th>
<th>Radiation Safety Talk</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>MON SEPT 9</td>
<td>Radiation protection issues in transhepatic interventions</td>
<td>B. Gebauer (Berlin/DE)</td>
</tr>
<tr>
<td>09:30 – 09:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>Dose management and quality enhancement capabilities of Digital Variance Angiography</td>
<td>J. Kiss (Budapest/HU)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>The benefits derived from the use of dose monitoring and management systems</td>
<td>G. Bartal (Kfar-Saba/IL)</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Image quality based dose regulation – how an innovative approach has changed my daily</td>
<td>B. Meyer (Hannover/DE)</td>
</tr>
<tr>
<td>12:30 – 12:45</td>
<td>IAEA perspectives of radiation protection in fluoroscopically guided interventions</td>
<td>J. Vassileva (Vienna/AT)</td>
</tr>
<tr>
<td>12:45 – 13:00</td>
<td>Peak Skin Dose as trigger level to implement dose optimization during embolisation procedures and support patient follow up</td>
<td>A. G. Rampoldi (Milan/IT)</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Radiation protection in percutaneous vertebral augmentation</td>
<td>K.E. Wilhelm (Bonn/DE)</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Using simulation to teach basic C-arm skills</td>
<td>Z. J. Haskal (Charlottesville, VA/US)</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>IAEA eLearning tools: How to improve radiation protection of patients and staff</td>
<td>J. Vassileva (Vienna/AT)</td>
</tr>
<tr>
<td>13:45 – 14:00</td>
<td>What you do affects your radiation exposure</td>
<td>F. Celén (Bilddal/SE)</td>
</tr>
<tr>
<td>TUE SEPT 10</td>
<td>The value of Medical simulation in management of patient and staff exposure</td>
<td>G. Bartal (Kfar-Saba/IL)</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Stereotactic navigation enables highly accurate, CT-guided ablation without radiation exposure for clinicians</td>
<td>M. Peterhans (Bern/CH)</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>Radiation exposure using radial vs. femoral vs. brachial access</td>
<td>E. Brountzos (Athens/GR)</td>
</tr>
<tr>
<td>13:30 – 13:45</td>
<td>Online resources of ESR dealing with radiation protection (Eurosafe Imaging)</td>
<td>W. Jaschke (Innsbruck/AT)</td>
</tr>
<tr>
<td>Official Name</td>
<td>Booth#</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>Abbott Vascular International</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Adept Medical</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Adria Srl</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>ALN Implants Chirurgiaux</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>Alvimedica</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Andanza International</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Andramed</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>AndraTec</td>
<td>5a</td>
<td></td>
</tr>
<tr>
<td>Angiodroid</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>AprioMed</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>APT Medical</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>AR Baltic Medical</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Argon Medical Devices</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Asahi Intecc</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>B.Braun Melsungen</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>Barty Medical</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>BD</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>Bentley Innomed</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>BiBB Instruments</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Bioteque Corporation</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Boston Scientific International</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Bracco Imaging</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>BTG</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Canon Medical Systems Europe</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Canyon Medical</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Cardionovum</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Control / Distal / PMT / Transit</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Cook Medical Europe</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Cordis, a Cardinal Health Company</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Deutsche Akademie für Mikrotherapie</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>ECO Microwave</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>Edizioni Minerva Medica</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>ElastraT</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Elesta</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Encapson</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Endocare / Varian</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>Official Name</td>
<td>Booth#</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>Endovascular Today</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Galt Medical</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>GEM</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>Getinge</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Guerbet</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>H.S. Hospital Service</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Hyprevention</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>IGEA Clinical Biophysics</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>Imactis</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>InnoTherapy</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>Interventional News/CX2020</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Invamed</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>Ivascular</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>IZI Medical</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Johnson &amp; Johnson Medical Devices Companies</td>
<td>Neuwave</td>
<td>15</td>
</tr>
<tr>
<td>KA Medical</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>KDL-INT Medical</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>LifeTech Scientific</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>medac</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Medcomp</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Medex Research</td>
<td>24a</td>
<td></td>
</tr>
<tr>
<td>Medcomp</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Medtron</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Medtronic International</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>Merit Medical</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>Mermaid Medical</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>MIM Software</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Möller Medical</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Noras MRI products</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>NUMA Engineering Services</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>OptiMed</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Pajunk</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>Penumbra Europe</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>PharmaCept</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Philips Medical Systems</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Piolax Medical Devices</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Praxis Medical Devices</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>QualiMed</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Official Name</td>
<td>Booth#</td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>Ra Medical Systems</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>RF Medical</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Rontis</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>Shionogi Europe</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>ShockWave Medical</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Siemens Healthcare</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>SIO</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Sirtex Medical Europe</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Sonar</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>STARmed</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Straub Medical</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>Stryker</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Surgnova Healthcare Technologies</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>Suzhou Leapmed Healthcare Corporation</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Teleflex</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Terumo Interventional Systems</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Tokai Medical Products</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Uresil</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Veryan Medical</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Vigeo</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>W.L. Gore &amp; Associates</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td>Wisepress</td>
<td>32a</td>
<td></td>
</tr>
<tr>
<td>Zhengjiang Zylox Medical</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Ziehm Imaging</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Z-Medica Corporation</td>
<td>25</td>
<td></td>
</tr>
</tbody>
</table>
## Technical Exhibition (Numerical List)

<table>
<thead>
<tr>
<th>Official Name</th>
<th>Booth#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mermaid Medical</td>
<td>1</td>
</tr>
<tr>
<td>Cardionovum</td>
<td>2</td>
</tr>
<tr>
<td>Philips Medical Systems</td>
<td>3</td>
</tr>
<tr>
<td>Boston Scientific International</td>
<td>4</td>
</tr>
<tr>
<td>BTG</td>
<td>5</td>
</tr>
<tr>
<td>AndraTec</td>
<td>5a</td>
</tr>
<tr>
<td>Terumo Interventional Systems</td>
<td>6</td>
</tr>
<tr>
<td>QualiMed</td>
<td>7</td>
</tr>
<tr>
<td>Getinge</td>
<td>8</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>9</td>
</tr>
<tr>
<td>Stryker</td>
<td>10</td>
</tr>
<tr>
<td>Medcomp</td>
<td>11</td>
</tr>
<tr>
<td>medac</td>
<td>12</td>
</tr>
<tr>
<td>SIO</td>
<td>13</td>
</tr>
<tr>
<td>OptiMed</td>
<td>14</td>
</tr>
<tr>
<td>Johnson &amp; Johnson Medical Devices Companies</td>
<td>15</td>
</tr>
<tr>
<td>Neuwave</td>
<td></td>
</tr>
<tr>
<td>Imactis</td>
<td>16</td>
</tr>
<tr>
<td>Canon Medical Systems Europe</td>
<td>17</td>
</tr>
<tr>
<td>Möller Medical</td>
<td>18</td>
</tr>
<tr>
<td>Veryan Medical</td>
<td>19</td>
</tr>
<tr>
<td>RF Medical</td>
<td>20</td>
</tr>
<tr>
<td>STARmed</td>
<td>21</td>
</tr>
<tr>
<td>Ra Medical Systems</td>
<td>22</td>
</tr>
<tr>
<td>IZI Medical</td>
<td>23</td>
</tr>
<tr>
<td>Praxis Medical Devices</td>
<td>24</td>
</tr>
<tr>
<td>Medex Research</td>
<td>24a</td>
</tr>
<tr>
<td>Z-Medica Corporation</td>
<td>25</td>
</tr>
<tr>
<td>Elastrat</td>
<td>26</td>
</tr>
<tr>
<td>Medicor Europe</td>
<td>27</td>
</tr>
<tr>
<td>MIM Software</td>
<td>28</td>
</tr>
<tr>
<td>KDL-INT Medical</td>
<td>29</td>
</tr>
<tr>
<td>Sonar</td>
<td>30</td>
</tr>
<tr>
<td>Bioteque Corporation</td>
<td>31</td>
</tr>
<tr>
<td>Galt Medical</td>
<td>32</td>
</tr>
<tr>
<td>Wisepress</td>
<td>32a</td>
</tr>
<tr>
<td>Piolax Medical Devices</td>
<td>33</td>
</tr>
<tr>
<td>Endovascular Today</td>
<td>34</td>
</tr>
<tr>
<td>Deutsche Akademie für Mikrotherapie</td>
<td>35</td>
</tr>
<tr>
<td>Official Name</td>
<td>Booth#</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Invamed</td>
<td>36</td>
</tr>
<tr>
<td>Tokai Medical Products</td>
<td>37</td>
</tr>
<tr>
<td>Encapson</td>
<td>38</td>
</tr>
<tr>
<td>PharmaCept</td>
<td>39</td>
</tr>
<tr>
<td>Vigeo</td>
<td>40</td>
</tr>
<tr>
<td>ShockWave Medical</td>
<td>41</td>
</tr>
<tr>
<td>AR Baltic Medical</td>
<td>42</td>
</tr>
<tr>
<td>Ziehm Imaging</td>
<td>43</td>
</tr>
<tr>
<td>Interventional News/CX2020</td>
<td>44</td>
</tr>
<tr>
<td>Ivascular</td>
<td>45</td>
</tr>
<tr>
<td>Adept Medical</td>
<td>46</td>
</tr>
<tr>
<td>Abbott Vascular International</td>
<td>47</td>
</tr>
<tr>
<td>Andanza International</td>
<td>48</td>
</tr>
<tr>
<td>Pajunk</td>
<td>49</td>
</tr>
<tr>
<td>Angiodroid</td>
<td>50</td>
</tr>
<tr>
<td>Sirtex Medical Europe</td>
<td>51</td>
</tr>
<tr>
<td>Cordis, a Cardinal Health Company</td>
<td>52</td>
</tr>
<tr>
<td>Guerbet</td>
<td>53</td>
</tr>
<tr>
<td>Cook Medical Europe</td>
<td>54</td>
</tr>
<tr>
<td>BD</td>
<td>55</td>
</tr>
<tr>
<td>Straub Medical</td>
<td>56</td>
</tr>
<tr>
<td>Medtronic International</td>
<td>57</td>
</tr>
<tr>
<td>Merit Medical</td>
<td>58</td>
</tr>
<tr>
<td>Argon Medical Devices</td>
<td>59</td>
</tr>
<tr>
<td>Suzhou Leapmed Healthcare Corporation</td>
<td>60</td>
</tr>
<tr>
<td>Andramed</td>
<td>61</td>
</tr>
<tr>
<td>Adria Srl</td>
<td>62</td>
</tr>
<tr>
<td>Alvimedica</td>
<td>63</td>
</tr>
<tr>
<td>ALN Implants Chirurgiaux</td>
<td>64</td>
</tr>
<tr>
<td>W.L. Gore &amp; Associates</td>
<td>65</td>
</tr>
<tr>
<td>Siemens Healthcare</td>
<td>66</td>
</tr>
<tr>
<td>H.S. Hospital Service</td>
<td>67</td>
</tr>
<tr>
<td>B.Braun Melsungen</td>
<td>68</td>
</tr>
<tr>
<td>Canyon Medical</td>
<td>69</td>
</tr>
<tr>
<td>Bracco Imaging</td>
<td>70</td>
</tr>
<tr>
<td>GEM</td>
<td>71</td>
</tr>
<tr>
<td>Shionogi Europe</td>
<td>72</td>
</tr>
<tr>
<td>Teleflex</td>
<td>73</td>
</tr>
<tr>
<td>Official Name</td>
<td>Booth#</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td>Uresil</td>
<td>74</td>
</tr>
<tr>
<td>Surgnova Healthcare Technologies</td>
<td>75</td>
</tr>
<tr>
<td>Bentley Innomed</td>
<td>76</td>
</tr>
<tr>
<td>Edizioni Minerva Medica</td>
<td>77</td>
</tr>
<tr>
<td>Noras MRI products</td>
<td>78</td>
</tr>
<tr>
<td>Rontis</td>
<td>79</td>
</tr>
<tr>
<td>NUMA Engineering Services</td>
<td>80</td>
</tr>
<tr>
<td>BiBB Instruments</td>
<td>81</td>
</tr>
<tr>
<td>ECO Microwave</td>
<td>82</td>
</tr>
<tr>
<td>Barty Medical</td>
<td>83</td>
</tr>
<tr>
<td>AprioMed</td>
<td>84</td>
</tr>
<tr>
<td>APT Medical</td>
<td>85</td>
</tr>
<tr>
<td>Asahi Intecc</td>
<td>86</td>
</tr>
<tr>
<td>InnoTherapy</td>
<td>87</td>
</tr>
<tr>
<td>Control / Distal / PMT / Transit</td>
<td>88</td>
</tr>
<tr>
<td>Zhengjiang Zylox Medical</td>
<td>89</td>
</tr>
<tr>
<td>Penumbra Europe</td>
<td>90</td>
</tr>
<tr>
<td>Elesta</td>
<td>91</td>
</tr>
<tr>
<td>LifeTech Scientific</td>
<td>93</td>
</tr>
<tr>
<td>Medtrion</td>
<td>94</td>
</tr>
<tr>
<td>KA Medical</td>
<td>95</td>
</tr>
<tr>
<td>IGEA Clinical Biophysics</td>
<td>96</td>
</tr>
<tr>
<td>Hyprevention</td>
<td>97</td>
</tr>
<tr>
<td>Endocare / Varian</td>
<td>98</td>
</tr>
</tbody>
</table>
Technical Exhibitors Guide

Abbott Vascular International BVBA
Park Lane
Culliganlaan 2B
1831 Diegem
BELGIUM
www.abbott.com

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.

Adept Medical
6 McDonald Street
Morningside
1025 Auckland
NEW ZEALAND
www.adeptmedical.com

Adept Medical has developed a range of table accessories to assist with Interventional Radiology, Cardiology and Neuro procedures. The innovative range of products have been designed and developed in conjunction with leading clinicians. The range of products have been engineered with both patient comfort and ease of use for clinicians in mind, with a quick and simple set-up. They offer ergonomic working platforms, patient and device positioning to gain vascular access, securing the patient to ensure sterility and managing their operational environment. High performance engineering plastics and carbon fibre composites have been selected, giving superior rigidity, strength and durability, which ensures that the products have a long life. As a result, the products have low radiolucency, are light-weight yet strong, and have excellent resistance to chemical attack associated with commonly used cleaning products. Adept Medical’s table accessory products are ergonomic to use, reduce set-up time and offer procedural repeatability, whilst ensuring patient security and comfort. Adept Medical is a leading specialist injection moulding and carbon fibre composite manufacturer to the medical market, located in Auckland, New Zealand. With an ISO 13485 certified quality management system and clean room facilities, we offer products to the global healthcare industry through an independent network of medical and surgical distribution companies.
Adria Srl
Via Modena 46
40017 san Giovanni in Persiceto
ITALY
www.adriamedical.com

Biopsy, Drainage and catheters, Vertebroplasty, Kyphoplasty;

ALN Implants Chirurgicaux
589 Chemin du niel
83230 Bormes Les Mimosas
FRANCE
www.aln2b.com

ALN is one of the leaders in its field with its ALN optional vena cava filter. This filter is well known in Europe for more than 28 years and is present for long on international markets including USA.
Products: ALN Optional vena cava filter with Hook, ALN Optional vena cava filter without Hook, Retrieval systems of the ALN filter including the 2in1 device, CE Mark & FDA approved (2008), Proven effectiveness, Retrieval after long placements (over 40 months), 1 Retrieval at 12 years.

Alvimedica
Via Crescentino
13040 Salufggia
ITALY
www.alvimedica.com

Alvimedica is a young, innovative company devoted to developing minimally-invasive technologies for medical professionals looking for the next level of innovation in the operating room. We provide an innovative endovascular and interventional cardiology product portfolio aim to cover the patients un-meet needs.
**Andanza International**

Zum Werrablick 4  
37276 Meinhard  
GERMANY  
www.andanza.de

Founded in 2005, Andanza International has evolved to an innovative manufacturer and for medical products, based in Germany. Our portfolio features our innovative „Premofix“ product line for compressive aftercare of femoral, radial and brachial interventions. Apart from that, we feature our closure device „Premoclose“ and several accessories. Our worldwide customers benefit from our global on-site service, innovativity, as well as from the experience of our professional staff.

**Andramed GmbH**

Schiesswieslenstrasse 18  
72766 Reutlingen  
GERMANY  
www.andramed.com

We are a family-owned and family operated medical device company. We are located near Stuttgart in one of the most important high-tech areas of Southwest Germany. In cooperation with doctors, universities and partners we develop excellent innovative medical devices. Our high-level products are manufactured in-house using the excellent craftsmanship of our highly qualified, motivated staff. We distribute all our sophisticated first-class medical devices all over the world. We are offering different kind of Retrieval Devices, great vessel stents, Valvulotomes and a big range of PTA Balloon Catheters in various sizes.
AndraTec GmbH
Simmerner Strasse 70
56075 Koblenz
GERMANY
www.andratec.com

AndraTec is highly innovative company located in Germany with a focus in the Interventional Cardio-Vascular field. AltoSa XL PTA Balloons, Optimus XL Stents, Exeter Snares, Pillar & Pillow Devices;

Angiodroid s.r.l.
Via Caselle 76
40068 San Lazzaro di Savena
ITALY
www.angiodroid.com

Angiodroid S.r.l. is an Italian innovative company that projects and trades solutions for the medical market. Angiodroid The CO2 Injector is our main product. It is a carbon dioxide (CO2) injector for interventional radiology procedures and represents the perfect solution for the treatment of patients with: diabetic disease, renal failure, intolerance to iodinated contrast media. The use of CO2 in peripheral angiography has been common practice for many decades. To date, however, it has not the proper success due to the lack of advanced technology which could support operators during the procedures. Angiodroid The CO2 Injector, whose main fields of application are interventional radiology & vascular surgery, is the perfect solution to all these problems and is the only injector: 100 % automatic, 100 % safe, 100 % digital, 100 % user friendly.
AngioDynamics
Haaksbergweg 75
1101 BR Amsterdam Z-O
THE NETHERLANDS
www.angiodynamics.com

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. Stop by AngioDynamics booth to find out more about our NanoKnife, Irreversible Electroporation (IRE), Solero Microwave Tissue Ablation (MTA), BioSentry tract sealant, BioFlo PICCs, ports and the AngioVac Cannula & Circuit System.

AprioMed AB
Virdings Allé 28
75450 Uppsala
SWEDEN
www.apriomed.com

AprioMed develops, manufactures, markets and sells innovative medical devices and related services within the field of interventional radiology. We aim to deliver, in close collaboration with healthcare practitioners, innovative quality tools to achieve the most favourable solutions for radiologists worldwide.
APT Medical Inc.
Room 804, the Integrated building, Qinghua Information Center, Keyuan Road, Nanshan District 518057 Shenzhen, Guangdong CHINA

APT Medical Inc. is a leading developer, manufacturer and vendor of advanced interventional medical devices for electrophysiology, cardiology and radiology. APT has a strong R&D and manufacturing ability with innovative ideas in Microcatheter, Hydrophilic Angiographic Catheter, Hemostasis Introducer, and so on. APT established 5 branch offices in China to provide fast and convenient service to clinical. Now APT’s products are CFDA, CE, CMDCAS, MFDS approved and widely sold to more than 50 countries/regions like Germany, Netherlands, Spain, Canada, Korea etc.

AR Baltic Medical
P. Luksio g. 5B
08221 Vilnius
LITHUANIA

AR Baltic Medical is engaged in the development and manufacturing of catheters and stents. The company is specialized in the field of invasive cardiology, radiology and neurology providing a range of treatment possibilities with drug eluting devices for several applications. The key products of AR Baltic Medical include paclitaxel coated PTA and PTCA balloons as well the unique paclitaxel coated balloon for intra-cranial applications. The company maintains strong relationship with universities, medical centers of clinical and scientific relevance and technical research centers for its development activities. AR Baltic medical has its main research and manufacturing facility in Vilnius, Lithuania and in Budapest, Hungary. The company offers its products through distributors across Europe, Middle East, Asia, Latin America and Africa as well as directly to hospitals.
Argon Medical Devices
Av. Mon Repos 14
1005 Lausanne
SWITZERLAND
www.argonmedical.com

Argon Medical Devices welcomes you to booth 59 at Cirse19. Argon is a global manufacturer of specialty medical products offering a broad range of single-use medical devices for interventional radiology, vascular surgery and interventional cardiology and oncology. Argon’s portfolio includes: CLEANER™ Thrombectomy Systems, Option™ ELITE IVC Filter, Atrieve™ Vascular Snare Kits, BioPince™ Full Core Biopsy Instrument, TLAB® Transjugular Biopsy Instrument and SKATER™ Drainage Systems, in addition to many other products for your interventional needs. Our products are sold globally through our sales teams and specialist distributors. The spirit of innovation thrives as we focus on improving the lives of caregivers and patients by delivering best-in-class medical device products, programs and services. And our commitment to quality is unwavering-achieved through the dedication of 800 highly-skilled employees globally. For years, medical professionals worldwide have trusted us to deliver consistent clinical performance. The Argon team will be delighted to meet you on stand 59 for presentations and hands-on sessions of our complete range of products. We are looking forward to your visit!

Supporting IRs in training at CIRSE 2019!

In order to encourage the participation of young IRs in the Annual Congress, CIRSE initiated a dedicated support programme for interventional radiologists in training.

The **IR Trainee Support Programme** allows CIRSE Junior Members who submitted an abstract for CIRSE 2019 as first or presenting author to attend the congress free of charge.

More than 160 IRs-in-training successfully applied for this programme and will benefit from this initiative. Argon Medical Devices is a proud supporter of the **IR Trainee Support Programme**.
Asahi Intecc Co., Ltd. Europe
Strawinskylaan 527
WTC Tower B 5F
1077 XX Amsterdam
THE NETHERLANDS
www.asahi-intecc.co.jp/en

Asahi Intecc is a Japanese company established in 1976, developing and supplying high-quality medical products for catheter treatment (guide wires, guiding catheters and balloon catheters) using an integrated in-house production system that covers everything from the selection and treatment of raw materials to the manufacturing of final products. Asahi Intecc’s leading products are currently for the cardiovascular system area, but treatment areas are expanding to encompass other areas such as peripheral vascular (lower-limb), abdominal and cerebrovascular areas.

B.Braun Melsungen AG
Sieversufer 8
12359 Berlin
GERMANY

B. Braun is one of the world’s leading healthcare suppliers. Its division Vascular Systems offers high quality products for peripheral interventional procedures. New in pipeline are the novel drug coated balloon SeQuent® Please OTW and the innovative Multiple Stent Delivery System VascuFlex ® Multi-LOC.

Barty Medical
South 2F, Building 2-1, NO.20 street, ETDZ
310018 Hangzhou, Zhejiang
CHINA
www.bartymedical.com

Barty Medical is engaged to vascular intervention. Our products include: paclitaxel-eluting balloon, introducer sheath, diagnostic catheter, guide catheter, HP PTA& PTA balloon catheter.
BeGraft peripheral

Peripheral Stent Graft System

Less trauma, faster procedures through low profile (8F compatibility up to Ø 8 mm)

Outstanding lesion access through exceptional flexibility

Predictable stent behaviour through low foreshortening & high radial force

www.bentley.global
BD
Forest House, Tilgate Forest Business Park
Brighton Road
RH11 9BP Crawley
UNITED KINGDOM
www.bd.com

BD is one of the largest global medical technology companies and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. In 2017, BD welcomed C.R. Bard into the BD family and through this collaboration is accelerating the delivery of innovative technologies, world-class clinical education, and disease awareness programs that are helping to transform the standard of patient care.

Bentley Innomed GmbH
Lotzenäcker 25
72379 Hechingen
Baden-Württemberg
GERMANY
www.bentley.global

Bentley’s passion is the development, manufacturing and distribution of innovative implants for minimal-invasive treatments of vascular diseases. Since market launch in 2012 we rapidly expanded worldwide. Thanks to our international network of exclusive distribution partners we are represented in more than 70 countries – in some we are already market leader.

BiBB Instruments
Medicon Village
22381 Lund
SWEDEN
www.bibbinstruments.com

BiBB Instruments AB, is a Swedish medical device company that develops and markets biopsy instruments under the brand name EndoDrill®, enabling earlier and more accurate cancer diagnosis compared to conventional biopsy instruments. BiBB develops a range of proprietary biopsy instruments for both flexible endoscopy and core needle sampling. EndoDrill® Core Needle, a unique core needle instrument for increased sampling control and accuracy, has recently been launched. The company is based in Medicon Village in Lund, Sweden, and was founded by Dr. Charles Walther, a cancer researcher at Lund University and a senior physician in surgical pathology and clinical cytology at Skåne University Hospital in Lund, Sweden.
Bioteque Corporation currently operates two manufacturing plants in Taiwan and one manufacturing plant in Philippines. The Bataan facility was established in 2013 by Bioteque Corporation. The facility employs approximately 300 people. The area (size) of the facility is 34,288 total square meters. Product categories manufactured are mainly Bloodline and Respiratory Care products. We provide solutions in many critical applications such as nephrology and dialysis, cardiovascular catheters, endourology, interventional radiology just about every field that exists. Manufacturing processes associated with full range of TPU (Thermoplastic polyurethane) catheters and full range of endovascular, endourology, interventional radiology products are manufactured by the Taiwan facilities. All our facilities are accredited with ISO 13485 and compliant with FDA, GMP and Quality System Regulations. In pursuit of extensive and everlasting growth, we are supplying quality products include: Pigtail Drainage Catheter / Double Pigtail Ureteral Stent / PCN kits for Nephrostomy, Hemodialysis Bloodline / AV Fistula Needles, IV Infusion Bags, Double Lumen Dialysis Catheter, CVC catheter, CAPD solution system. Our facility is ISO13485, CE-2460 accredited and passed FDA establishment audit. For more information, please visit our website www.bioteq.com.tw

BIOTEQUE is continuously dedicated to develop innovative products and provide total solutions for all its customers.

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs. Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS) and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology. The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. To learn more about Bracco Imaging, visit www.braccoimaging.com

BTG is a global healthcare company focused on Interventional Medicine. Our mission is to provide imaginative new ways to treat disease; making a real difference for patients, and a valuable contribution to healthcare. Today we have a growing portfolio of products that advance the treatment of cancer and vascular conditions. We strive to develop ground breaking technologies, administered using minimally-invasive, image-guided therapies. Modern medicine is evolving and at BTG we believe intelligent science is the way forward. For more information visit BTGplc.com, or @BTGIO and @BTGVascular on Twitter
Canon Medical Systems Europe B.V.
Zilverstraat 1
2718 RP Zoetermeer
THE NETHERLANDS
eu.medical.canon

Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features. At Canon Medical we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.

Canyon Medical Inc.
Bldg 3, Phase 2 Accelerator, No. 11 Yaogu Ave.
Jiangbei New Area
210032 Nanjing
CHINA
www.canyonmedical.com.cn

Canyon Microwave Ablation is indicated for use in percutaneous, laparoscopic, and intraoperative coagulation (ablation) of soft tissue, including partial or complete ablation of non-resectable liver and lung tumors. It mainly includes Microwave Ablation System and Microwave Ablation Antennas, which are designed to realize a reliable, predictable and uniform ablation zone. Canyon Medical is specialized in Microwave Ablation for over 20 years with the largest accumulated cases done successfully with our system in China. By innovating with clinical practices hands in hands, we are pioneering to solve clinical challenges in this field. In view of our continuous and prominent contribution, our company was granted with many great honors, like the National Award for Scientific and Technological Invention in 2014. In 2015, Canyon Medical joined the family of Micro-Tech. In virtue of Micro-Tech’s international platform and management philosophy, Canyon Medical is advancing towards a greater international stage at a higher level. As a leading brand in China with endless efforts in product design and R&D, we are proud to continue delivering solutions Accurate, Stable, Safe and more. Email: sales@canyonmedical.com.cn.
**Cardionovum GmbH**
Am Bonner Bogen 2  
53227 Bonn  
GERMANY  
www.cardionovum.com

Cardionovum GmbH is a leading company in innovative coronary and peripheral drug coating technologies improving clinical outcomes and quality of life. LEGFLOW RX/OTW® is our paclitaxel releasing peripheral balloon dilatation catheter for the safest SFA & BTK revascularization therapy. APERTO OTW®, the paclitaxel releasing hemodialysis shunt balloon dilatation catheter protects AV fistulas and shunt grafts from early restenosis. For the prevention and successful dilatation of intimal hyperplasia. RESTORE DEB® drug coated balloon and XLIMUS® drug eluting stent are the latest coronary innovations with highest patient safety guarantee.

**Control/ Distal/ PMT/ Transit**  
2757 s 300 w, Suite F  
UT-84115 Salt Lake City  
UNITED STATES OF AMERICA  
www.xoscore.com

Transit’s XO Score Sheath is a low-profile, one-piece metal alloy “shell” that converts standard off-the-shelf PTA balloons into scoring vessel prep and infusion systems. The proprietary Roto-strut design accommodates multiple balloon diameters and lengths to deliver controlled, predictable, circumferential scoring for effective dilatation. Control’s ASPIRE Mechanical Thrombectomy Systems deliver new speed, power, force, and volume. FDA cleared ASPIREs are sold alone and/or in a kit with catheters. Distal’s Pilot: optimized device for bone access & tissue resection. PowrSyringe provides high quality images potentially using less contrast & reducing radiation. AirTight Control Syringe with Slip-Ring Technology, provides easy connection and disconnection with enhanced connection integrity and improved patient safety.
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials, and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees, and our communities. For more information, visit www.cookmedical.eu, and for the latest news, follow us on Twitter, Facebook, and LinkedIn.

Cordis, a Cardinal Health company, is a worldwide leader in marketing innovative solutions and devices for cardiovascular disease management. Cordis is committed to deliver the right combination of solutions, products, services and evidence to treat millions of patients who suffer from vascular disease.
Microtherapy or minimally-invasive medicine opens a perspective of completely new therapeutic dimensions in numerous medical subspecialties. Technical advances enable treatment of an increasing number of diseases with a minimum of trauma and discomfort to the patient. However, such strategies demand a highly developed sense of interdisciplinary strategies and a culture of teamwork and communication across medical specialties. The same challenges apply for the development of new materials, tools and interventional techniques, which can only be successfully implemented in close cooperation of physicians, scientists and industrial developers to meet the demands of patients and users. The Deutsche Akademie für Mikrotherapie (DAfMT) understands itself as a platform for this interdisciplinary dialogue. Main feature at present is academic teaching in practical courses and workshops. Our philosophy is based on a disease-centered approach, with physicians of various specialties gathering to teach conceptual interdisciplinary thinking in addition to practical skills in microtherapy. Scholars will be guided to develop treatment algorithms including microtherapeutic techniques, and they will additionally undergo training using phantoms and animal models to learn essential practical skills. The DAfMT also renders specific services for preclinical science and development in microtherapeutic techniques and the according tools.

Since 2000, ECO Medical has been a leading medical device manufacturer in China that specializes in microwave ablation, high frequency, and physical therapy products. Our mission is to deliver the most advanced technology and solutions to those who are in need all over the world. ECO microwave ablation system is intended for the ablation of soft tissues during open, percutaneous or laparoscopic procedure with image guidance. Please visit www.ecomircrowave.com for more information.
Edizioni Minerva Medica
C.so Bramante 83-85
10126 Torino
ITALY
www.minervamedica.it

Since 1909, Edizioni Minerva Medica publishes specialist journals and books which are distributed worldwide, among which the Journal of Cardiovascular Surgery. The journal is indexed by Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus and has an Impact Factor.

Elastrat Sàrl
43, av. de Châtelaine
1203 Genève
SWITZERLAND
www.elastrat.com

Elastrat Sàrl is a worldwide leader in the development and realization of anatomical human vascular phantoms. Based in Geneva Switzerland, our flow models contain various pathologies as aneurysms, stenoses and loops. We manufacture Head, Thoracic, Heart, Abdominal and peripheral models. You will find Elastrat at booth 26. The models work with a small pump in a closed water circuit and are appropriate for education, Hands-On trainings, R&D purposes to enhance new intervention technologies, product development and procedure improvements. As they are transparent to light they are suitable for use with video and photographic monitoring. Elastrat’s phantoms offer quality hands-on training experience. We also supply custom-made phantoms of patient’s specific pathologies with STL files received from clients. All our models train in a most realistic medical environment. Elastrat’s in-vitro models are compatible with all imaging technologies such as angiographies with contrast liquid, CI, IRM and, provided the appropriate circulating fluid is used, trans-cranial Doppler techniques. Elastrat maintains close working relationship with renowned medical centers as the GRAC (Groupe de Recherches en Anatomie Clinique) University of Geneva and HUG Geneva Hospitals.
Elesta S.r.l.
Via Baldanzese 17
50041 Calenzano
Firenze
ITALY
www.elesta-echolaser.com/?lang=en

We develop innovative hi-tech therapeutic applications for interventional medicine. Our main product is EchoLaser: the first and unique integrated Laser-Ultrasound system that allows for the diagnosis and micro-invasive treatment of benign and malignant tumours. EchoLaser uses the laser radiation transmitted by independent sources (up to 4) through extremely thin optical fibres (0.3 mm) inserted percutaneously under a proprietary ultrasound guiding system (which includes a planning and simulation software). EchoLaser Therapy can induce a cyto-reduction process on benign lesions (e.g.: BPH, thyroid nodules, etc.) or destroy cancerous tissue of malignant lesions (e.g.: metastatic lymph nodes, liver, prostate and kidney cancer, etc.). No general anesthesia is generally required. Procedures can be performed in an outpatient regimen, with consequent faster recovery after treatment. We want to play an important role in the new frontier of Precision Medicine, which is more than genomics and bespoke pharmacological treatment, but includes more accurate imaging and non-surgical treatments (e.g. ablation). Core EchoLaser Thermotherapy applications are: ModîLite - lesions of the neck, such as benign thyroid nodules and metastatic lymph nodes. SoracteLite - urinary system disorders like Benign Prostatic Hyperplasia (BPH), low-risk localized Prostate Cancer (PCa) and Kidney Cancer. PBLite - primary and secondary malignant liver cancers

Encapson BV
Institutenweg 25a
7521PH Enschede
THE NETHERLANDS
www.encapson.com

Encapson is a medical technology company with the mission to improve patient care through innovative echogenic visibility solutions for medical devices. Sono-Coat™ is a best in class coating-based visibility system that significantly improves the ultrasound visibility of medical devices in the body leading to better patient outcomes. The unmatched ultrasound visibility of Sono-Coat™ enables doctors carrying out difficult minimally invasive procedures. Sono-Coat™ is a game-changing technology in situations “when precision counts”. It enables precise targeting of objects in deeper tissue structures (e.g. liver and kidney biopsies) and supports the physician in performing accurate, safe and error-free ultrasound-guided minimally invasive procedures.
Varian’s interventional oncology business offers a spectrum of ablation and embolics solutions encompassing cryoablation, microwave ablation, and embolic microspheres. The company’s Velocity™ RapidSphere software offers image-guided voxel-based dosimetry for radioembolization using Y90 Selective Internal Radiation Therapy (SIRT). Varian has also long been the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and proton therapy, and brachytherapy. Varian is uniquely positioned to develop innovations in interventional oncology with a wider range of cancer care solutions delivered through Varian’s proven global platform. Varian employs approximately 7,000 people at sites around the world. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.

Endovascular Today Europe is the premier publication for all specialists engaged in endovascular therapies. Published 7 times a year with a weekly e-news, each issue of Endovascular Today Europe features timely articles on new techniques, clinical trial results, case studies, and advances in technology for endovascular practitioners. Endovascular Today Europe is distributed to 9,200 endovascular specialists in Europe.
Galt Medical Corp. has been a leading provider of vascular and interventional medical devices for almost 30 years, developing and manufacturing a range of products for interventional procedures. Galt offers a wide range of products, including private label products for medical device OEMs and Galt branded products to clinicians worldwide through a network of distributors. Our facilities are located in Texas, Massachusetts, Costa Rica, and now, Ireland. Galt products are used for a range of Interventional Radiology, Interventional Cardiology, Vascular Surgery, and IV Therapy procedures.

Galt is pleased to announce the recent acquisitions of Arrotek and Concert Medical. Arrotek is a product design and development services business focused on minimally invasive medical devices that are an excellent complement to Galt’s vascular access product line. Concert Medical has over 30 years’ experience designing, developing and manufacturing interventional guidewires for the world’s largest medical device companies. The Concert Medical engineering team will support your Interventional Guidewire new product development, new process development, equipment design & build and manufacturing needs. We have the ability to provide a full range of device delivery solutions from initial access, to the final placement of novel therapeutic devices. For additional information, please visit www.galtmedical.com.
GEM S.r.l.
Via dei Campi, 2
LU-55049 Viareggio
ITALY
www.gemitaly.it/en

GEM S.r.l., Italian company established in 1994 produces (under Glubran brand) and distributes all over the world Glubran 2, synthetic sealant for Surgical and embolic agent for Endovascular use and Glubran Tiss for skin application. The company also produces and distributes devices to apply Glubran 2 in different ways: Dispensing Tips; Catheters for Laparoscopy; Drop Control Devices; Nebulizers; 1 ml Luer lock syringes and Vascular Closure Devices specific for femoral accesses.
All Glubran products are CE marked. Glubran 2 is an embolising agent used in interventional radiology and neuroradiology. The definitive solution for: AVM, Trauma, Bleedings, Tumors, Varicocele, Portal Vein, Type II endoleaks; Glubran 2 is a medical device Class III CE marked for internal, endvascular and external use. Glubran 2 is a synthetic biodegradable n-butyl-cyanoacrylate basis glue, modified by the addition of MS, a monomer synthesized by GEM.
Glubran 2 is ready for use, with high adhesive, sealing and haemostatic properties. Once it is polymerised, creates an efficient antiseptic barrier against the most diffused infective or pathogenic agents during surgical intervention.

Getinge
Kehler Strasse 31
76437 Rastatt
GERMANY
www.getinge.com

Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Our extensive portfolio of trusted products, solutions and consulting services have been brought together under one single brand – Getinge. With brands like Maquet, Lancer, Atrium, Pulsion, Datascope, Steritec and Stericool – just to name a few - we are now a global market leader in many healthcare and life science segments. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving every-day life for people, today and tomorrow. www.getinge.com
Guerbet is a pioneer with more than 90 years’ experience in the field of contrast agents and a world leader in medical imaging. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. Guerbet allocates 8% of its revenue to R&D and relies on over 200 employees in various work sites in France, Israel and the United States, making of the company a significant investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in sales in 2018. For more information on Guerbet, please visit www.guerbet.com

Supporting IRs in training at CIRSE 2019!

In order to encourage the participation of young IRs in the Annual Congress, CIRSE initiated a dedicated support programme for interventional radiologists in training.

The IR Trainee Support Programme allows CIRSE Junior Members who submitted an abstract for CIRSE 2019 as first or presenting author to attend the congress free of charge.

More than 160 IRs-in-training successfully applied for this programme and will benefit from this initiative. Guerbet is a proud supporter of the IR Trainee Support Programme.
H.S. Hospital Service S.p.A.

Via Zosimo, 13
00178 Roma
ITALY
www.hshospitalservice.com

HS Hospital Service Spa is a leading player in the international interventional oncology market, from RF and MW tumor ablation systems to soft tissue and bone marrow biopsy needles, catheters, drug infusion devices and all sorts of products for surgery, interventional radiology and critical care. In the field of health technologies, success may only be achieved through excellence. We are committed to deliver excellence all the way from product design and manufacturing to post-sale customer care. We transfer know-how and expertise from industrial research to the clinical field and back. Everyday we work side by side with physicians and interact with all the stakeholders in interventional oncology for better understanding and fulfilling their needs and requirements, so to deliver to the market top level devices, with optimum performance, minimum invasiveness and unmatched usability. Let us show you our new products and projects and let us share with you information, ideas, plans and strategies for the future! Please come and visit us at booth number 67!

Hyprevention

PTIB - Hopital X. Arnozan
Avenue du Haut-Leveque
33600 Pessac
FRANCE
www.hyprevention.com

Hyprevention’s products aim at reinforcing bone sites, weakened by osteoporosis or metastasis such as the proximal femur - Y-STRUT - or vertebra - V-STRUT. These two implants in polymer, implanted by minimally invasive surgery, are part of the STRUTPLASTY technique developed by Hyprevention. Visit us for more information!
IGEA S.p.A. Clinical Biophysics
Via Parmenide 10/a
41012 Carpi
ITALY
www.igeamedical.com

IGEA works to improve patient’s Quality of Life developing and producing, from own original projects, innovative, effective and safe therapeutic systems for clinical practice. IGEA develops biophysical treatments in two main areas: Orthopaedics - to improve bone healing and joint preservation, Oncology - to treat cancer. The Cliniporator® is the most advanced electroporation technology for Electrochemotherapy of tumour nodules located to the skin, subcutaneous tissues, parenchyma and bone.

Imactis
20 Rue du Tour de l Eau
38400 Saint Martin d Heres
FRANCE
www.imactis.com

Specialized in computer assisted interventional radiology Guidance, assistance and 3D navigation to reach the target organ or lesion, with improved accuracy and speed, and with reduced radiation, have been consistently identified as key unmet needs worldwide in percutaneous interventional radiology. Founded in 2009 in the French Alps, Imactis created CT-Navigation, a unique solution which addresses these needs, in an intuitive and efficient way, with minimal set up time and a short learning curve.
Vascular & Endovascular Consensus Update

21–24 APRIL 2020
TUESDAY–FRIDAY
OLYMPIA LONDON • UNITED KINGDOM

See you next year!
WWW.CXSYMPOSIUM.COM
InnoTherapy Inc.
25, Seonyu-ro 13-gil, Yeongdeungpo-gu
07282 Seoul
KOREA, REPUBLIC OF
www.innotherapy.com

InnoTherapy Inc. has been developing a series of innovative biopolymer & medical devices in the surgical sealant field with its "bio-inspired" technology since 2010, and is currently listed on KOSDAQ. Product Information: InnoSEAL, launched in 2016, InnoSEAL has been marketed with Korean MFDS approval, US FDA 510(k) clearance, and Japanese PMDA registration. Currently under Class III CE Marking review and expected to be launched in the expanded global market in 2019. InnoSEAL Plus in Completion of Pivotal Trial. Exploratory study confirmed its safety and efficacy, and 96 patients pivotal study was completed in Oct. 2018.

Interventional News/CX2020
BIBA Medical Ltd
526 Fulham Road
SW6 5NR London
UNITED KINGDOM
www.interventionalnews.com

Interventional News is an editorially independent, expertly curated news provider that brings you the news, as it happens. With a brand new website, fortnightly newsletters, social media presence, and an app with worldwide readership, we also have a quarterly print edition for subscribers in Europe and North America. Published by BIBA Medical, Interventional News is steered by renowned editors-in-chief, Professor Andy Adam and Dr. Brian Stainken, and reaches over 12,000 interventionalists. Interventional News contains the latest news, summaries of cutting-edge research and spotlights controversies in interventional radiology. We publish expert analysis, conference coverage and key updates on the latest products and medical device industry. Have you visited us yet? Free subscription at www.interventionalnews.com.
As Invamed Company from Turkey, we’re dedicated to continuous innovation in order to shape everything we do. Our purpose is to improve health of the patients all around the world with our strong, hard-working, dedicated and clinically driven biomedical solutions team. Our products and technologies are mostly focused on endovascular treatment solutions with addition of wide range of medical conditions. RD’s mission dictates human healthcare and welfare above everything. Our mission is to contribute to heritage of humanity by achieving the best in multiple disciplines of medicine and biomedical engineering in order to serve optimal healthcare solutions.

We produce products in the Cardiovascular and Radiology fields mainly as below:
- **Varicose Vein Treatments:** Varicose Vein Glue Treatment, Small Varicose Vein Glue Treatment, Varicose Vein RF Ablation System 5 cm Active Tip, Valve Repair Device Internal Compression Therapy
- **Thrombus Management:** Fistulla Thrombectomy Device, Pulmoner Emboli Thrombolysis Device, Pharmacomechanical Thrombolysis Catheter, Thrombectomy Aspiration Device, Simple Temporary Vena Cava Filter, Waterjet Thrombus Management System
- **Arterial Intervention:** Drug Eluting Balloon (Paclitaxel), Atherectomy Catheters, Support Catheters (Peripheral, Coronary, Neurology)
- **Embolization Systems:** Embolic Adhesive (NBCA), Embolic Agents (non-adhesive high density), Haemorrhoid Glue Treatment
- **Vascular Access:** Vascular Closure Device, Micro Catheter (Coronary/Neuro), Introducer Set, Guidewires, Guiding Catheters
**iVascular, S.L.U.**
Camí de Can Ubach, 11
(Pol. Ind. Les Fallulles)
08620 Sant Vicenç dels Horts, Barcelona
SPAIN
www.ivascular.global

iVascular S.L.U is a fast-growing company based in Barcelona that has developed exclusive technologies in a vertically integrated project to innovate and produce coronary and endovascular devices from basic raw materials to the final device or implant, including DCB, DES, nitinol stents, CoCr Bare Metal Stents, thrombus extractors and angioplasty balloons.

**IZI Medical**
5 Easter Ct # J
MD-21117 Owings Mills
UNITED STATES OF AMERICA
www.izimed.com

IZI Medical Products, LLC develops minimally invasive diagnostic and therapeutic spine solutions, radiology and radiation therapy products, and image-guided surgery products to restore patients’ quality of life. Our spine product offerings include vertebroplasty, vertebral compression fracture solutions and vertebral augmentation systems. We embrace the legacy of the Osteo-site portfolio acquired from Cook Medical, as well as the recently added Kiva® and Blazer® systems acquired from Benvenue Medical. We look forward to working together to improve patient care.

Our Vertebral Compression Fracture offering includes: Osteo-Site Murphy needle developed in collaboration with Dr. Kieran Murphy has set the standard for percutaneous entry needles globally, Innovative range of PMMA bone cements indicated to vertebroplasty and kyphoplasty, The Kiva® VCF Treatment System provides a new implant-based approach to vertebral augmentation in the treatment of painful VCF’s, The Blazer-C® utilizes a unique cannulated curved wire, offering mechanical channel creation, predictable cement deposition across the entire vertebral body and an MIS unilateral approach. Our radiology and radiation therapy products include patient immobilization thermoplastic masks and associated warmer, radiopaque markers, multi-modality markers, and soft tissue fiducial markers. The image-guided surgery product line includes passive reflected markers for navigation systems, disposable passive array probes and dynamic reference frame, pedicle access needles, navigated biopsy needles. As a leading innovator, manufacturer, and distributor of quality medical devices, we ensure that all our products reduce procedural time and enhance precision.
About the Johnson & Johnson Medical Devices Companies: The Johnson & Johnson Medical Devices Companies have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.

About Neuwave Ethicon: The NEUWAVE™ Microwave Ablation System, now a part of the Ethicon™ portfolio of products, is the first intelligent ablation system and the only system that has it all. The versatile probe portfolio with multi-probe synchronized energy delivery allows physicians to tailor ablations with 1, 2 or 3 probes. In addition, the 17-gauge NEUWAVE™ PR probe is the only probe available with distal energy control to help protect non-target tissue. The unique computer-controlled system now includes Ablation Confirmation™ software, offering the only integrated in-procedure confirmation to help confirm probe placement and evaluate the technical success of your procedure.

KA Medical was founded by Kurt Amplatz, MD to continue his legacy of developing innovative solutions to advance patient treatments in the areas of interventional radiology and cardiology.

KA Medical’s first product is the Dr. Amplatz Micro Plug. This product recently received FDA 510(k) clearance and CE Mark approval and is indicated for arterial embolization in the peripheral vasculature.

The Dr. Amplatz Micro Plug, available in sizes 3, 4, 5 & 6 mm, allows physicians to effectively occlude blood vessels in the peripheral vasculature. The product includes a Micro Plug Device, a 2.9F Microcatheter, a flexible Delivery Wire, a Loader and accessories that provide for controlled delivery with the ability to reposition and recapture the Micro Plug Device prior to release. The company is based in Minneapolis, Minnesota, USA.
Shanghai Kindly Medical Instruments Co., Ltd (hereinafter referred to as ‘The company’) was established in 2006, and it focuses on R&D, Production and Global Trade in High-Tech intervention products. Since our establishment, the company integrated quickly kinds of resources including mold design, mold processing, injection, assembling, packaging, sterilization and so on. The company has strong ability for scientific research and development of high-tech medical products with independent intellectual property. With obtaining ISO9001, ISO 13485, CE certificates and FDA approval, The company has extended its business to the United States, Europe, South America, the Middle East, South Africa, India and other 40 countries and regions. Now we have become one of the most popular professional manufacturer in high-tech medical products in China, products including: Cardiovascular Intervention Accessories: Inflation Device, Manifolds, Angiography Syringe, Seldinger Needle, Introducer Set, Y connector Kit, Pressure Bandage, Guidewire, High Pressure Line, Pressure Transducer. Catheter: Vascular MircoCatheter, Neural MircoCatheter, Peripheral MircoCatheter, Angiography Catheter, Guiding Catheter, Supporting Catheter, Biliary Ston Extraction Balloon Cathether, Embolectomy Catheter; Guidewires: MircoGuidewires, Neural MircoGuidewires, Hydrophilic Guidewires; Non-Vascular Stent: Biodegradable Sinus Stent, Biodegradable Biliary Stent and others; Orthopedic Intervention: PVP Kit, Spine Tool Kit, ECTR Disposable Kit.

LifeTech Scientific Corporation (Stock Code: 1302.HK) is the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases. The company specializes in R&D, manufacture and sales, and its high-quality, innovative, proprietary products are extensively marketed in more than 100 countries by over 100 distributors. At present, the company is the world second largest supplier (and the largest among BRIC countries) of occluders to treat congenital heart diseases and the second largest supplier of aortic repair device in Asia Pacific.
**medac GmbH**

Theaterstrasse 6  
22880 Wedel  
GERMANY  
www.medac.de

medac Gesellschaft für klinische Spezialpräparate mbH: medac is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business. Established 1970 in Northern Germany, medac is specialised in the treatment of oncological, haematological, urological and autoimmune diseases as well as in the development of diagnostic devices. Besides an already established product portfolio, medac is dedicated to the refining of existing and the development of new therapeutic products providing patients with leading-edge individualised treatments. Further information about the company and its products can be found online at www.medac.de

**Medcomp**

1499 Delp Drive  
PA-19438 Harleysville  
UNITED STATES OF AMERICA  
www.medcompnet.com

Medcomp is a major supplier of Venous Access Systems. This year Medcomp is proud to introduce you to the next generation of ECG PICC placement with the C3 Wave. The C3 Wave is an easy-to-use, app-based wireless ECG system designed to free up clinicians’ hands by removing excess wires and allowing more focus on patient care. As well as showcasing our new C3 Wave Medcomp will also be exhibiting: Hemodialysis Catheters, cuffed and uncuffed. This will include its series of Split Tipped designs. Rounding off the dialysis line will be DuraLock-C, Trisodium Citrate antibacterial-anticoagulant catheter locking solution. For drug/chemotherapy administration, CT-Power Injectable PICC lines and Ports will be demonstrated. Rated at 300psi, these venous access devices allow contrast delivery to 5cc/second, facilitating superior contrast enhanced CT studies. Also the new DIRECT MICROPUNCTURE PORTS will be shown Neonatal micropuncture access will be showcased as well. Significant features include: a .010” mini-mandrel wire, a mini-sheath/dilator, and a 1.9 French neonatal line.
Medex Research Ltd
2 Chapel St
PO19 1BU Chichester, West Sussex
UNITED KINGDOM
www.medexresearch.com

We help medical device companies wishing to explore growth opportunities and develop marketing strategies for new and existing products in developed and emerging markets.

Medicor Europe AG
Wingepark 5B 101
3110 Rotselaar
Belgium
www.medicor-international.com

The contrast agent injectors of the Japanese manufacturer Nemoto offer innovative functions for each imaging modality. Whether CT, MR or angiography - the Nemoto contrast agent injectors are extremely reliable, easy to use and secure. In MR field the Nemoto Sonic Shot 7 is the only injector worldwide which gives you the opportunity to use pre-filled syringes of any manufacturer. Simply click the syringe into the appropriate adapter and the device does the rest for you. Modern functions such as determination of the injection protocol on the basis of body weight, auto-fill, storage options for custom protocols and the unique anatomical interface with touch screen round out the features of the devices.

Nemoto and Medicor are proud to introduce this year the finest power injector for interventional which is the PRESS DUO ELITE, a unique dual head high pressure injector dedicated for the interventional Nemoto and Medicor offer only the best for your imaging!
Medtron AG
Hauptstrasse 255
66128 Saarbruecken
GERMANY
www.medtron.com

Medtron AG is a globally active company working in the field of medical engineering. As one of the leading manufacturers of ultramodern contrast medium injectors, Medtron AG has made its name on the market: Across the globe, many thousand doctors, hospitals and diagnostic centres place their trust in Medtron’s contrast medium injectors made in Germany. Our innovative and high-quality injector systems complement virtually all modern methods of examination which can be performed with the help of medical engineering imaging systems, such as magnetic resonance imaging, computed tomography and angiography. Our goal is to combine improved diagnostics, patient-friendliness and cost effectiveness. To facilitate the optimization of the examination techniques, we run development projects involving all renowned manufacturers of radiological imaging systems and devices. Medtron offers a wide range of device-specific and high-quality consumables for its injectors. Medtron AG – Essential for contrast.

Medtronic International
Rte de Molliau 31
1131 Tolochenaz
SWITZERLAND
www.medtronic.com

Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems — such as rising costs, aging populations, and the burden of chronic disease — we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value – for healthcare systems, providers, and the people they serve. Learn more at Medtronic.com.
Founded in 1987, Merit Medical Systems, Inc. is a leading manufacturer and marketer of disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Starting with the world’s most studied spherical embolic – Embosphere® Microspheres – Merit Medical has built a comprehensive embolotherapy suite of products, including tools to deliver your embolics right to the target. We also offer a diverse, integrated portfolio of products that support radial procedures from preparation to close and support physicians with training programs and practice support tools. Our focus on interventional spine continues to increase, with tools for various spine treatments including spinal ablation and vertebroplasty. Merit’s peripheral intervention division offers solutions for Interventional Radiologists, including access and drainage products, angiography and intervention catheters, wires and snares, and a suite of biopsy devices. We also support Renal Therapies with the HeRO® Graft family of products and systems for Peritoneal Dialysis, as well as physician training programs. With a global work force and cutting-edge manufacturing facilities equipped with the most-advanced technology, Merit Medical constantly delivers quality products that are backed by excellent customer service and professional expertise. Please visit www.merit.com for product information, including instructions for use. Our team will be happy to meet you at booth # 58 and Learning Centre for hands-on sessions and to present our new products. We look forward to seeing you at CIRSE 2019.

The Mermaid Medical Group is an international medical device company focused on interventional radiology, vascular surgery and Breast Medicine. In keeping with our commitment to excellence, Mermaid Medical is dedicated to providing physicians with the best patient care solutions. Our products are offered in a wide variety of sizes to meet your clinical needs. Products: D-Clot Mechanical Thrombectomy system for peripheral and hemodialysis applications, Angel Catheter system including a combined vena cava filter and central venous catheter, M-Drain™ All Purpose Drainage Catheters in locking and non-locking configurations, Nephrostomy, Biliary and Centesis Drainage Catheters, M-Drain® Percutaneous Introducer Systems, Amplatz Guidewires, Access Needles, M-Fixx™ Catheter Securement Device, M-Biopsy Semi-Automatic Biopsy Instruments.
MIM Software Inc.
25800 Science Park Dr
Suite #180
OH-44122 Cleveland
UNITED STATES OF AMERICA
www.mimsoftware.com

MIM Software Inc. offers a comprehensive suite of applications that support Radiology and Nuclear Medicine’s important role in the patient care pathway. MIM Software products emphasize the importance of quantitation, collaboration, and data management in order to provide physicians with the necessary information needed to generate confident clinical guidance and to inform effective treatments. MIM SurePlan™ LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and post-treatment dosimetry using Y90-PET and Bremsstrahlung SPECT. Use it alone, or integrate SurePlan LiverY90 into the larger MIM ecosystem and take advantage of a comprehensive, vendor-neutral platform for Nuclear Medicine processing and review. MIM SurePlan LiverY90 allows you to read PET/CT, PET/MR, SPECT/CT, and planar Nuclear Medicine images from any major manufacturer - all in one system.

Möller Medical GmbH
Wasserkuppenstrasse 29-31
36043 Fulda
GERMANY
www.moeller-medical.com

Möller Medical is a German medical device manufacturer who belongs to medimondi group. medimondi group is part of Centrotec Sustainable AG and covers all corporate activities concerning medical devices and engineering plastics. Möller Medical manufactures components and highly sensible medical devices. Our product portfolio consist of own brands (interventional radiology, urology, neurosurgery, aesthetics, blood banks) and OEM business (human cannulae, nano-coatings, HPLC hardware, peristaltic pumps). Our product line BiopC is based upon decades of experience in developing and manufacturing all kinds of cannulae and needles for human medicine as well as in the field of intensive care. Creating high quality products with the utmost respect for patient’s well-being has been an unspoken mission statement ever since the foundation of the company 60 years ago. This guideline directly influenced the development of the BiopC product range and will remain a determining factor to continuous developments of the product portfolio.
Noras MRI products GmbH
Leibnizstrasse 4
97204 Hoechberg
GERMANY
www.noras.de

Noras has been present internationally within the MRI industry for 30 years and has built a solid reputation due to its customer-oriented service. Besides our standard products, our slogan „we build your vision“ reflects exactly what we offer our customers: We are a competent partner with the planning and realization of your individual ideas and concepts. Our development and production is taking place mainly in Germany. The final assembly and inspection is done manually by skilled employees, which provides an extra quality advantage.

Numa
Block 1 Quayside Business Park
A91 DP8R Dundalk, Louth
IRELAND
www.smart-mict.de

Image-guided Minimally Invasive Cancer Treatments (MICTs) form a rapidly growing field of alternatives to full surgical resection, allowing an interventionalist to perform highly targeted treatments. Prediction of the precise ablation boundary is crucial to ensure both complete tumour destruction and the protection of sensitive structures. To assist radiologists in the training and planning for these interventions, a web-based planning and simulation software tool has been developed through a European Commission FP7 programme. The GoSmart software provides a unified web environment, enabling interventionalists to upload patient scans, identify important structures and simulate a range of key MICTs. It is highly extensible, with an interface for manufacturers, researchers and medical technicians to incorporate new equipment, treatment protocols and theoretical models. An introduction to the software can be found at the attached web address.
Optimed
Ferdinand-Porsche-Strasse 11
76275 Ettlingen
GERMANY
www.opti-med.de

Optimed, based in Ettlingen/Germany, was founded in 1995. The company is engaged in the research and development, production and global distribution of medical products for minimal invasive therapy. Optimed employs more than 100 people in its administration center and 2 production sites in Ettlingen near Karlsruhe. As optimed continuously invests in the research, development and production of the products of tomorrow, we are the ideal partner for innovative medical practitioners working in the field of minimal invasive therapy, specifically in Interventional radiology, Vascular interventions, Urology, Gastroenterology, Orthopedics / traumatology.

Pajunk GmbH
Karl-Hall Strasse 1
78187 Geisingen
GERMANY
www.pajunk.com

PAJUNK® - Pioneering medical technology. More than 50 years Pajunk stands for innovative medical technology, made in Germany. The Pajunk Group is an internationally operating and owner-managed company with its headquarters in Geisingen, Baden-Württemberg and sales offices in Atlanta and Newcastle. Pajunk is a leading medical technology manufacture in the areas of regional anesthesia, neurology, pain management, minimally invasive surgery, and biopsy. Pajunk’s portfolio includes cannulas and systems for punch biopsy, aspiration and puncture cannulas for core, fine needle aspiration biopsy and bone biopsy as well as ultrasound guided central line access. Come and try out our products at our booth.

Penumbra Europe GmbH
Am Borsigturm 44
13507 Berlin
GERMANY
www.penumbrainc.com

Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets medical devices and has a broad portfolio of products that addresses challenging medical conditions and significant clinical needs.
PharmaCept GmbH

Bessemerstrasse 82
12103 Berlin
GERMANY
www.pharmacept.com

PharmaCept stands for the successful development of niche products for various cancer indications with a special focus on research in Interventional Oncology. The main pillar of our company’s development is the chemoembolization therapy. Based on the Barcelona guidelines for the treatment of primary liver cell carcinoma, chemoembolization has become an integral part of the therapy of hepatocellular carcinoma patients. With our product EmboCept® S, the only short-term degradable starch microspheres, tumor growth can be considerably reduced. New clinical studies will continue to explore scientifically already known advantages of degradable embolic agent and unlimited combination with cytostatic agents, e.g. with our new Cisplatin powder PlatiCept®. Cisplatin powder is the second most commonly used chemotherapeutic agent for primary liver cancer. It can be used as an alternative drug to doxorubicin, within a combination or after a tumor progression under anthracyclines. Our experimental data show a significantly increased accumulation of platin products in tumor tissue when it is used in combination with starch microspheres (EmboCept® S).

Philips Medical Systems Nederland B.V.

Amstelplein 2, Breitner Center
P.O. Box 77900
1070 MX Amsterdam
THE NETHERLANDS
www.philips.com

Philips is a health technology company focused on improving people’s lives through meaningful innovation across the health continuum – from healthy living and prevention to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips partners with customers to deliver integrated solutions that address the Quadruple Aim: improved patient experience, better health outcomes, improved staff experience, and lower cost of care.
Piolax Medical Devices, Inc.
2F 3-18-20 Shin-Yokohama Kohoku-ku
2220033 Yokohama
JAPAN
www.piolax-md.co.jp/en

We “Piolax Medical Devices, Inc.” are specialized in manufacturing high quality medical intervention devices like micro-catheters, guidewires, micro-coils for not only vascular field, but also for GI field. Since our company was found in 1999, we have been developing and producing user friendly devices based on Made in Japan Quality with an honor of being one of the medical members devoted to patients. We are relatively new to enter international markets so we would be glad to hear your comments for our products and we are looking for potential business partners including OEM supply.

Praxis Medical Devices
500 N Willow Ave
STE 101
FL-33606 Tampa
UNITED STATES OF AMERICA
www.praxismedicaldevices.com

CytoCore: An oscillating FNA biopsy device.

QualiMed
Boschstrasse 16
21423 Winsen/Luhe
GERMANY
www.qualimed.de

QualiMed is a recognized worldwide leader in the design, development and selling of medical devices, with over 20 years of experience in all interventional surgical areas. The company has extensive expertise with devices used in interventional vascular and non-vascular spaces including various catheter, therapeutic drug and novel bioresorbable material technologies.
Ra Medical Systems, Inc.
2070 Las Palmas Dr
CA-92011 Carlsbad
UNITED STATES OF AMERICA
www.ramed.com

Ra Medical Systems, Inc. develops, manufactures, and markets excimer laser-based medical equipment. The DABRA Catheter and Laser System photochemically ablates arterial blockages. Ra Medical Systems transforms the lives of cardiovascular patients around the world by saving their limbs and lives.

RF Medical Co., Ltd.
#502,503,505,506,507,511, 254 Beotkkot-ro, Geumcheon-gu
08511 Seoul
KOREA, REPUBLIC OF
www.rfa.co.kr

As a manufacturer, RF Medical is dedicated to popularizing radiofrequency ablation treatments since 2003. Our extensive product range spans from tumor ablation such as liver and thyroid nodule ablation to even varicose vein treatments. Our sophisticated technology has allowed us to spread our business to more than 50 countries and our proven quality has granted us a strong reputation on the market. As always, RF Medical strives with all its capabilities to create a healthier world by continuous investment in research and development.
**Rontis AG**
Bahnhofstrasse 7
6300 Zug
SWITZERLAND
www.rontis.com

Rontis AG, a Swiss-based international company consists of four (4) divisions: Medical Devices, Pharmaceutical, Consumer Healthcare and Healthcare (dialysis) Services. Our three E.U.-based factories serve also as an R&D platform for medical devices like PTCA and PTA balloons, guidewires and stents systems, as well as pharmaceuticals for customers worldwide; also provides OEM / private label services for international customers. Rontis is selling its products in 40+ countries worldwide and is also a full-service OEM Contract Manufacturer of medical devices. For medical devices (endovascular products), among others, we produce (www.rontismedical.com): PTCA: Abrax™, Sirolimus DES with a biodegradable polymer, Leader® Plus, CoCr BMS, InRo® semi-compliant balloon with RBP up to 21atm, Europa Ultra™ semi-compliant balloon, Europa Ultra NC™, balloon, Europa Ultra CTO™ balloon (Rx & OTW, starting from 1.00mm), Lotus II™ & Lotus XP™ coronary and peripheral wires, also for CTOs & BTK applications. PTA: Zeus® CC (CoCr) stent system (up to 80mm), Zeus® SX (Nitinol) self-expanding stent, Cronus® Advanced / Cronus® NV (non-vascular) balloons, Cronus® HP, 0.035” OTW balloon (RBP: up to 32atm) - FDA approved for a special project in U.S. market, Triton® Plus, 0.018” Rx balloon, Triton® BTK 0.014” (Rx & OTW) below-the-knee balloon (up to 210mm).

**Shionogi Europe**
33 Kingsway
WC2B 6UF London
UNITED KINGDOM
www.shionogi.eu

From our beginnings over 140 years ago in Osaka, Japan, Shionogi & Co. Ltd. has built a strong heritage in research-based medicine, matched by world-class market access and patient insight capabilities. Shionogi Europe was launched in 2012 and is committed to applying our patient-first approach in everything we do across the region. Our research-led organisation is defined by a distinct openness and close partnership approach to discovering and developing medicines addressing unmet medical needs. Our development approach goes hand in hand with the collaborative drug discovery process that lies at the heart of Shionogi and our people.
Shockwave Medical
5403 Betsy Ross Drive
CA-95054 Santa Clara
UNITED STATES OF AMERICA
www.ShockwaveIVL.com

Shockwave Medical is a company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. We aim to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through our differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which we refer to as ‘Intravascular Lithotripsy.’ For more information, visit www.shockwavemedical.com.

Siemens Healthcare GmbH
Karlheinz-Kaske-Strasse 5
91052 Erlangen
GERMANY
www.siemens-healthineers.com

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
Established by WCIO, the Society of Interventional Oncology (SIO) serves as the only membership-based organization dedicated to the emerging field of Interventional Oncology. SIO works to further promote the mission to advance Interventional Oncology (IO) as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. Members receive discounted registration to SIO’s Annual Scientific Meeting and opportunities to apply for exclusive research grants and earn free CME online at IO University. Become a member today and join us at SIO2020 taking place in New Orleans, LA from January 31-February 3, 2020. Visit www.sio-central.org for the latest news and society updates.

Sirtex Medical Europe GmbH
Joseph-Schumpeter-Allee 33
53227 Bonn
GERMANY
www.sirtex.com

Sirtex is a global life-sciences company actively engaged in the field of liver-directed therapies for cancer patients. The innovative technology of Sirtex, SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads), is a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, to the liver. This treatment for inoperable liver cancer delivers high doses of radiation directly to the site of tumour(s) whilst conserving normal liver parenchyma. Our business revolves around helping medical professionals understand and use our product to improve clinical outcomes and the quality of life for people with liver cancer. Approximately 92,000 doses SIR-Spheres microspheres have been supplied to treat patients in over 1,230 certified hospitals in more than 40 countries. SIR-Spheres® microspheres were approved in 2002 for use in the treatment of a variety of unresectable liver tumours within the European Union under a CE Mark. The 2016 European Society for Medical Oncology (ESMO) guidelines for physicians recommend the use of SIR-Spheres Y-90 resin microspheres to treat liver tumours that have spread from the bowel and do not respond anymore to chemotherapy. Further information please visit www.sirtex.com.
Sonar
15 Bd Grawitz
13016 Marseille
FRANCE
www.sonar-broadcast.com

Created by Incathlab, Sonar is a turnkey solution to record, edit and broadcast videos of medical interventions in your own network or all around the world. The system includes: A full audiovisual system - High quality videos, Smooth communication, Powerfull server; Easy to use digital tools - Professional & customizable design, Simplified tool to edit your videos, Share your work locally or worldwide.

STARmed Co. Ltd.
#B-14th floor Daebang Triplaon 158
Haneulmaeulro, Ilsandong gu
10355 Goyang
KOREA, REPUBLIC OF
www.starmed4u.com

STARmed Co., Ltd. is a young and fast-growing company from South Korea, specializing in Radiofrequency technology. Passionately working on the best possible RF treatment, STARmed has collaborated with a number of Key Opinion Leaders in developing the most innovative Electrodes and leading-edge RF Technology specific to certain tumour types and clinical applications, in thyroid, liver, lung, kidney, myoma, bone, etc. STARmed is now recognized as global leader in Thyroid RFA.

Straub Medical AG
Straubstrasse 12
7323 Wangs
SWITZERLAND
www.straubmedical.com

Straub Medical AG is an internationally leading enterprise in the field of treating vascular disease. We aim to be the first brand to come to a physician’s mind when a patient presents with vascular occlusion. We manufacture the Straub Endovascular System with its Rotarex®S and Aspirex®S catheter families. A range of endovascular tools, including the Capturex® peri-interventional filter catheter, adds to our portfolio. Our Swiss-made products are of highest quality and precision. Our innovative minimally-invasive technologies contribute worldwide to improving the outcomes of endovascular intervention.
Back to shape

For 35 years, osteoporotic vertebral compression fracture (VCF) treatment has focused primarily on pain management. Traditional fracture treatments did not seek to address reduction, fixation and restoration due to the limits of the instrumentation. The SpineJack® system gives you the tools to take control of the procedure, and is designed to help restore vertebral body height and help protect your patients from adjacent level fractures.

SpineJack mechanical vertebral augmentation system

The products depicted are CE marked in accordance with applicable EU Regulations and Directives. Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: SpineJack and Stryker. All other trademarks are trademarks of their respective owners or holders. The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker’s trademark or other intellectual property rights concerning that name or logo.

The information presented is intended to demonstrate the breadth of Stryker product offerings. Stryker does not endorse or support the unapproved uses of its products. A physician must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that physicians be trained in the use of any particular product before using it in surgery. A physician must always refer to the package insert, product label and/or instructions for use before using any Stryker product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Stryker representative if you have questions about the availability of Stryker products in your area.

Bone cement: Complications are rare. Serious adverse events, some with fatal outcome, associated with the use of bone cements for vertebroplasty, kyphoplasty and sacroplasty include myocardial infarction, cardiac arrest, cerebrovascular accident, pulmonary embolism and cardiac embolism. Although it is rare, some adverse events have been known to occur up to one year post-operatively. Additional risks exist with the use of bone cement. Please see the IFU for a complete list of potential risks.
Stryker is working hard to make healthcare better by investing in reimbursement tools, educational materials and training events that are an investment in you, our customer. We provide the most advanced medical technology for interventional spine procedures. As we share this patient-centered focus, you can trust Stryker’s product portfolio for vertebral augmentation, vertebroplasty, radiofrequency ablation, disc diagnostics and decompression treatments for disc herniations. From the office to the operating room and every stop in between, we’re here to serve you with a portfolio built on innovation and a legacy of customer support.

The old way isn’t always the better way.

Discover the benefits of powered access for bone biopsies

Manual biopsy needles may be the original approach, but today there’s a powered solution that is raising the standard for biopsies: The Arrow OnControl Powered Bone Access System for bone marrow and bone lesion biopsies. As compared to manual needles, it has been shown to deliver consistently larger, high-quality core specimens. It could be the key to bone biopsies that are less painful, provide more usable area for diagnosis, and may result in improved patient compliance with ongoing testing. All while providing clinicians with precise control and the ability to access hard-to-reach lesions.

To learn more, meet with us at our booth during CIRSE

To place an order, contact Customer Service at orders.intl@teleflex.com

References:


Teleflex, the Teleflex logo, Arrow, and OnControl are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. Revised: 03/2019. © 2019 Teleflex Incorporated. All rights reserved. MCI-2019-0376-EN.
**Suzhou Leapmed Healthcare Corporation**

38# North Guandu Road, Wuzhong District Suzhou City  
NO.2& NO.3 Building  
21500 Suzhou  
Jiangsu  
CHINA  
www.leapmed.com

Leapmed, a professional manufactory for ultrasound biopsy kits supplier, was founded in 1994. Since 2011, Leapmed founded first R&D team to develop biopsy kits, which is the 1st team specialized in the biopsy kits development field in China. After years of development, the 1st Chinese metal biopsy kits manufacturing certification was issued by CFDA in 2012, by 2015, Leapmed developed over 250 biopsy kits models, and was certified by CE, and ISO 13485. By year 2017, Leapmed launched it new generation of biopsy to China and all over the world. Leapmed’s team has developed biopsy kits for GE, Philips, Siemens, Esaote, Medison, Toshiba, Hitachi, Aloka and other famous transducers, covering applications for abdominal, superficial, cardial, endo and 3D. Leapmed can also customize biopsy guides with different angle or shape for clinical doctors. Leapmed’s vision is: Becoming the leading biopsy kits supplier in precision medical imaging.

**Teleflex**

IDA Business & Technology Park Dublin Road  
N37 EC90 Athlone, Co Westmeath  
IRELAND  
www.teleflex.com

Innovations to Simplify Interventions. As the interventional cornerstone of Teleflex, we offer a growing portfolio of specialty-focused solutions to support interventionalists around the globe. Our products are known for their innovative ability to simplify complex procedures and common clinical challenges. Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers.
Terumo Interventional Systems
Interleuvenlaan 40
3001 Leuven
BELGIUM
www.terumo-europe.com

Founded in Tokyo in 1921, Terumo is a multinational company with more than 90 years’ experience in developing best in class medical devices. Terumo Interventional Systems constantly work to refine and perfect our products so that interventionists can do more. We are committed to innovation that embraces intricacies and complexities. Our exceptional tools and education programs empower physicians with the confidence they need to perform ever-more challenging procedures and spark progress. Terumo offers intervention in all dimensions: from access to closure. Peripheral Intervention: In Peripheral Interventions, Terumo is able to provide a full portfolio ranging from Access (Introducer Kits and Radifocus® Guidewires) through Interventions (Roadsaver® Carotid Artery Stent and a selection of PTA Balloons) to Closure (AngioSeal™ and FemoSeal™). Our product range is covering solutions for Carotid Artery Stenting as well as for Below The Knee and FemoroPopliteal procedures; Interventional Oncology: In Interventional Oncology, Terumo Interventional Systems develops innovative products for interventional radiologists focused on disease-based solutions in liver cancer and non-tumor settings. Rising to the challenge of creating innovative treatments for patients, we bring you a complete range of interventional oncology products that focus on: Access, Loco-regional treatments ranging from ablation, TACE and SIRT, Endovascular embolization. As a pioneer in interventional oncology, Terumo Interventional Systems is committed to bringing you cutting-edge technology to support your loco regional patient needs. We are committed to supporting our comprehensive product portfolio by a well-trained field force and solid clinical evidence.
Tokai Medical Products, Inc.
1485 Sarayashiki, Taraga-cho
486-0808 Kasugai-city
JAPAN
www.tokaimedpro.co.jp/en

Tokai Medical Products, Japanese medical device manufacturer was founded by Nobumasa Tsutsui who succeeded in developing the first Japanese-made IAB-Intra Aortic Balloon catheter more than 30 years ago. Since then, we've been focusing on manufacturing/development of interventional devices and enjoying a good reputation in several medical fields such as cardiology, radiology, neurosurgery, gastroenterology, pediatrics and emergency IVR. Tokai offers a large selection of premium microcatheters for super selective embolization. Japan’s best seller microcatheter, Carnelian ranges 2.7 Fr high flow to 1.7 Fr ultra selective. All are compatible with micro particles, coils and DMSO. For more information, please visit www.tokaimedpro.co.jp/en

Uresil, LLC
5418 Touhy Ave.
IL-60077 Skokie
UNITED STATES OF AMERICA
www.Uresil.com

UreSil is a global provider of innovative devices and services for the specialized field of interventional radiology. Our ongoing commitment is to produce cost-effective products, maintain superior quality, and serve the needs of the patient and the medical community. UreSil offers a variety of drainage catheters and drainage accessories.

Veryan Medical Limited
Unit 15, City Business Centre
Brighton Road
RH13 5BB Horsham
UNITED KINGDOM
www.veryanmed.com

Veryan Medical has developed BioMimics 3D®, a self-expanding, nitinol SFA/prox popliteal stent which imparts a natural, 3D curvature to the artery, to generate swirling flow, increase wall shear and reduce intimal hyperplasia. In the Mimics randomised study BioMimics 3D, the Swirling Flow® Stent, achieved significantly better performance than straight control stents; it is the ideal alternative to drug elution. Veryan is an Otsuka Medical Devices company.
Vigeo s.r.l. (Headquarter)
Via dell’Alpino 2
46031 Bagnolo San Vito
ITALY
www.vigeosrl.it

Vigeo is a private and independently owned company founded in 2005 and headquartered in Mantova, Italy. Vigeo is a global manufacturer of Biopsy devices for Interventional Radiology, Interventional Urology, Breast Care and Oncology. The product portfolio offers a broad and innovative range of minimally invasive disposable instruments in the following areas: Mama interventions (wire & clip marking), Soft tissue and bone marrow biopsy, Cyst drainage. Vigeo’s brand is recognized for best-in-class products that improve patient outcomes via percutaneous, image-guided procedures. Vigeo serves its global customers through a direct sales organization and through long-standing relationships with medical device distributors, strategic partners and OEMs. Vigeo is the exclusive distributor for several world-leading producers of medical devices, too.

W. L. Gore & Associates GmbH
Hermann-Oberth-Strasse 22
85640 Putzbrunn
GERMANY
www.goremedical.com/eu

Gore Medical Products Division engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. www.goremedical.com/eu. W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments — from revolutionizing the outerwear industry with GORE-TEX® fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and continued recognition from the Great Place to Work® Institute. Headquartered in Newark, Del., Gore employs approximately 9,500 Associates and generates annual revenues that exceed $3 billion. www.gore.com
Wisepress Ltd
15 Lyon Road
Merton
SW19 2RL London
UNITED KINGDOM
www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.

Zhengjiang Zylox Medical Device Co., Ltd
Floor 2, Building 1, No. 18 Keji Avenue
311121 Hangzhou
Zhejiang
CHINA
www.zyloxmedical.com

Zylox Medical Device Co., Ltd was founded in Hangzhou, China, in 2012 by a group of highly skillful and experienced returnees from the US and Europe. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, DCB, SFA stent, drug-eluting stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.
Shaping your business success

Daily clinical work means a wide variety of demands and challenges. We help you meet your needs by offering a solution tailored for your individual set-up.

Ziehm Vision RFD Hybrid Edition¹

→ Extend your cardiovascular surgical capabilities with a powerful 25 kW mobile C-arm
→ Take your OR to the next level with a mobile hybrid solution
→ Plug in and start your hybrid procedure with zero room preparation
→ Reduce exposure significantly with the next-generation SmartDose²

Endovascular aneurysm repair (EVAR)

[Image of an endovascular procedure]

¹ Ziehm Vision RFD Hybrid Edition represents a group of optional hardware and software that creates an option package on the device named Ziehm Vision RFD. The SmartDose Concept includes a variety of hardware and software features. Due to regulatory reasons, the availability of each feature may vary. Please contact your local Ziehm Imaging sales representative for detailed information.

www.ziehm.com/RFDHE
Ziehm Imaging GmbH
Donaustrasse 31
90451 Nuremberg
GERMANY
www.ziehm.com

Founded in 1972, Ziehm Imaging has stood for the development, manufacturing and worldwide marketing of mobile X-ray-based imaging solutions for more than 45 years. Employing more than 500 people worldwide, the company is the recognized innovation leader in the mobile C-arm industry and a market leader in Germany and other European countries. The Nuremberg-based manufacturer has received several awards for its ground-breaking technologies and achievements, including the Frost & Sullivan Award (various years), the IF Design Award 2011 and 2016, the Top100 award for innovative mid-size companies 2012, the Stevie Awards 2013, 2014, 2015 and 2017, the German Stevie Award 2016 and the IAIR Global Awards 2014 as “Best Company for Innovation & Leadership”.

Z-Medica
4 Fairfield Blvd
CT-06492 Wallingford
UNITED STATES OF AMERICA
www.z-medica.com/Z-Medica

Z-Medica develops, manufactures and markets innovative hemostatic agents to support a broad range of markets including healthcare, military, first responders and consumers, around the world.
QuikClot is a proprietary technology, which consists of a non-woven material impregnated with kaolin. Kaolin activates Factor XII on the intrinsic pathway, which in turn accelerates the clotting cascade leading to faster bleeding control.
QuikClot allows for: quicker and safer ambulation post coronary diagnostic and PCI via the femoral approach, shorter compression times reduce the total time of the procedure and may lessen discomfort for patients, shorter procedure times allow the hospital to move patients through the system faster and add more procedures onto the daily schedule; QuikClot is ready to go right out of the package and simple to use. Product uses the same placement techniques as standard gauze.
QuikClot is used for controlling bleeding and tract oozing.
### Technical Exhibition RPP (Alphabetical List)

<table>
<thead>
<tr>
<th>Official Name</th>
<th>Booth#</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D Systems Simbionix</td>
<td>7</td>
</tr>
<tr>
<td>Biotronik</td>
<td>10</td>
</tr>
<tr>
<td>Bracco</td>
<td>3</td>
</tr>
<tr>
<td>CAScination</td>
<td>6</td>
</tr>
<tr>
<td>DRGEM Corporation</td>
<td>5</td>
</tr>
<tr>
<td>EuroSafe Imaging</td>
<td>11</td>
</tr>
<tr>
<td>Kinepict Health</td>
<td>9</td>
</tr>
<tr>
<td>Mavig</td>
<td>14</td>
</tr>
<tr>
<td>MDT X-Ray</td>
<td>1</td>
</tr>
<tr>
<td>Mentice</td>
<td>8</td>
</tr>
<tr>
<td>Radpad Worldwide</td>
<td>12</td>
</tr>
<tr>
<td>RaySafe &amp; Landauer</td>
<td>4</td>
</tr>
<tr>
<td>Siemens Healthcare</td>
<td>2</td>
</tr>
<tr>
<td>Tecres</td>
<td>13</td>
</tr>
</tbody>
</table>
## Technical Exhibition RPP (Numerical List)

<table>
<thead>
<tr>
<th>Official Name</th>
<th>Booth#</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT X-Ray</td>
<td>1</td>
</tr>
<tr>
<td>Siemens Healthcare</td>
<td>2</td>
</tr>
<tr>
<td>Bracco</td>
<td>3</td>
</tr>
<tr>
<td>RaySafe &amp; Landauer</td>
<td>4</td>
</tr>
<tr>
<td>DRGEM Corporation</td>
<td>5</td>
</tr>
<tr>
<td>CAScination</td>
<td>6</td>
</tr>
<tr>
<td>3D Systems Simbionix</td>
<td>7</td>
</tr>
<tr>
<td>Mentice</td>
<td>8</td>
</tr>
<tr>
<td>Kinepict Health</td>
<td>9</td>
</tr>
<tr>
<td>Biotronik</td>
<td>10</td>
</tr>
<tr>
<td>EuroSafe Imaging</td>
<td>11</td>
</tr>
<tr>
<td>Radpad Worldwide</td>
<td>12</td>
</tr>
<tr>
<td>Tecres</td>
<td>13</td>
</tr>
<tr>
<td>Mavig</td>
<td>14</td>
</tr>
</tbody>
</table>
Experience a hands-on demo of the Simbionix ANGIO Mentor endovascular training simulator platforms. The ANGIO Mentor Suite is ideal for team training, the ANGIO Mentor Flex is an easy-to-use portable solution for remote meetings and courses and the NEW ANGIO Tab Pro ultra-portable, carry-on solution is packed in a small and light-weight suitcase that can be setup in less than a minute. Don’t miss the new iCase endovascular simulation case editor that enables unlimited, independent case creation. It provides program directors as well as training managers the opportunity to create new clinical training scenarios and simulation cases using a simple and short procedural flow. Also, the ever-expanding library of modules include 30+ endovascular procedures with over 230 patient scenarios including Endovascular Basic Skills, Peripheral Interventions, Peripheral Embolization, Aortic Interventions, Transradial and Transfemoral Coronary Interventions, Structural Heart Diseases, Electrophysiology and Neurovascular Interventions. Request a demo at healthcare@3dsystems.com or learn more at www.simbionix.com.

Biotronik is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, Biotronik innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. Biotronik is headquartered in Berlin, Germany, and represented in over 100 countries.
Bracco
Via E. Folli 50
20134 Milan
ITALY
www.braccoimaging.com

Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs. Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS) and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology. The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. To learn more about Bracco Imaging, visit www.braccoimaging.com

CAScination
Steigerhubelstrasse 3
3008 Bern
SWITZERLAND
www.cascination.com

CAScination AG is a highly innovative Swiss company established as a global leader in stereotactic navigation and image fusion, offering products that enable safer and more effective minimally invasive treatments. The company’s product portfolio includes commercially available solutions for open and laparoscopic liver surgery and CT-guided percutaneous interventions in soft tissue organs. With extensive clinical experience of more than 1000 procedures performed, CAScination’s technologies have proven they can safely expand indications for minimally invasive surgery in several applications, while enabling significant savings in time and resources for the hospital. Collaborating closely with leading clinicians and institutions, CAScination is also supporting important research to generate further evidence on how its products can improve patient outcomes. In addition, the company’s growing development pipeline integrates augmented reality, navigation and robotic technologies setting the standards for the next generation of minimally invasive surgical applications.
**DRGEM Corporation**

7F. E-B/D Gwangmyeong Techno-Park, 60 Haan-ro
14322 Gwangmyeong-si
Gyeonggi-do
KOREA, REPUBLIC OF
www.drgem.co.kr

Main Business: - X-ray Generator, Radiography System, DR System, Vet DR

DRGEM Corporation is one of the world’s leading manufacturers of diagnostic radiography systems, specializing in high frequency x-ray generators, conventional radiography systems, and digital radiography systems.

**EuroSafe Imaging**

Am Gestade 1
1010 Vienna
AUSTRIA
www.eurosafeimaging.org
www.myESR.org

EuroSafe Imaging is the European Society of Radiology’s flagship campaign to promote quality and safety in medical imaging. The mission of EuroSafe Imaging is to support and strengthen medical radiation protection across Europe following a holistic, inclusive approach. EuroSafe Imaging has recently issued the ‘EuroSafe Imaging Call for Action 2018’, a 13-point action plan to achieve EuroSafe Imaging’s objectives of promoting appropriateness in radiological imaging, maintaining radiation doses within diagnostic reference levels, promoting the use of up-to-date equipment, empowering patients, and joining forces with various stakeholders. EuroSafe Imaging has celebrated its 5th anniversary this year. Visit the EuroSafe Imaging booth (No. RPP 11) to learn about our activities and support us by becoming a EuroSafe Imaging Star.
Kinetic imaging consists of data acquisition and analysis obtained from X-ray image series. The new digital variance angiography (DVA) represents contrast medium motion inside the patient. Kinetic imaging can visualize blood vessel structures by detecting the movement of the iodinated or CO2 contrast medium bolus. The advanced statistical data analysis yields better image quality than DSA. Replacing DSA with kinetic imaging obtains better image quality, reduced contrast agent amount or X-ray dose. Our ongoing clinical neuroangiology and lower limb studies indicate that the quality reserve provided by our technology can be effectively converted to significant contrast media (50%) and X-ray dose reduction. This brings significant economical and health benefits – less adverse events, reduced radiation risk - to the medical staff and patients.

Mavig, founded in 1921, designs, manufactures and markets personal protection devices and X-Ray accessories, as well as ceiling- and table-mounted equipment. The patented Mavig ceiling tracks and suspension systems, like its modern LCD-monitor suspensions comply with the latest requirements of the industry. All MAVIG products are certified according to the EU Medicinal Product Directives and the EU Directive for Personal Safety Gear, bearing the corresponding CE Symbol. Most of the Mavig Ceiling Suspension Systems are UL-listed or –registered. Mavig is market leader in its business fields. Our product quality and service “Made in Germany” is acknowledged worldwide. Mavig also offers VivaScope®, the first Confocal Laser Scanning Microscope for in-vivo, real-time examination of human skin.

The most innovative Personal X-Ray protection manufacturer in Europe. From X-Ray aprons Thyroid shields and personal X-ray protective glasses; all made in Europe.
Mentice
Odinsgatan 10
41103 Gothenburg
SWEDEN
www.mentice.com

Mentice is the world leader in virtual reality-based performance solutions for endovascular therapies. Our solutions help healthcare professionals with skills acquisition, continuous professional development and pre-procedural planning – leading to improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com.

RaySafe & Landauer
Uggledalsvägen 29
42740 Bilddal
SWEDEN
www.raysafe.com

RaySafe and Landauer focus on measuring and reducing radiation exposure for healthcare professionals. The RaySafe i3 system is the latest generation of the real-time dosimetry family. The system includes the new RaySafe real-time personal radiation dosimeters coupled with a display and software to provide a complete, immediate visual of radiation exposures. Visualize X-ray exposure with the new i3 real-time personal radiation dosimeter using easy-to-read bar graphs. Instant feedback empowers your medical staff to learn and adapt their behavior on the go, minimizing unnecessary radiation exposure. http://raysafe.com/Home/Products/Staff/RaySafe%20i3
Come by the booth to see the New i3i. The RaySafe Real-time Dosimetry System just got better. Landauer dosimetry service: Landauer is the world leader in passive dosimetry. Over 2 million workers trust Landauer for their radiation protection. The solutions provided by Landauer meet your dosimetry requirements in accordance with radiation protection regulations. LANDAUER INLIGHT® – Personal dosimetry. Landauer offers a complete range of services including for body, ring and lens of eye dosimetry monitoring. LANDAUER VISION® - Discrete and multi-support lens of eye dosimeter Ergonomic, compact and flexible, VISION measures Hp(3) photon dose to the lens from 0.1 mSv to 10 Sv. Your workers are being monitored precisely with the highest comfort. www.landauer-fr.com/en/home
Siemens Healthcare GmbH
Karlheinz-Kaske-Strasse 5
91052 Erlangen
GERMANY
www.siemens-healthineers.com

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

Tecres SpA
Via A. Doria 6
37066 Sommacampagna
ITALY
www.tecres.it

Tecres has got over thirty years of experience in orthopaedics and is also active in minimal invasive surgery. Mendec Spine HV System is the unique all in one closed mixing device specifically developed for the preparation of high density acrylic resin to be used for vertebroplasty. Mendec Spine is our acrylic resin specifically developed for the filling of vertebral cavities, that goes with a complete kit for the vertebroplasty procedures with Mendec Spine Kit. Mendec Aqva is an hydraulic delivery device that allows the surgeon to extrude high viscosity cement remaining distant from the x-ray beam.
Worldwide Innovations & Tech., Inc.
14740 W. 101st Terrace
KS-66215 Leawood
UNITED STATES OF AMERICA
www.radpad.com

Manufacturer of RADPAD® Shields, Worldwide Innovations & Technologies, Inc. is committed to developing and producing quality products providing medical personnel and patients with protection from the deadly and debilitating effects of radiation. Our products have been independently tested, studied, and proven effective in reducing radiation exposure and are ISO 13485 certified confirming and enhancing our commitment to quality products and customer service. RADPAD® products are lead free and can be sterilized as necessary. They are completely disposable and create no environmental issues. Further, RADPAD® products allow medical facilities to comply with the ALARA (As Low As Reasonably Achievable) standard of the radiation protection industry. WIT has also developed a line of products designed to protect patients from unnecessary exposure to radiation. RADPAD® Radiation Protection Shields & Drapes, the world leader in scatter radiation protection; dramatically reduce scatter radiation exposure to medical personnel during fluoroscopy procedures. Lightweight, flexible, disposable and lead-free, RADPAD® shields and drapes have been documented in more than 35 independent third party clinical studies to provide up to a 95% reduction rate in scatter radiation. American made and procedure specific, RADPAD® Shields are designed to provide the maximum possible scatter radiation reduction without impairing the physician’s interventional techniques.
Apply Now
and boost your career in IR

The EBIR is a globally recognised certification designed to give practising interventional radiologists the opportunity to certify their expertise and build their career from early on.

Upcoming examinations:
• March – ECR 2020
• September – CIRSE 2020

Submit your application online at
www.cirse.org/ebir
## Societies (Alphabetical List)

<table>
<thead>
<tr>
<th>Official Name</th>
<th>Booth#</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSIR</td>
<td>S20</td>
</tr>
<tr>
<td>CIRSE 2020</td>
<td>S12</td>
</tr>
<tr>
<td>CIRSE Academy</td>
<td>S2</td>
</tr>
<tr>
<td>CIRSE Clinical Research</td>
<td>S24</td>
</tr>
<tr>
<td>CIRSE Library</td>
<td>S1</td>
</tr>
<tr>
<td>CVIR</td>
<td>S22</td>
</tr>
<tr>
<td>CVIR Endovascular</td>
<td>S23</td>
</tr>
<tr>
<td>DeGIR/ÖGIR/IROS/SSVIR</td>
<td>S16</td>
</tr>
<tr>
<td>EBIR</td>
<td>S3</td>
</tr>
<tr>
<td>ECIO 2020</td>
<td>S13</td>
</tr>
<tr>
<td>ESIR</td>
<td>S10</td>
</tr>
<tr>
<td>ESR</td>
<td>S19</td>
</tr>
<tr>
<td>ET 2020</td>
<td>S14</td>
</tr>
<tr>
<td>GSIR</td>
<td>S18</td>
</tr>
<tr>
<td>HSIR</td>
<td>S17</td>
</tr>
<tr>
<td>IASIOS</td>
<td>S21</td>
</tr>
<tr>
<td>ICCIR 2020</td>
<td>S11</td>
</tr>
<tr>
<td>IESIR</td>
<td>S15</td>
</tr>
<tr>
<td>ISVIR</td>
<td>S6</td>
</tr>
<tr>
<td>SERVEI</td>
<td>S9</td>
</tr>
<tr>
<td>SIDI</td>
<td>S8</td>
</tr>
<tr>
<td>SIR</td>
<td>92</td>
</tr>
<tr>
<td>SNRIR</td>
<td>S5</td>
</tr>
<tr>
<td>SOBRICE</td>
<td>S7</td>
</tr>
<tr>
<td>TSIR</td>
<td>S4</td>
</tr>
</tbody>
</table>
### Societies (Numerical List)

<table>
<thead>
<tr>
<th>Official Name</th>
<th>Booth#</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIRSE Library</td>
<td>S1</td>
</tr>
<tr>
<td>CIRSE Academy</td>
<td>S2</td>
</tr>
<tr>
<td>EBIR</td>
<td>S3</td>
</tr>
<tr>
<td>TSIR</td>
<td>S4</td>
</tr>
<tr>
<td>SNRIR</td>
<td>S5</td>
</tr>
<tr>
<td>ISVIR</td>
<td>S6</td>
</tr>
<tr>
<td>SOBRICE</td>
<td>S7</td>
</tr>
<tr>
<td>SIDI</td>
<td>S8</td>
</tr>
<tr>
<td>SERVEI</td>
<td>S9</td>
</tr>
<tr>
<td>ESIR</td>
<td>S10</td>
</tr>
<tr>
<td>ICCIR 2020</td>
<td>S11</td>
</tr>
<tr>
<td>CIRSE 2020</td>
<td>S12</td>
</tr>
<tr>
<td>ECIO 2020</td>
<td>S13</td>
</tr>
<tr>
<td>ET 2020</td>
<td>S14</td>
</tr>
<tr>
<td>IESIR</td>
<td>S15</td>
</tr>
<tr>
<td>DeGIR/ÖGIR/IOSE/SSVIR</td>
<td>S16</td>
</tr>
<tr>
<td>HSIR</td>
<td>S17</td>
</tr>
<tr>
<td>GSIR</td>
<td>S18</td>
</tr>
<tr>
<td>ESR</td>
<td>S19</td>
</tr>
<tr>
<td>BSIR</td>
<td>S20</td>
</tr>
<tr>
<td>IASIOS</td>
<td>S21</td>
</tr>
<tr>
<td>CVIR</td>
<td>S22</td>
</tr>
<tr>
<td>CVIR Endovascular</td>
<td>S23</td>
</tr>
<tr>
<td>CIRSE Clinical Research</td>
<td>S24</td>
</tr>
<tr>
<td>SIR</td>
<td>92</td>
</tr>
</tbody>
</table>
The BSIR is a charitable foundation founded to promote and develop the practice of interventional radiology.

What are the main objectives of the society?
- To support and develop access to high quality information on interventional radiology for patients and all healthcare professionals.
- To support audit and research in interventional radiology
- To support education and training in interventional radiology

CIRSE 2020
As the largest interventional radiology meeting of the year, the CIRSE Annual Congress is an essential event for every IR. Within this vibrant setting of discussion and debate, delegates are able to discover new research and technological advances across a wide range of fields, from oncological interventions to clinical management and more! Join us at CIRSE 2020 from September 12-16 in Munich, Germany for another year of science, education and innovation. Visit our booth or learn more on our website at cirse.org.

CIRSE Academy
The CIRSE Academy aims to provide comprehensive knowledge on IR procedures through online courses based on the European Curriculum and Syllabus for IR. These courses, all peer-reviewed by experts, include theory, example cases and teaching videos. Currently, 26 courses are available on oncology, embolisation, arterial, venous, aortic, neurointervention and non-vascular interventions. All CIRSE Academy courses are CME-certified, and CIRSE members are eligible for a reduced fee. For more information, please visit cirse.org/academy
CIRSE Clinical Research

Research is a key building stone of any medical specialty, and the fast pace of change within interventional radiology makes it doubly so. Since 2013, CIRSE has been gradually redefining its role within IR research by developing an in-house research infrastructure tailored to high-quality observational studies. With grants by our industry partners and guidance from scientific steering committees, the CIRSE Clinical Research Department has successfully designed and conducted observational studies in post-market as well as national reimbursement settings.

Together with our clinical research operations and projects, the requirements on our infrastructure have grown too, and we are steadily developing our services to be able to even better meet the demands for high-quality data collection in the IR community.

Stop by our CIRSE Clinical Research Booth in the entrance hall, visit cirse.org/research, or contact research@cirse.org for more information about our services and our network of partners.

CIRSE Library

CIRSE proudly offers an online resource for congress recordings: the CIRSE Library.

A wealth of IR knowledge in one convenient location, the Library features lectures and posters from current and previous congresses, with more than 8,000 available titles. Watch HD quality webcasts, browse a wide-ranging collection of educational topic packages, find related content and view selected lectures to prepare for the EBIR examination. Members enjoy year-round access, and non-members have a range of access options. Find out more and discover the most extensive online educational tool in interventional radiology at library.cirse.org!

CVIR – CardioVascular and Interventional Radiology

CardioVascular and Interventional Radiology (CVIR) is an official journal of CIRSE. Founded in 1978 by Professors Herbert L. Abrams and Eberhard Zeitler, CVIR is the longest-running journal covering a broad field of topics in vascular and interventional radiology. CVIR enjoys a vast international readership, and in addition to its association with CIRSE, CVIR is also an official organ of various IR societies representing over 20 countries. www.cvironline.org
CVIR Endovascular

CVIR Endovascular is CIRSE’s online-only, open-access journal focusing on endovascular therapies and research beneficial for daily IR practice. It features an open peer-review model and is intended for all specialists working in the field of endovascular treatment. The journal operates on article-processing charges, and more than 600 institutions worldwide support their affiliated authors to publish open access by paying some or all publication costs. Applications for waivers or discounts on article-processing charges can be completed during manuscript submission. www.cvirendovascular.org

DeGIR – German Society of Interventional Radiology

DeGIR is the German society for interventional radiology and minimally invasive therapy (www.degir.de). Founded in 2008, the society now has over 1,500 members and works closely with the German Roentgen Society (DRG). DeGIR has a permanent office located in Berlin. The society runs an elaborate national registry of interventional procedures, collecting data from 180,000 interventions, documented by over 294 institutes in 2019 alone. The data is used for quality assurance in interventional radiology as well as for scientific analyses. DeGIR established a qualification initiative in interventional procedures similar to the EBIR, which is divided into six different modules including vascular recanalisation techniques, embolisation, non-vascular interventions and neurointerventions. Qualification requires both a written and oral exam, as well as sufficient practical experience and to date, more than 1,000 certificates of personal qualification in interventional radiology have been issued. A network of training facilities is also offered to its members. For further information, please contact the society directly at degir@drg.de.

EBIR

The European Board of Interventional Radiology (EBIR) is a voluntary supplemental examination designed to evaluate interventional radiologists on the clinical and technical knowledge necessary to safely and effectively carry out treatments for patients. Through taking this examination, IRs can certify their expertise and demonstrate their ongoing commitment to pursuing a career in IR. The EBIR is held three times every year, twice in Europe and once in Australasia. For more information, please visit cirse.org/ebir.
ECIO 2020
The European Conference on Interventional Oncology (ECIO) provides a comprehensive forum for experts to share and learn about important innovations, keeping experts up to date on IO’s latest research and developments. As interventional oncologists continue to play an increasingly important role alongside oncologists and surgeons in cancer treatment, this annual event emphasises the importance of multidisciplinary tumour boards and discussions, while encouraging registrants to bring along a non-radiologist colleague at no extra cost. The 11th annual European Conference on Interventional Oncology will take place from April 26-29, 2020 in Nice. Abstract submission will open on September 16. To find out more, visit our booth or ecio.org.

ESIR Courses
Year after year, the ESIR Clinical Procedure Training courses continue to provide premier education to IR professionals, helping participants stay up to date on the latest developments in the field. Since 2006, ESIR has offered 91 first-rate, practice-oriented courses in over 23 countries on a wide range of IR topics. Skilled specialists guide participants in perfecting their performance through featured state-of-the-art devices and technology, as well as live or video cases, where appropriate. The upcoming course, Reliability in Percutaneous Tumour Ablation, will be held in Innsbruck, Austria from December 12-13, 2019. Visit cirse.org/esir to learn more and stay tuned for information on 2020 courses.

ESR – European Society of Radiology
The European Society of Radiology (ESR) represents more than 113,000 members worldwide and annually hosts the European Congress of Radiology (ECR) in Vienna, Austria. The ECR is one of the largest medical congresses in the world, attracting more than 30,000 congress participants. With 300 companies exhibiting, its exhibition is also one of the largest medical exhibitions in Europe. Visit our booth to learn more about ECR and our education and training offers.
ET Meets GEST 2020

The first ET – the European Conference on Embolotherapy – took place in Valencia this June with a programme covering the entire spectrum of established and new embolotherapies. Bringing more than 800 medical experts together to engage in 120 lectures and a cutting-edge technical exhibition, the congress exceeded expectations across the board, pushing embolotherapy education into high gear. The second European Conference on Embolotherapy – ET meets GEST 2020 – will build on the success of its first year, challenging the IR community to take embolotherapy even further. ET meets GEST 2020 will take place from June 24-27 in Vienna at the state-of-the-art Messe Wien Exhibition and Congress Centre. Stay tuned for updates and visit etconference.org for more information.

GSIR – Greek Society of Interventional Radiology

20 Papadiamantopoulou str
11528 Athens
Greece
www.epemvatiki.gr

The Greek Society of Interventional Radiology was founded in 1989 by Greek Radiologists who applied the techniques of interventional radiology to the daily clinical practice. It collaborates closely with the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) and all its members are members of the European Society. In 2012, a Government Gazette defining interventional radiology was published as a special curriculum specialisation, training centres and recognised interventional radiologists.

HSIR – Hungarian Society of Interventional Radiology

info@macirt.hu
www.macirt.hu

Founded in 1998, HSIR (Hungarian Society of Interventional Radiology) is an educational and scientific society with 90 members dedicated to raising and maintaining the standards of the medical practice of interventional radiology. The mission of our society is to advance and represent the profession of interventional radiology, serve the professional needs of its members, promote patient safety, and improve patient outcomes. The HSIR collaborates with other national and international societies/organisations for better clinical practice. Official journal of the society: Interventional Medicine and Applied Science (IMAS)
**IASIOS**
The International Accreditation System for Interventional Oncology Services (IASIOS) offers a unique opportunity to achieve a seal of quality and recognition for its interventional oncology services performed according to the CIRSE Standards of Quality in IO. The goal of IASIOS is to certify better patient care, support quantifiable benchmarks and encourage development of IO. By enrolling in this programme, IO facilities can prove their compliance with the CIRSE IO Standards and their commitment to providing high quality care to cancer patients. For more information, visit iasios.org.

**ICCIR 2020 – International Congress on Complications in Interventional Radiology**
The ICCIR is a unique event offering doctors with diverse experience levels a discreet forum to explore the difficult but necessary subject of procedural complications. To encourage frank discussion, the faculty is carefully selected to discuss a selection of hand-picked case reports and overall participation is limited. ICCIR has quickly established itself as the main complications meeting in Europe, and attracts a very diverse but dedicated group. The last congress brought near 300 participants together to discuss more 50 cases. The next congress, ICCIR 2020, will again take place in Poertschach, Austria from June 4-6. For more information, visit iccir.eu.

**IESIR – Italian-European Society of Interventional Radiology**
Founded in 2015, the Italian-European Society of Interventional Radiology (IESIR) is an independent and autonomous society, whose main objective is to develop and promote the clinical practice of the interventional radiologists in Italy and in Europe. IESIR actively supports scientific activities, represents the interests of Italian IRs, actively contributes to the creation of guidelines and reports, and strengthens connections of the European IR community. To find out more, visit iesir.org.

**IROS 2020 – Interventionell Radiologisches Olbert Symposium**
Neutorgasse 9
1010 Vienna
Austria
www.irosonline.org

IROS 2020 is the joint annual meeting of the Austrian, German and Swiss Societies of Interventional Radiology. Next year, the meeting will take place in Salzburg, Austria, from January 16-18. In addition to lectures and workshops, delegates will have the possibility to participate in recorded procedure demonstrations (Live in Box), Satellite Symposia and intensive courses tailored to the daily needs of interventional radiologists. For further information, please visit our booth or our website at www.irosonline.org.
ISVIR – Indian Society of Vascular and Interventional Radiology
Room No - 20A, Department of Interventional Radiology
Sir Ganga Ram Hospital, New Delhi – 110060
India
www.isvirindia.org

The Indian Society of Vascular & Interventional Radiology (ISVIR) has been floated to provide a platform for exchange of knowledge in field of IR. ISVIR was formed in Trivandrum in November, 1997. The objectives of the society include providing a common platform for discussions, formulating guidelines for performing and documenting IR procedures, creating opportunities for certified training programmes in IR, evolving guidelines for medico-legal aspects of the practice, creating public awareness, and helping the fledgling subspecialty with turf battles. The society has more than 700 members at present with approximately 100 student members. The official journal of the society is “Journal of Clinical Interventional Radiology” which is a peer-reviewed, open access, online and print journal that supports the science and practice of IR worldwide.

ÖGIR – Austrian Society of Interventional Radiology
Neutorgasse 9
1010 Vienna
Austria
www.oegir.at

ÖGIR is the Austrian Society of Interventional Radiology and Minimally Invasive Therapy (www.oegir.at). Founded in 2007, the society now has over 200 members. ÖGIR has a permanent office located in Vienna and organises the IROS annual meeting together with the German Society of Interventional Radiology (DeGIR) and the Swiss Society of Interventional Radiology (SSVIR). In 2012, ÖGIR, in cooperation with DeGIR, introduced a qualification initiative in interventional procedures similar to the EBIR, which is divided into 6 different modules including vascular recanalisation techniques, embolisation, non-vascular interventions and neurointerventions.

For more information, please visit www.oegir.at or email oegir@oegir.at.
SERVEI – Spanish Society of Vascular and Interventional Radiology
C/ Alcalá, 135 1
28009 Madrid
Spain
www.servei.org

The Spanish Society of Vascular and Interventional Radiology (SERVEI) is a non-profit medical and scientific association, founded in 1987, with the aim of promoting training, development, research, knowledge sharing and the diffusion of Vascular and Interventional Radiology (RVI). SERVEI celebrates a National Congress with biannual periodicity and multiple courses and training and research days. At the moment SERVEI has around 400 active members.

SIDI – Sociedad Iberoamericana de Intervencionismo
https://intervencionismosidi.org/
info@intervencionismosidi.org

SIDI is a medical-scientific non-profit organisation with a significant track record aiming to foster interventional radiology activities. Nowadays it is comprised of more than 200 members, mainly or exclusively focused on image-guided minimally invasive procedures. Our society was created in 1994 and at the present time has members from 15 Spanish-speaking countries in Latin America, Spain and Portugal. Additionally, the scope of action is extended to other countries in Europe and the USA.

The most significant projects that SIDI performs according to its goals are as follow:
• Call for student grants and IR fellowship programmes
• Organisation of scientific meetings, seminars and other activities
• Publication of the quarterly medical-scientific Journal Intervencionismo
The Society of Interventional Radiology is a nonprofit, professional medical society representing more than 8,000 practicing interventional radiology physicians, trainees, students, scientists and clinical associates, dedicated to improving patient care through the limitless potential of image-guided therapies. SIR’s members work in a variety of settings and at different professional levels—from medical students and residents to university faculty and private practice physicians. Visit sirweb.org. SIR Foundation is a scientific foundation dedicated to fostering research and education in interventional radiology for the purposes of advancing scientific knowledge, increasing the number of skilled investigators in interventional radiology and developing innovative therapies that lead to improved patient care and quality of life. Visit sirfoundation.org.

The Romanian Neuroradiology and Interventional Radiology Society (SNRIR) is a non-profit, educational and scientific association that aims to improve patient care by supporting teaching, science, research and clinical practice in the field of interventional radiology.

Interventional radiology is at the cutting edge of modern medicine, providing maximum benefit to the patient through minimally invasive techniques. SNRIR supports this innovative field by providing the best educational and scientific resources possible. SNRIR’s mission is to provide continuous education and training for its members as well as other physicians and scientists with implications and personal interests active in interventional radiology and to promote the exchange of ideas and information to further define the role, the mission of interventional radiology as a subspecialty of radiology. SNRIR aims to improve ethical, technical and material conditions in interventional radiology to improve patient care.
SOBRICE –
Sociedade Brasileira de Radiologia Intervencionista e Cirurgia Endovascular
Av. Paulista, 37 – 7º andar – conj. 71
01311-902 – Sao Paulo/SP
Brazil
www.sobrice.org.br

The Brazilian Society of Interventional Radiology and Endovascular Surgery (SOBRICE) is a non-profit, educational and scientific national association dedicated to improve patient care through minimally invasive image-guided interventions. SOBRICE was founded in 1997 and since the beginning aims to support education, research and clinical practice in the field of interventional radiology through scientific meetings, publications and media activity. The society also provides a board examination for its members, in order to certify their qualification in the specialty. Furthermore, SOBRICE collaborates with other scientific national and international societies in order to achieve shared goals of interest to interventional radiology.

TSIR – Turkish Society of Interventional Radiology

tgrd@tgrd.org.tr
www.tgrd.org.tr

Turkish Society of Interventional Radiology (TSIR) was established in 2000. Its office was located first in Istanbul and is now located in the capital city, Ankara. Interventional radiology has not yet become a government-recognised subspecialty of radiology in Turkey. For interventional radiology, the routine residency programme has a three- to ten-month rotation, and after completion most radiologists are capable of performing basic interventions. Therefore, education on interventional radiology has become the most important mission of the society. The society arranges courses and annual national meetings in the field of interventional radiology. The mission of the Turkish Society of Interventional Radiology is to contribute to the education and training of radiologists who are occupied with all kind of interventional process and to pursue research and development in this field. Our 15th Annual Scientific Meeting will be held as Joint Meeting with EVIS 2020 in Susesi Convention Center-Antalya-Turkey, on March 6-10, 2020. A lot of attendees including interventional radiology doctors, technicians, nurses and industry members are expected to participate to this meeting.
Mezzanine 2

Meeting Room

Room M220
Photography Studio
Room M219
Room M218
Room M217
Room M216
Media Studio
Hotel Hilton Diagonal Mar – First Floor

Meeting Room

Floor Plans

MR 1
MR 2
MR 3
MR 4
MR 5
MR 6
MR 7
MR 8
MR 9
MR 10
Want to learn more?
Peer to peer, shoulder to shoulder, doctors teaching doctors.

To register for a course, visit cookmedical.eu/CIRSE19
Boost occlusive capacity with fiber

Polymer fibers allow significantly fewer embolization coils to achieve acute occlusion of arteries than bare metal coils.¹

Visit cookmedical.eu/FiberStudy
Learn about the impact of fiber from peer-reviewed, statistically significant in-vivo data.